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Stellingen 
1. Ondanks een lange traditie van voedingsvoorlichting is het totaal cholesterolgehalte in 
de algemene Nederlandse bevolking in de afgelopen decennia niet substantieel gedaald. 
Dit proefschrift 
2. Voor de vertaling van epidemiologisch onderzoek naar volksgezondheidsbeleid is het 
van groot belang te kijken naar absolute risico's en niet alleen naar relatieve risico's. 
Dit proefschrift 
3. Eventuele gezondheidsrisico's van een laag totaal cholesterolgehalte vormen in 
Nederland geen belangrijk volksgezondheidsprobleem. 
Dit proefschrift 
4. Dat een gezonde leefstijl met betrekking tot coronaire hartziekte ontdaan is van elk 'joie 
de vivre' wordt gelogenstraft door de observatie in de Zeven Landen Studie, dat de sterfte 
aan coronaire hartziekte in de mediterrane Zuideuropese cohorten een factor 4 lager was 
dan die in de Noordeuropese cohorten. 
Dit proefschrift 
5. Het ontbreken van betrouwbare (trend-) gegevens over de incidentie van hart- en 
vaatziekten maakt het onmogelijk na te gaan welk deel van de daling in sterfte aan hart-
en vaatziekten toe te schrijven is aan primaire preventie. 
6. Bij het rekenen met persoonsjaren follow-up in epidemiologisch onderzoek, moet 
rekening worden gehouden met het feit dat 5 jaar follow-up van 50.000 mensen andere 
informatie levert dan 25 jaar follow-up van 10.000 mensen. 
7. De snelheid waarmee nieuwe produkten op de markt verschijnen is vele malen groter 
dan de snelheid waarmee de NEVO tabel kan worden uitgebreid met nieuwe produkten. 
8. Door de grote aandacht voor genetica en de bijna dagelijkse ontdekking van een nieuwe 
mutatie of polymorfisme, kan bij de leek gemakkelijk fatalisme ontstaan over de 
mogelijkheid van het individu met betrekking tot primaire preventie. 
9. De publikatiedruk op wetenschappers, 'publish or perish', kan vruchtbare, 
onbaatzuchtige samenwerking flink in de weg staan. 
10. De tijdwinst die scan-kassa's de klant aanvankelijk opleverden bij Albert Heijn is 
inmiddels verdwenen door tijdrovende handelingen als het verstrekken van air-miles, 
kristalzegels en gewone zegels. 
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Voor Bennie 
Cholesterol is poisonous, 
so never never eat it; 
sugar too may murder you, 
there is no way to beat it. 
Fatty food may do you in, 
dessert, do avoid it. 
Some food was rich in vitamins, 
but processing destroyed it. 
So let your life be ordered 
by each documented fact, 
and die of malnutrition 
but with arteries intact. 

ABSTRACT 
BLOOD CHOLESTEROL — A PUBLIC HEALTH PERSPECTIVE 
PhD Thesis. Agricultural University Wageningen, the Netherlands and the National Institute of 
Public Health and the Environment, Bilthoven, the Netherlands. 
W.M. Monique Verschuren 
Changes in total cholesterol levels (TC) were studied using data from three epidemiological 
studies: about 30,000 men and women aged 37-43 were examined between 1974 and 1980 (CB 
Project), about 80,000 men aged 33-37 between 1981 and 1986 (RIFOH Project) and 42,000 men and 
women aged 20-59 from 1987 to 1992 (Monitoring Project on CVD Risk Factors). In men a decline 
in TC of 6.5% was observed between 1974 and 1992. However, the largest decrease took place 
between 1981 and 1986 in men in a limited age range (33-37 years), and there were indications that 
this decrease was not generalizable to other age groups. From 1987 to 1992, a decrease of 7% in HDL 
cholesterol levels (HDL-C) was observed in men, leading to an increase in the non-HDL-C/HDL-C 
ratio. In women, no changes in TC and HDL-C were observed. 
Analyses of data from 36,000 men and women aged 20-59 years showed that between ages 30 
and 50 about 19-38% of the gender difference in TC was explained by differences in body mass index 
(BMT) and cigarette smoking between men and women. After age 50, the higher TC in women 
compared to men was largely due to the effect of the menopause. The TC increase associated with 
menopause was 0.45 mmol/1 in non-smokers and 0.28 mmol/1 in smokers. The difference between a 
low-risk and a high-risk lifestyle was 0.58 mmol/1 for TC and 0.38 mmol/1 for HDL-C in men, and 
0.40 mmol/1 for TC and 0.45 mmol/1 for HDL-C in women. 
Twelve year follow-up of 50,000 men and women aged 30-54 (CB Project) showed that the 
adjusted relative risk for coronary heart disease (CHD) mortality for the highest compared to the 
lowest cholesterol quintile was 3.0 (95% CI 1.8-5.1) in men and 3.8 (95% CI 1.1-13.1) in women. It 
was estimated that a TC reduction of 0.6 mmol/1 was associated with a 20% lower CHD mortality. 
Low TC was not associated with non-cardiovascular mortality. All-cause mortality was positively 
related to total cholesterol, with a 60% and 46% higher risk in the highest compared to the lowest TC 
quintile for men and women respectively. 
Twenty-five year follow-up of the Seven Countries Study, in which over 12,000 men aged 40-59 
at baseline participated, showed that relative risks for CHD mortality were similar in different cultures, 
but the absolute risks were strikingly different. At a cholesterol level of about 5.4 mmol/1 age-
standardized CHD mortality rates varied from 4% to 5% in Japan and Mediterranean Southern Europe 
to 15% in Northern Europe after adjustment for age, smoking and blood pressure. It was concluded 
that other factors, such as diet, typical for low-risk countries, modify the effect of TC on CHD 
mortality. In the Seven Countries Study, in non-smokers no association of TC with cancer mortality 
was observed, while non-cardiovascular/non-cancer mortality was elevated only at TC below 4.15 
mmol/1. In smokers, cancer mortality and non-cardiovascular/non-cancer mortality were inversely 
associated with TC. All-cause mortality showed a J-shaped association with TC in non-smokers (lowest 
all-cause mortality for TC between 4.15 and 5.15 mmol/1), while all-cause mortality was unrelated to 
TC in smokers. Absolute mortality rates were higher in smokers than in non-smokers for all endpoints. 
Lowering the average TC level in the population is concluded to contribute to a reduction in the 
burden of CHD. Low cholesterol levels are not considered an important public health concern in the 
Netherlands. Changes in the lipid profile should preferably be achieved by lifestyle interventions such 
as a diet low in saturated fat and rich in fruits and vegetables, no cigarette smoking, a desirable body 
mass index (less than 25 kg/m2) and a physically active lifestyle. Such a lifestyle will not only have 
a favorable impact on coronary heart disease, but is also compatible with recommendations on the 
prevention of other chronic diseases such as diabetes and cancer. 
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General Introduction 
The problem of coronary heart disease 
Cardiovascular diseases form an important public health problem in the Netherlands, 
causing about 50,000 deaths every year.1 Coronary heart disease constitutes about half of 
the cardiovascular mortality. The majority of coronary heart disease mortality is due to 
acute myocardial infarction. In 1992, more than 9,000 men and 7,000 women died of 
acute myocardial infarction. Between 1972 and 1990, age-standardized mortality rates for 
coronary heart disease decreased in the Netherlands by about 29% in men and 38% in 
women.2 It is not quite clear to what extent changes in cardiovascular risk factors have 
contributed to the decline in coronary heart disease mortality and to what extent 
improvements in medical care have played a role. However, although age-standardized 
mortality rates decreased substantially, the increasing population size and proportion of 
elderly persons has led to the absolute number of deaths decreasing only slightly in men 
and remaining the same in women. No accurate nationwide data are available on the 
incidence of coronary heart disease. It is important to know whether the declining 
mortality rates are due to primary prevention of the disease or to better survival after a 
first event. If the latter is the case, the burden of the disease to the population will 
increase, which has large implications for the health-care system. An indication that higher 
survival rates play a role is the fact that standardized hospital admission rates have been 
increasing steadily over the past 20 years.1 
Serum total cholesterol and coronary heart disease 
Not only in the Netherlands, but also in a number of other industrialized countries, it was 
noticed that since the Second World War, increasing affluence has been accompanied by 
an epidemic level of coronary heart disease. As early as the 1950s it was suspected that 
serum total cholesterol was an important risk factor for coronary heart disease and that 
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diet was an important determinant of the serum total cholesterol concentration.3 A great 
number of studies to investigate the role of serum total cholesterol in the etiology of 
coronary heart disease started around that time. It became clear that serum total cholesterol 
was one of three major risk factors for coronary heart disease, the other two being blood 
pressure and cigarette smoking.4"7 
Cholesterol metabolism 
For an understanding of the role of cholesterol in the etiology of coronary heart disease, 
insight in the atherosclerotic process is needed. Cholesterol is transported through the body 
in lipoproteins.8 The liver is the central organ in cholesterol metabolism. Low density 
lipoproteins (LDL) transport cholesterol from the liver to the tissues throughout the body. 
About 70% of the cholesterol is contained in LDL particles. The removal of LDL from 
the plasma is mediated by the LDL receptors that are present at the cell surface9, and most 
of the removal occurs by the liver. However, LDL is also taken up by the arterial wall. 
High LDL concentrations in the plasma will increase LDL concentrations in the intima, 
where oxidation of LDL can take place. It has been shown that especially the oxidized 
form of LDL plays an important role in causing the atherosclerotic lesions.10 Oxidized 
LDL is taken up rapidly by macrophages causing the formation of foam cells. 
Furthermore, oxidized LDL is cytotoxic, causing damage to the endothelial wall. Oxidation 
of LDL and the formation of foam cells give rise to the formation of fatty streaks, the 
early stages of the atherosclerotic lesion. From there on progression takes place to more 
serious lesions.11 Although the LDL fraction is the atherogenic component of the total 
cholesterol level in plasma, in large-scale epidemiological studies total cholesterol is 
measured as an indicator of LDL levels because of the strong correlation between total 
cholesterol and LDL cholesterol levels. 
High density lipoproteins (HDL) transport cholesterol from the tissues back to the liver 
(reverse cholesterol transport) where it can be degraded and excreted in the gut in the 
form of bile acids, or incorporated again, primarily in LDL particles. About 20% of 
cholesterol is transported in HDL particles. The mechanisms underlying this reverse 
cholesterol transport by HDL particles is much less understood than that of cholesterol 
transport by LDL particles. Epidemiological studies have shown that HDL cholesterol is 
inversely associated with the occurrence of coronary heart disease.12 
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Cholesterol lowering and mortality 
Although many observational studies showed the importance of serum total cholesterol 
levels in the etiology of coronary heart disease, the most convincing evidence that a factor 
is causally related to a disease is provided by intervention studies. After the observation 
that persons with a high cholesterol level are at an increased risk for coronary heart 
disease, intervention trials were initiated to show that lowering cholesterol levels would 
lower coronary heart disease risk. A large number of trials have been carried out to assess 
the effect of cholesterol lowering on coronary heart disease morbidity and mortality. A 
meta-analysis of 28 randomized controlled trials showed that lowering total cholesterol 
levels led to a decrease in coronary heart disease mortality.13 In a number of trials, 
however, total mortality did not decrease as a consequence of cholesterol lowering. This 
raised concern about unfavorable side-effects of cholesterol lowering14, especially since 
in many countries guidelines had been adopted for lowering of elevated cholesterol 
levels.15"16 Several meta-analyses of randomized trials reached different conclusions about 
the effect of cholesterol lowering on non-cardiovascular mortality.17"20 The most recent 
meta-analysis by Law et al. shed some light on these inconsistencies and showed that 
dietary trials did not show increased mortality in the intervention group while drug trials 
did, and that secondary prevention trials did not show increased mortality while primary 
prevention trials did.21 This would imply that dietary intervention has no adverse effects, 
and that drug intervention should be limited to individuals with existing coronary heart 
disease. A recent secondary prevention trial with the newest type of cholesterol-lowering 
drugs (HMG-CoA reductase inhibitors) showed both a reduction in coronary heart disease 
and total mortality.22 
Low cholesterol levels 
Apart from concern about possible side-effects of cholesterol lowering in individuals with 
a high cholesterol level, concern was also recently raised about an increased risk for non-
cardiovascular mortality in individuals with a low cholesterol level. 2 3 , 2 4 If a low cholesterol 
level were related to non-cardiovascular mortality, this would mean that cholesterol 
lowering would not be beneficial to persons with a relatively low cholesterol level. 
However, although excess non-cardiovascular mortality at low cholesterol levels has been 
observed in many studies, the question to what extent the observed associations are causal 
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is still in debate. The fact that this association was present in cohorts based on a sample 
of the general population and not observed in cohorts consisting of young or working 
persons ("healthy" cohorts), suggests that the association arises from reversed causality or 
bias. 2 5* 
Outline of the thesis 
Given the importance of cholesterol in the etiology of coronary heart disease it is 
important to have information on cholesterol levels in the general population. This 
information is necessary to determine the number of persons at increased risk and to be 
able to anticipate future developments and demands of health care. Since 1974 a number 
of projects have been carried out in the Netherlands that have measured cholesterol levels 
in the general population. On the basis of these projects, changes in total cholesterol levels 
over the period 1974-1986 are described in Chapter 2. In Chapter 3, total and HDL 
cholesterol levels in the general population aged 20-59 are reported as well as changes 
over the period 1987-1992. To be able to prevent hypercholesterolemia, it is important to 
have insight into biological and lifestyle factors that determine total cholesterol levels. In 
Chapters 4 and 5 the effect of age and gender on total and HDL cholesterol levels is 
presented, as well as the contribution of body mass index, smoking, alcohol consumption, 
physical activity and (in women) the menopause. The public health impact of cholesterol 
levels depends on the strength of the relation between total cholesterol and subsequent 
mortality from different causes. The relation between total cholesterol and mortality in a 
large cohort of Dutch men and women is described in Chapter 6. The relation between 
total cholesterol and coronary heart disease mortality in different cultures is reported in 
Chapter 7, and in Chapter 8 the association between total cholesterol and mortality from 
causes other than coronary heart disease is described. In the general discussion (Chapter 
9) the public health implications of the results are discussed. 
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2 Trend in serum total cholesterol level in the Netherlands from 1974 to 1986 
Abstract 
Background. Age-standardized mortality rates from coronary heart disease have declined 
in the Netherlands since 1972. The extent to which changes in cardiovascular risk factors 
might have contributed to this decline is, however, not known. 
Methods. Data from two screening projects on cardiovascular risk factors were used to 
analyze the trend in serum total cholesterol level in the Netherlands between 1974 and 
1986. Cholesterol levels were measured in a single reference laboratory of the World 
Health Organization throughout the entire study period. Between 1974 and 1980, about 
30,000 men and women aged 37 to 43 years (mean age, approximately 40 years) were 
screened. 
Results. A decrease in mean serum total cholesterol level was observed until the end of 
1977, when it was followed by an increase. This resulted in a net change over the entire 
study period of -0.07 mmol/liter (3 mg/dl) in men and -0.03 mmol/liter (1 mg/dl) in 
women. Between 1981 and 1986, about 80,000 men aged 33 to 37 years (mean age, 35 
years) were screened. During this period, a decrease of 0.20 mmol/liter (8 mg/dl) in the 
mean total cholesterol level was observed. 
Conclusion. In spite of the decline in the mean total cholesterol level, the prevalence of 
cholesterol values of > 6.5 mmol/liter (> 251 mg/dl) in young adult men was still high in 
1986 (16%). A further reduction is therefore desirable. The decline in the mean total 
cholesterol level in young adults might indicate that a further decline in mortality from 
coronary heart disease can be expected. 
Published as: 
Verschuren WMM, Al M, Blokstra A, Boerma GJM, Kromhout D. Trend in serum total cholesterol 
level in 110,000 young adults in the Netherlands, 1974 to 1986. Am J Epidemiol 1991;134;1290-1302. 
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Introduction 
In 1972, mortality from coronary heart disease reached its peak in the Netherlands. Since 
that time the age-standardized death rate for coronary heart disease fell from 2,537/106 in 
1972 to 1.810/106 in 1988 for men and from 1.697/106 in 1972 to 1,146/106 in 1988 for 
women.1 The extent to which this fall can be attributed to primary prevention or improved 
health care is not known. To estimate the effect of primary prevention, it is of interest to 
know what happened with regard to the established risk factors for coronary heart disease 
during the last decades. Serum total cholesterol is a major risk factor for coronary heart 
disease.2 From 1974 to 1986, two screening projects on cardiovascular risk factors were 
carried out in the Netherlands. Throughout the entire study period, all measurements of 
serum total cholesterol were made in a single laboratory that serves as the lipid reference 
laboratory for the Netherlands and participates in the standardization program of the World 
Health Organization. The standards of the World Health Organization for cholesterol 
detennination were met throughout the entire study. These continuously collected data 
provided a unique opportunity for analyzing the trend in serum total cholesterol in young 
adults in the Netherlands over a period of 13 years. The results of these analyses are 
reported here. 
Materials and Methods 
Study population 
The screening projects were carried out according to a standardized protocol. From 
October 1974 to December 1980 a total of about 50,000 men and women from five 
different towns in the Netherlands were examined in the Consultation Bureau Heart 
Project. The project was begun in 1974 in two towns: Doetinchem, a small town in a rural 
area in the eastern part of the country with about 40,000 inhabitants, and Tilburg, a town 
in the southwest with about 150,000 inhabitants. Because the project was considered 
successful, three other cities were added to the study in 1976: Amsterdam, the capital, 
located in the western part of the country, with more than 700,000 inhabitants, and Leiden 
in the west and Maastricht in the south, both with about 100,000 inhabitants. In each 
town, a list of all inhabitants in a defined age range was obtained from the civil registry. 
These individuals were invited by mail to participate in the examination. They had to send 
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back a registration card in order to be scheduled for the examination. After 4 weeks, a 
reminder was mailed to all who had not yet responded. Everyone who registered was 
scheduled for the examination and received a confirmation notice 1 to 2 weeks before the 
appointment was scheduled. 
The response rate was about 80% at the beginning of the study period, and dropped to 
about 70% at the end of the study.3 The age range differed from city to city: in the small 
town of Doetinchem, the ages of the participants ranged from 30 to 54 years; in 
Amsterdam, from 40 to 42 years; in Maastricht, from 35 to 40 years; in Tilburg, from 38 
to 42 years; and in Leiden, from 30 to 35 years. Because age is a very strong predictor 
of serum total cholesterol, it was necessary to exclude the possibility that the observed 
trend would be confounded by age. Therefore, a subsample with a narrower age range was 
selected for trend analyses. All respondents aged 37 to 43 years were included in the trend 
analyses. This resulted in a stable mean age across the entire study period, and small 
fluctuations in age could be corrected with regression analysis because the relation 
between age and serum total cholesterol is linear within this age range. Because of the age 
restriction, Leiden was excluded, and the number of respondents eligible for trend analysis 
was reduced to about 30,000. 
The examination included measurement of blood pressure, weight, and height. The subject 
was not required to fast before blood was drawn for determination of serum total choles-
terol. All subjects completed a questionnaire requesting information about smoking habits, 
cardiovascular complaints, family history of premature cardiovascular mortality, physical 
activity, history of hypertension, and diabetes. 
In 1981 the study protocol changed. The decision made to examine men only, because 
they were at higher risk for cardiovascular diseases than women. From July 1981 to 
October 1986, about 80,000 men with a mean age of 35 years (range, 33-37) were 
screened in the study Risicofactoren Onderzoek Hart- en Vaatziekten (Risk Factor Project 
on Coronary Heart Disease, hereafter referred to as the RJPOH Project). This project was 
carried out in the same five towns in which the Consultation Bureau Heart Project took 
place. Potential respondents were again identified from the civil registry and invited to 
participate according to the same procedure followed in the Consultation Bureau Heart 
Project. For each 2-year period, certain birth cohorts were invited to participate: from 1981 
to 1982, all men born in 1946 and 1947; from 1983 to 1984, all men born in 1948 and 
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1949; and from 1985 to 1986, all men born in 1950 and 1951. This ensured a narrow age 
range across the entire study period, and no respondents had to be excluded in the trend 
analyses. The average response rate was 65%; in Amsterdam, it was approximately 55%, 
and in the other towns approximately 70%. The main purpose of the RIFOH Project was 
to measure the three major risk factors for coronary heart disease: serum total cholesterol, 
blood pressure, and cigarette smoking. Weight and height were measured, and the 
questionnaire was restricted to questions about smoking habits, cardiovascular complaints, 
and history of hypertension and diabetes. 
Cholesterol determination 
Throughout the entire study measurements of serum total cholesterol were made at the 
Central Clinical Chemistry Laboratory of the University Hospital Dijkzigt in Rotterdam. 
This laboratory participates in the standardization program of the World Health 
Organization through the World Health Organization Regional Lipid Center for Europe 
in Prague, Czechoslovakia. It is the lipid reference laboratory for standardized 
determination of cholesterol in the Netherlands and also participates in the network of 
reference laboratories of the national Heart, Lung, and Blood Institute and the Centers for 
Disease Control in the United States. 
During the entire study period, the quality standards for certified laboratories of the World 
Health Organization as adopted by the Centers for Disease Control, were met, ensuring 
that the measurement of cholesterol concentration differed no more than 5% from the true 
level. However, this is not sufficient for a valid trend analysis. Changes in cholesterol over 
time, if any, were expected to be small. Therefore, a small laboratory drift, unimportant 
for clinical practice, could disturb the trend analyses. Therefore, the internal quality control 
data were also analyzed to detect possible small changes over time. 
The laboratory routinely checked the precision and accuracy of the cholesterol 
measurements. Three control sera (sometimes two) were included in all series of 
measurements, or "runs". In each run, two out of three control sera had to yield values 
within a range of two standard deviations from the previously determined mean value. 
Otherwise, the run was rejected. The stability of lyophilized serum is such that a shelf-life 
of 2 years is typical. Therefore, several batches of control sera were used during the study 
period. Consequently, the entire study period was divided into periods during which a 
certain combination of control sera was used. During such a period, the regression 
coefficient for the change in the level of a control serum over time (months) was 
20 
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calculated with regression analysis. If one or more of the sera had a statistically significant 
regression coefficient, the null hypothesis that there was no laboratory drift was rejected. 
Correction was made throughout that period with the average regression coefficient of the 
two or three control sera. If only one out of three regression coefficients was statistically 
significant, correction was still based on the mean of the three regression coefficients. For 
example, if the mean correction factor was -0.01 mmol/üter/month over a certain period, 
0.01 mmol/Uter was subtracted from all cholesterol values of the respondents in month 1, 
0.02 mmol/liter was subtracted in month 2, etc. During the Consultation Bureau Heart 
Project the magnitude of the correction factor was -0.022 mmol/üter/month between 
October '74 and April '75; -0.017 mmol/Uter/month between June '75 and January '77; -
0.0051 mmol/liter/month between February '77 and February '78; and -0.0054 
mmol/liter/month between March '78 and May '79. No correction was necessary between 
June '79 and December '80. The total study period of the RIFOH Project was also divided 
into five periods, because of different combinations of control sera. The correction factor 
was -0.0195 mmol/Uter/month between July 1981 and July 1982; 0.0049 mmol/Uter/month 
between August 1982 and June 1983; and 0.009 mmol/Uter/month between July 1983 and 
March 1984. Between April 1984 and May 1985, no correction was necessary, and 
between June 1985 and December 1986, the correction factor amounted to -0.0016 
mmol/Uter/month. 
During the Consultation Bureau Heart Project, cholesterol was determined according to 
a direct Liebermann-Burchard method as described by Huang et al.4 At the beginning of 
the RIFOH Project in 1981 the laboratory switched from this method to an enzymatic 
method described by Katterman et al..5 After a test period of 2 months, cholesterol was 
measured for 4 months in more than 5,000 serum samples using both the Huang and the 
enzymatic methods. The equation for conversion from Huang to enzymatic values was 
estimated with regression analysis, as foUows: 
total cholesterol (enzymatic) = 1.004 * total cholesterol (Huang) - 0.299 mmol/Uter. 
AH cholesterol values of the Consultation Bureau Heart Project reported in this paper were 
converted to enzymatic values with this equation. This was done because the prevalence 
of hypercholesterolemia was analyzed according to the criteria of the Netherlands 
Cholesterol Consensus.6 These criteria are based on enzymatically determined cholesterol 
values. According to this consensus, total cholesterol values below 5.0 mmol/Uter (194 
mg/dl) are considered "ideal"; values between 6.50 and 7.99 mmol/Uter (251-309 mg/dl) 
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are considered "moderately elevated"; and values of 8.0 mmol/liter or more 310 mg/dl) 
are considered "highly elevated". 
Statistical Methods 
Analyses were carried out on a personal computer using the Statistical Package for the 
Social Sciences for personal computers, SPSS/PC+, version 2.O.7 Regression analyses were 
carried out with time (months) as the independent variable and total cholesterol as 
dependent variable. Because regression analysis with 80,000 respondents is very time 
consuming on a personal computer, weighted regression analyses were performed using 
monthly means. Both methods give exactly the same results. Adjustments for age and 
laboratory drift were made on an individual basis, adjustment for town was done by 
analysis of covariance. Trends in the mean age of the study population across the study 
period or changes in the cholesterol determination level of the laboratory could cause an 
artificial time trend. To exclude age effects, the relation between age and total cholesterol 
was quantified in a regression analysis. This regression coefficient was used to extrapolate 
every individual's cholesterol value to what the value would be if that person were 40 
years of age (Consultation Bureau Heart Project) or 35 years of age (RJPOH Project). To 
exclude laboratory drift effects, the data of the measurements of the control sera were 
used, and each individual's cholesterol value was adjusted for laboratory drift as described 
above under "Cholesterol determination". There were differences in the mean cholesterol 
level between towns. During the study period, the number of respondents per town 
differed. An increasing number of respondents from a town with the lowest mean 
cholesterol level could cause an artificially decreasing time trend. Therefore, dummy 
variables for town were included in all regression models, Amsterdam being the reference. 
Because the trend could differ between towns, a test was performed to determine whether 
a calculation of an overall regression coefficient for the towns together was justified. This 
was done by comparing the total variance explained by calculating separate regression 
equations for each town with the variance explained by calculating an overall regression 
equation with town included as a dummy variable.8 Fitting separate regression equations 
per town did not significantly increase the explained variance, both for the Consultation 
Bureau Heart Project and the RIFOH Project. Therefore, overall regression equations with 
town included in the model as a dummy variable were used. Because the data of the 
Consultation Bureau Heart Project indicated a decrease followed by an increase, a test was 
performed to determine whether a V-shaped regression line should be fitted. This was 
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done by comparing the variance explained by a V-shaped regression line with the variance 
explained by a straight regression line. The V-shaped line significantly increased the 
explained variance. The "breakpoint" in the line was determined by optimizing the 
explained variance. The analysis was performed with two time variables: one for the total 
period (Bj) and one for the period after the breakpoint (Bj). The change in cholesterol 
across the first period (up to the breakpoint) is given by B„ the change across the second 
period (after the breakpoint) is given by B1+B2. For the RJFOH Project, no increase in 
explained variance was achieved by allowing an extra time variable; therefore, a straight 
regression line was fitted. 
All tables presented here contain crude data, data adjusted for age and town and data 
adjusted for age, town, and laboratory drift. In the text of this paper, however, only data 
adjusted for age, town, and laboratory drift are discussed. 
Results 
Consultation Bureau Heart Project (1974-1980) 
Table 1 gives mean total cholesterol levels per year for men and women in the four towns. 
After adjustment for age, town and laboratory drift, a statistically significant decrease in 
mean total cholesterol of 0.10 mmol/liter (4 mg/dl) per year was observed in men from 
October 1974 until December 1977; between January 1978 and December 1980, a 
statistically significant increase of 0.09 mmol/liter (4 mg/dl) per year was observed (table 
2, figure 1). In women a statistically significant decrease in mean total cholesterol of 0.08 
mmol/liter (3 mg/dl) per year was observed until August 1977. This decline was followed 
by an increase of 0.06 mmol/liter (2 mg/dl) per year from September 1977 to December 
1980 (table 2, figure 1). Across the entire study period, a net decrease in mean cholesterol 
levels of 0.07 mmol/liter (3 mg/dl) in men and 0.03 mmol/liter (1 mg/dl) in women was 
observed. 
The decrease in mean total cholesterol followed by an increase was also reflected in the 
prevalence of moderately and highly elevated cholesterol values, according to the criteria 
of the Netherlands Cholesterol Consensus. Regression coefficients for changes in the 
prevalence of hypercholesterolemia are given in table 2. The percentage of distribution per 
year for the four serum cholesterol categories according to the Netherlands Cholesterol 
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Consensus is given in table 3 for men and women. For comparison, the distribution 
according to the US National Cholesterol Education Program9 is given in table 3 as well. 
Table 2 shows a statistically significant decline of 2.1 percentage points per year in the 
prevalence of moderately elevated cholesterol values (6.50-7.99 mmol/liter, 251-309 
mg/dl) in men until December 1977. In women, this decline was 1.8 percentage points per 
year until August 1977. This decrease was followed by an increase of 1.4 percentage 
points per year in men and of 1.0 percentage points per year in women until December 
1980. The prevalence of highly elevated cholesterol values (£ 8.0 mmol/liter, or S310 
mg/dl) showed a statistically significant decrease in men of 0.7 percentage points per year, 
followed by an increase of 0.5 percentage point per year until December 1980. 
Table 1. Mean total cholesterol (mmol/lf adjusted for age and laboratory drift in men 
and women aged 37-43 years: Findings of the Consultation Bureau Heart Project, the 
Netherlands, 1974-1980 
1974" 1975° 1976 1977 1978 1979 1980 N 
Men 
Amsterdam 5.56 5.63 5.49 5.59 5.64 3,478 
Doetinchem 5.67 5.50 5.37 5.35 5.34 5.42 1,818 
Maastricht 5.55 5.51 5.44 5.53 5.77 3,672 
Tilburg 5.88 5.71 5.57 5.48 5.55 5.55 5.71 5,163 
Total mean 5.81 5.66 5.53 5.51 5.47 5.55 5.70 14,131 
S.D. 1.14 1.11 1.13 1.05 1.03 1.06 1.10 
Women 
Amsterdam 5.16 5.20 5.17 5.22 5.27 4,180 
Doetinchem 5.36 4.99 4.91 4.95 4.98 4.89 1,999 
Maastricht 5.06 5.13 5.02 5.17 5.33 3,796 
Tilburg 5.35 5.21 5.15 5.12 5.12 5.22 5.28 5,372 
Total mean 5.36 5.16 5.10 5.13 5.08 5.19 5.29 15,347 
S.D. 0.99 1.01 1.00 0.94 0.95 0.96 1.00 
a: 1 mmol/1 = 38.67 mg/dl 
b : In 1974 and 1975 the Consultation Bureau Heart Project was only 
carried out in Doetinchem and Tilburg 
c : In 1980 no respondents aged 37-43 were examined in Doetinchem 
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Table 2. Regression coefficients ifif for the relation between total cholesterol and time, 
and the net change across the entire study period for men and women aged 37-43 years: 
Findings from the Consultation Bureau Heart Project, the Netherlands, 1974-1980 
Crude Adjusted" Adjusted0 
Men (N=14,128) 
Mean 
Intercept4 5.91 5.95 5.77 
B (Oct '74-Dec '77) -0.13*** -0.13*** -0.10*** 
B (Jan '78-Dec '80) +0.08*** +0.05** +0.09*** 
Net change Oct '74-Dec '80' -0.19 -0.28 -0.07 
Moderately elevated (6.50 - 7.99 mmol/1) 
Intercept 24.07 24.00 20.24 
B (Oct '74-Dec '77) -2.89*** -2.65*** -2.08*** 
B (Jan *78-Dec '80) +1.38* +0.70 +1.37** 
Net change Oct '74-Dec '80 -5.27 -6.49 -2.67 
Highly elevated (^ 8.0 mmol/1) 
Intercept 4.18 4.59 3.64 
B (Oct '74-Dec '77) -0.76*** -0.87*** -0.69*** 
B (Jan '78-Dec '80) +0.33 +0.34 +0.53** 
Net change Oct '74-Dec '80 -1.49 -1.80 -0.66 
Women (N=15,381) 
Mean 
Intercept 5.41 5.45 5.29 
B (Oct '74-Aug '77) -0.10*** -0.10*** -0.08*** 
B (Sep '77-Dec *80) +0.05** +0.02 +0.06*** 
Net change Oct '74-Dec '80 -0.12 -0.22 -0.03 
Moderately elevated (6.50 - 7.99 mmol/1) 
Intercept 12.72 13.48 11.10 
B (Oct *74-Aug '77) -1.99*** -2.22*** -1.83*** 
B (Sep '77-Dec '80) +0.92* +0.48 +1.03*** 
Net change Oct '74-Dec '80 -2.76 -4.87 -1.90 
Highly elevated (S 8.0 mmol/1) 
Intercept 1.63 1.60 1.28 
B (Oct '74-Aug '77) -0.31* -0.25* -0.19 
B (Sep '77-Dec *80) +0.20* +0.05 +0.11 
Net change Oct '74-Dec '80 -0.23 -0.56 -0.19 
a: B in mmol/1 per year for mean cholesterol and in percent per year for changes in prevalence of 
moderately/highly elevated values; 1 mmol/1 = 38.67 mg/dl 
b: Adjusted for town and age 
c: Adjusted for town, age and laboratory effects 
d: Intercept is the weighted average of each town's intercept, weighted by the sample size from the 
town 
e: calculated as the predicted value in the first month minus the predicted value in the last month, 
based on the regression equation 
*: p < 0.05 , **: p < 0.01 , ***: p < 0.001 
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Table 3. Percentage distribution of cholesterol categories according to the Cholesterol 
Consensus of the Netherlands and of the United States for men and women aged 37-43 
years: Findings of the Consultation Bureau Heart Project, the Netherlands, 1974-1980° 
Total cholesterol 
(mmol/l)b 1974 1975 1976 1977 1978 1979 1980 
Men 
N 449 
Netherlands Consensus 
< 5.0 24.5 
5.0 - 6.49 49.2 
6.5 - 7.99 22.7 
>= 8.0 3.6 
American Consensus 
< 5.17 29.2 
5.17 - 6.19 36.7 
>= 6.20 34.1 
Women 
N 511 
Netherlands Consensus 
< 5.0 39.5 
5.0 - 6.49 48.3 
6.5-7.99 11.4 
>= 8.0 0.8 
American Consensus 
< 5.17 45.2 
5.17 - 6.19 37.4 
>= 6.20 17.4 
1070 3370 2968 
29.4 33.9 33.2 
48.8 47.8 50.4 
19.3 16.0 14.6 
2.5 2.3 1.9 
34.3 39.8 39.8 
36.4 35.2 37.0 
29.3 25.0 23.2 
1171 3457 3362 
48.0 49.4 48.3 
42.8 42.5 44.1 
7.9 7.1 7.0 
1.3 1.0 0.7 
55.5 56.9 56.1 
30.0 30.6 31.3 
14.5 12.5 12.6 
2801 1736 1737 
33.5 31.6 26.1 
51.2 50.9 52.2 
13.8 15.6 18.7 
1.5 2.0 3.0 
40.7 37.5 32.1 
37.1 37.9 37.9 
22.2 24.6 30.0 
2982 1946 1918 
50.5 44.8 41.0 
42.8 46.7 48.2 
6.1 7.5 9.5 
0.6 1.0 1.2 
57.2 53.4 48.0 
31.7 33.3 35.7 
11.1 13.3 16.3 
a: based on age and laboratory drift adjusted cholesterol values 
b: 1 mmol/l = 38.67 mg/dl 
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total cholesterol (mmol/1) 
1974 1975 1976 1977 1978 1979 1980 
year 
•*• Crude + Age adjusted Age & lab adjusted * Regression line 
Figure 1. Crude and adjusted mean serum total cholesterol in men and women aged 37-43 over 
the period 1974-1980. The Consultation Bureau Heart Project, The Netherlands. 
In women, a decrease of 0.2 percentage points per year was observed until August 1977, 
followed by an increase of 0.1 percentage points per year until December 1980; this was 
not statistically significant. Across the entire study period, the net decrease in the 
prevalence of moderately elevated cholesterol levels was 2.7 percentage points in men and 
1.9 percentage points in women. The net decrease in the prevalence of highly elevated 
cholesterol values was 0.7 percentage points in men and 0.2 percentage points in women. 
RIFOH Project (1981-1986) 
Mean total cholesterol levels per year for the five towns are given in table 4. Statistically 
significant changes were seen in all cholesterol parameters (table 5, figure 2). After 
adjusting for age, town, and laboratory drift, the changes became smaller, but remained 
statistically significant, mean total cholesterol decreasing by 0.04 mmol/liter (1.5 mg/dl) 
per year. The total decline in mean cholesterol level across the study period amounted to 
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0.20 mmol/liter (8 mg/dl). The prevalence of cholesterol values between 6.50 and 7.99 
mmol/liter (251-309 mg/dl) decreased significantly by 0.8 percentage points per year. The 
prevalence of cholesterol values of 8.0 mmol/liter or more (£310 mg/dl) decreased by 0.2 
percentage points per year. The total decline in the prevalence of moderately and highly 
elevated cholesterol levels over the entire study period was 4.4 and 1.0 percentage points 
respectively. 
Table 4. Mean total cholesterol (mmol/lf adjusted for age and laboratory drift in men 
aged 33-37: Findings of the RIFOH Project, the Netherlands, 1981-1986 
1981 1982 1983 1984 1985 1986 N 
Amsterdam 5.68 5.66 5.63 5.52 5.46 5.51 21,622 
Doetinchem 5.66 5.64 5.61 5.55 5.53 5.54 13,411 
Leiden 5.59 5.54 5.59 5.51 5.49 5.40 14,151 
Maastricht 5.66 5.67 5.56 5.54 5.54 5.56 16,345 
Tilburg 5.63 5.65 5.63 5.56 5.51 5.55 15,138 
Total mean 5.64 5.64 5.61 5.53 5.50 5.52 80,667 
S.D. 1.10 1.13 1.12 1.08 1.10 1.08 
a: 1 mmol/) = 38.67mg/dl 
Table 6 gives the percentage of distribution per year for the different serum cholesterol 
categories according to the Netherlands Cholesterol Consensus and, for comparison, 
according to the US National Cholesterol Education Program. The percentage of 
distribution and the mean total cholesterol levels per year suggest that cholesterol levels 
were stable over the period from 1981 to 1983. In fact, during the first 2 years of the 
RIFOH Project, month-to-month variation was greater than it was during the rest of the 
study period. When separate regression equations were fitted over the first 2 years 
(1981/1982) and over the next 4 years (1983-1986), a non-significant regression coefficient 
was found for the first period and a statistically significant negative regression coefficient 
was found for the second. However, the separate regression equations did not significantly 
increase the explained variance (F = 1.46, p > 0.10). Therefore, one regression coefficient 
encompassing the entire period was calculated. 
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Table 5. Regression coefficients {fit for the reunion between total cholesterol and time, 
and the total change across the study period, for men aged 33-37 years. Findings from 
the RIFOH Project, The Netherlands, 1981-1986 
Mean total cholesterol 
intercept4 
6 
total change '81-*86 
% Moderately elevated (6.50-7.99 mmol/1) 
intercept 
B 
total change '81-'86 
% Highly elevated (à 8.0 mmol/1) 
intercept 
B 
total change '81-'86 
Crude Adjustedb Adjusted0 
5.72 5.72 5.67 
-0.05*** -0.05*** -0.04*** 
-0.27 -0.27 -0.20 
19.99 19.18 18.13 
-1.12*** -1.12*** -0.84*** 
-5.89 -5.87 -4.42 
3.45 3.25 3.04 
-0.27*** -0.25*** -0.20*** 
-1.43 -1.34 -1.04 
a: B in mmol/1 per year for mean cholesterol and in percent per year for changes in prevalence of 
moderately/highly elevated values; 1 mmol/1 = 38.67 mg/dl 
b: Adjusted for town and age 
c: Adjusted for town, age and laboratory effects 
d: Intercept is the weighted average of each town's intercept, weighted by the sample size from the 
town 
***: p < 0.001 
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Table 6. Percentage of distribution of cholesterol categories according to the Cholesterol 
Consensus of the Netherlands and of the United States for men aged 33-37 years: 
Findings of the RIFOH Project, the Netherlands, 1981-1986' 
Total cholesterol 
(mmol/l)b 1981 1982 1983 1984 1985 1986 
N 8,083 12,251 17,608 14,860 15,873 11,992 
Netherlands Consensus 
<5.0 29.6 30.3 30.7 33.5 34.3 33.6 
5.0-6.49 50.9 49.1 50.3 49.3 48.8 50.2 
6.5-7.99 16.7 17.7 16.2 15.0 14.6 14.1 
>= 8.0 2.7 2.8 2.8 2.2 2.2 2.1 
American Consensus 
< 5.17 36.1 35.9 37.2 39.8 40.8 39.8 
5.17-6.19 36.7 36.0 36.2 36.0 35.6 36.9 
>=6.20 27.2 28.2 26.6 24.3 23.6 23.3 
a: based on age and laboratory drift adjusted cholesterol values 
b: 1 mmol/l = 38.67 mg/dl 
total cholesterol (mmol/l) 
year 
Crude + Age adjusted •* Age & lab adjusted ••• Regression line (1) 
Figure 2. Crude and adjusted mean serum total cholesterol per year in men aged 33-
37 over the period 1981-1986. The RIFOH Project, The Netherlands. 
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Discussion 
An advantage of the present study was the availability of continuous cholesterol 
measurements across the study period from large numbers of respondents. This enabled 
us to describe changes in cholesterol level in detail for a 13-year period. In analyzing a 
long-term trend in serum total cholesterol level, the accuracy of the cholesterol data is 
very important. In our study, cholesterol measurements were made in a single laboratory, 
which serves as the lipid reference laboratory for the Netherlands, throughout the study 
period. Although the criteria for the World Health Organization were met throughout the 
study period, adjustments were made for changes in the determination level of the 
laboratory. This was done because even when a laboratory stays within the range allowed 
by the World Health Organization, considerable differences in determination level can 
occur.10 Because the changes in cholesterol level over time were small, even a small 
laboratory drift would cause a substantial error in the trend analysis. Our results show that, 
in certain years, (for example, 1976 and 1982), cholesterol levels with and without 
adjustment for laboratory drift differed considerably. This illustrates the necessity of 
adjusting for the possible effects of laboratory drift when comparing cholesterol levels 
over time. 
From 1974 to 1980, a decrease in the mean total cholesterol level followed by an increase 
was observed in men and women (mean age, 40 years). This resulted in a net decrease 
across this period of 0.07 mmol/liter (3 mg/dl) in men and 0.03 mmol/1 (1 mg/dl) in 
women. From 1981 to 1986, a decrease of 0.20 mmol/liter (8 mg/dl) in the mean total 
cholesterol level was observed in men with a mean age of 35 years. Unfortunately, during 
this period, no information was obtained about cholesterol levels in women. However, the 
data of the Consultation Bureau Heart Project suggest that trends in men and women were 
in the same direction, although the changes in women were somewhat smaller than those 
in men. 
With respect to the implications for public health, it is important to know whether the 
trend observed in relatively young adults can be generalized to the total population. Data 
from the Zutphen Study11, the Dutch contribution to the Seven Countries Study, were used 
to analyze changes in mean total cholesterol levels in men of other age groups. The 
Zutphen Study is a longitudinal study of risk factors for cardiovascular diseases begun in 
1960 with 872 men aged 40 to 59 years. In 1960, the average serum total cholesterol level 
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of these men was 6.09 mmol/liter (236 mg/dl). In 1985, a new small random sample of 
men aged 40 to 59 years was examined in Zutphen. The mean total cholesterol level of 
this new sample was compared with that of the original cohort of the Zutphen Study. The 
mean total cholesterol level of the men aged 40 to 59 years in 1985 was 0.2 mmol/hter 
(8 mg/dl) higher than that of the men aged 40 to 59 years in 1960. Men aged 65 to 69 
years were examined in the Zutphen Study in 1970, 1977-1978, and 1985. Mean total 
cholesterol levels were 6.05 mmol/liter in 1970, 5.91 mmol/liter in 1977-1978, and 6.34 
mmol/liter in 1985 (234, 229, and 245 mg/dl, respectively). From these data, it can be 
concluded that the U-shaped relation between serum cholesterol and time observed in the 
present study in 40-year-old men between 1974 and 1980 was also present in men aged 
65 to 69 years examined in Zutphen in 1970, 1977-78 and 1985. The results from the 
present study for men aged 35 years suggested a decline in serum total cholesterol 
between 1981 and 1986. The data for men aged 40 to 59 years and 65-69 examined in 
1985 in Zutphen, however, did not indicate a decline, in serum total cholesterol in these 
age groups, but an increase, suggesting that the decline in serum total cholesterol in the 
1980s is restricted to young adults. 
At present, a number of other countries are experiencing favorable changes in mortality 
from coronary heart disease. Changes in serum total cholesterol levels in different 
countries during the last decades are, however, different in magnitude. At the beginning 
of the Seven Countries Study in the late 1950s and early 1960s, average serum total 
cholesterol levels in middle-aged men in the United States and the Netherlands were 
comparable (about 6.1 mmol/Uter, or 235 mg/dl).12 Today, the average serum total 
cholesterol level in Dutch adults is about 0.5 mmol/liter (19 mg/dl) higher than that of 
their counterparts in the United States. 1 3 1 4 This is the result of a decline in serum total 
cholesterol levels during the last decades in the United States. This decline was illustrated 
with data of three national surveys in men and women aged 20 to 74 years (the National 
Health Examination Survey and the first and second National Health and Nutrition 
Examination Surveys).15 A decrease in mean serum total cholesterol of 0.16 mmol/liter (6 
mg/dl) in men and 0.21 mmol/liter (8 mg/dl) in women was observed between 1960 and 
1980. In men, the largest decrease was seen in the age group of 35 to 44 years; in women, 
the decrease was largest in the oldest age group, 65 to 74 years. The Minnesota Heart 
Survey compared the total cholesterol values of men and women in 1973-1974 with values 
in 1985-1987.16 In all age strata, a decline in the mean total cholesterol level was 
observed, averaging 0.21 mmol/liter (8 mg/dl) for men and 0.28 mmol/liter (11 mg/dl) for 
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women. In Finland, where serum total cholesterol levels and mortality from coronary heart 
disease are high, mean serum total cholesterol levels in men and women aged 30 to 59 
years declined by 0.8 mmol/Uter (31 mg/dl) and 0.6 mmol/liter (23 mg/dl), respectively, 
between 1972 and 1982." In the Nine Communities Study in Italy, no change in mean 
serum total cholesterol in men and women aged 20 to 59 years was found between 1978 
and 1983.18 The change in mean total cholesterol level observed in the present study 
between 1981 and 1986 amounted to 3% to 4%. A decrease in mean total cholesterol level 
of a few percent can be important with respect to mortality from coronary heart disease. 
It is known from intervention studies that lowering total cholesterol is associated with a 
reduction of the incidence of and mortality from coronary heart disease. It is estimated that 
a reduction of 1% in serum total cholesterol will result in a reduction of 2% to 3% in 
coronary heart disease.1 9 , 2 0 However, in observational studies like the present one, 
quantification of the effect of the observed change in total cholesterol level on the 
observed change in mortality pattern remains difficult. First, the trend in total cholesterol 
may differ according to age. The Dutch data suggest that a decreasing trend in total 
cholesterol is limited to young adults. Therefore, relations between changes in serum total 
cholesterol and mortality from coronary heart disease should not be analyzed for the total 
population but for specific age strata. Second, there is a lag between the occurrence of a 
decrease in mean serum total cholesterol level and the resulting decline in mortality from 
coronary heart disease. A decrease in the total cholesterol level in the population has an 
effect on mortality years later.19"21 Third, other risk factors might also change. In the 
present study substantial changes in cigarette smoking from 1974 to 1986 were observed, 
while changes in blood pressure and body mass index (weight/height2) were small 
(unpublished results, Consultation Bureau Heart Project and RTFOH Project).22 
A recent investigation in the Netherlands compared mortality from coronary heart disease 
and hospital admission rates for acute ischemic heart disease for the period from 1971 to 
1973 with those from 1985 to 1987.23 For all 10-year age strata of subjects S 30 years of 
age, mortality rates for ischemic heart disease had declined substantially (15-50%). The 
patterns for men and women were quite similar. However, hospital admission rates for age 
strata of > 50 years increased, while hospital admission rates for the age strata of 30 to 
39 and 40 to 49 years decreased. This is an indication that reduction of mortality in the 
older age strata may be caused by improved medical care, while in the younger age strata, 
an effect of primary prevention also plays a role. This is in accordance with our finding 
of a decline in total cholesterol level in relatively young adults in the RTFOH Project, and 
33 
Chapter 2 
an indication of an increase in total cholesterol levels in middle-aged and elderly men in 
the Zutphen Study. 
From the present study, it can be concluded that serum total cholesterol levels in young 
adults in the Netherlands are declining, especially in the 1980s. Data from other Dutch 
investigations (Kromhout D, unpublished results) indicate that this decline is limited to 
younger age groups.23 Detailed information about trends in serum total cholesterol levels 
in different age groups is, however, lacking. Because mean total cholesterol levels and the 
prevalence of hypercholesterolemia in the Netherlands are still high, a further lowering of 
average total cholesterol levels in the Dutch population seems a useful tool for enhancing 
the decline in morbidity and mortality from coronary heart disease.24 
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3 Trends in total and HDL cholesterol levels in the Netherlands from 1987 to 1992 
Abstract 
Background. To gain insight into the prevalence of and trends in plasma cholesterol levels 
in the general population of the Netherlands, a monitoring project was carried out from 
1987 to 1992. 
Methods. Each year a random sample of men and women aged 20-59 years in three towns 
in the Netherlands was invited to participate in the study. Overall response rate was 50% 
for men and 57% for women and a total of almost 42,000 men and women participated. 
Total (TC) and HDL cholesterol (HDL-C) was measured and the non-HDL-C/HDL-C ratio 
was computed. Data were age-standardized to the Dutch population distribution aged 20-
59 years. 
Results. The prevalence of hypercholesterolemia (TC > 6.5 mmol/1) in men ranged from 
5% in the youngest (20-29 years) to 29% in the oldest age group (50-59 years), and from 
4% to 38% in women. Low HDL-C levels (< 0.9 mmol/1) in men ranged from 15% in the 
youngest to 26% in the oldest age group, and in women from 4% in the youngest to 7% 
in the oldest age group. The lipid profile of those with a higher educational level was 
more favorable than that of the less educated. From 1987 to 1992, in men, TC decreased 
by 0.12 mmol/1, HDL-C decreased by 0.07 mmol/1 and the non-HDL-C/HDL-C ratio 
increased by 0.22. In women no statistically significant changes were observed. Changes 
over time did not differ according to age and educational level. 
Conclusion. Prevalence of hypercholesterolemia is still high in the Netherlands. During 
the period 1987-1992 lipid profile worsened in men and remained stable in women. 
Published as: 
Verschuren WMM, Boerma GJM, Kromhout D. Total and HDL cholesterol in the Netherlands: 1987-
1992. Levels and changes over time in relation to age, gender and educational level. Int J Epidemiol 
1994;23:948-56. 
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Introduction 
In recent decades both longitudinal and intervention studies have shown that plasma total 
cholesterol (TC) is an important risk factor for coronary heart disease (CHD).M More 
recently, evidence has accumulated that a low high density lipoprotein level (HDL-C) is 
an independent risk factor for coronary heart disease.5"6 Coronary heart disease mortality 
in the Netherlands has declined during the last two decades, but it is still the most 
important cause of death.7 Detailed information on the distribution of plasma total and 
HDL cholesterol levels and other risk factors in (subgroups of) the Dutch population was 
not available. For primary prevention it is important to know whether changes in CHD 
risk factors are taking place and whether high-risk groups can be identified in the general 
population. Therefore, in 1987 a monitoring project was started to gain insight into the 
distribution of the major CHD risk factors and changes in these risk factors. From 1987 
to 1992 almost 42,000 men and women aged 20-59 years participated in this project In 
this paper the data on plasma total and HDL cholesterol will be reported. 
Methods 
Study population 
The Monitoring Project on Cardiovascular Disease Risk Factors has been carried out in 
the Netherlands from 1987 to 1992.8 The aim of this project was to monitor the major risk 
factors for cardiovascular diseases, e.g. plasma cholesterol, blood pressure and smoking 
habits. The project was carried out at the municipal health services in three towns in the 
Netherlands: Amsterdam, the capital city in the western part of the country with about 
700,000 inhabitants; Doetinchem, a small town in a rural area in the eastern part of the 
country with about 40,000 inhabitants, and Maastricht, a town in the south with about 
100,000 inhabitants. Each year a new random sample of men and women aged 20-59 
years was selected from the municipal registry of each town and invited to participate in 
the study. The overall response rate was 50% for men and 57% for women. In the years 
1987-1992 a total of almost 42,000 men and women were examined. 
To examine to what extent selection bias had taken place, a non-response survey was 
conducted. For this survey all non-respondents in the period August-December 1991 were 
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selected.9 If possible a telephone interview was conducted, if no telephone number could 
be obtained a questionnaire was mailed that was identical to the one used in the telephone 
interviews. Because information on biological risk factors such as plasma cholesterol could 
not be obtained from the non-respondents, educational level was considered an important 
indicator variable.10"12 
Data collection 
The examination included measurement of weight, height and blood pressure.8 A total of 
30 ml blood was drawn (non-fasting). A questionnaire was filled out providing information 
about demographic variables, education, presence and family history of cardiovascular 
diseases, presence of a number of other chronic diseases, use of medication, smoking 
habits, selected dietary habits (by means of a short semi-quantitative food frequency 
questionnaire), physical activity, psycho-social factors and (for women) reproductive 
history. Education was assessed at seven levels ranging from primary education or less to 
university education. For the present analyses education was collapsed into three 
categories: low (intermediate secondary education or less), medium (intermediate 
vocational or higher secondary education) or high (higher vocational or university 
education). 
Cholesterol determination 
Total and HDL cholesterol determinations were performed at the Clinical Chemistry 
Laboratory of the University Hospital 'Dijkzigt' in Rotterdam. This laboratory takes part 
in the standardization program of the World Health Organization (WHO) through the 
WHO Regional Lipid Center for Europe in Prague, Czechoslovakia and the Centers for 
Disease Control (CDC), Atlanta, USA. It is the Lipid Reference Laboratory for 
standardized cholesterol determinations in the Netherlands and also serves as an 
international member of the Cholesterol Reference Method Laboratories Network in the 
USA.13 
Plasma total cholesterol was determined enzyrnatically using a Boehringer testkit.14 HDL 
lipoproteins were isolated by precipitation of the apo-B-conlaining lipoproteins with 
magnesium phosphotungstate.15 Subsequently the cholesterol content of the HDL 
lipoproteins was determined, in the same way as total cholesterol. During the entire study 
period the quality control standards of the WHO were met. Furthermore, the internal 
quality control data of the laboratory were analyzed to detect whether, within the range 
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allowed by the WHO criteria, there had been laboratory 'drifts' that would influence the 
observed trend in cholesterol. If this was the case, the cholesterol values had to be 
corrected, as was done in earlier projects.16 
Small adjustments were necessary over three periods. In two periods there had been a 
problem with calibration of the enzymatic method to the Abell-Kendal method, which is 
considered to be the 'gold standard'. From May 1990 to March 1991 a calibration error 
resulted in an overestimation of the samples by 0.92%. Over this period all cholesterol 
values were divided by 1.0092. From April 1991 to December 1992 there was a drift in 
the calibration serum of 0.05% per month. Therefore, over this period the cholesterol 
values were multiplied by (1.0005)m o n t h, where 'month' equals 1 for April 1991,2 for May 
1991,... and 21 for December 1992. 
Quality control sera at a low (± 1 mmol/1), medium (± 4.5 mmol/1) and high level (± 7 
mmol/1) were, as a rule, included in all series of measurements. A shift in the values of 
the control sera indicates a shift in the results of the enzymatic method. With regression 
analysis the change in the level of a control serum over the study period was quantified. 
In the period September 1990 to March 1991 (after adjustment for the calibration error) 
the method shifted towards a lower level by 0.3% per month. Therefore, cholesterol values 
in this period are multiplied by (1.003)m o n , h, where month equals 1 for September 1990 and 
7 for March 1991. The coefficients of variation for the quality control sera at the low, 
medium and high level were 2.6%, 1.6% and 2.3% respectively, based on about 3,000 
measurements for each level of the control serum. 
Cutoff point for hypercholesterolemia was 6.5 mmol/1 (250 mg/dl), according to the 
Netherlands Cholesterol Consensus.17 For low HDL cholesterol the internationally used 
cutoff point of 0.9 mmol/1 (35 mg/dl) was used.18 The non-HDL-C/HDL-C ratio was 
computed, but no internationally used cutoff points are available for this parameter. 
Statistical analyses 
Compared to the Dutch population aged 20-59, in our study sample the older age groups 
were overrepresented. Therefore cholesterol levels were age-standardized to the age 
distribution of the Dutch population aged 20-59 years in 1990, by weighing age-specific 
data based on 5-year age groups. Because the primary goal of our analyses was to assess 
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changes over time, an age-standardized mean was computed for each month. 
Subsequently, monthly means were used in the analyses. 
Statistical analyses were carried out using the statistical package SAS (version 6.07) on 
a minicomputer.19 All pregnant women were excluded from the analyses. Trends over time 
were analyzed using linear regression analysis with time (month) as independent variable 
and the age-standardized monthly mean of the cholesterol parameter as dependent variable. 
Differences between age-standardized yearly means (computed as the average of the age-
standardized monthly means) were tested by analysis of variance, using the ScheffS-test 
for multiple comparisons. Differences in trends between the three study centers, between 
different age groups and between different educational strata were examined using 
interaction terms. By including interaction terms (study center*month, age group*month 
and educational level*month) in the regression models we investigated if the interaction 
terms significantly increased the explained variance (tested with an F-statistic).20 
Results 
Levels 
In table 1 the total number of people examined is presented by age, gender and 
educational level. In table 2 the observed age and gender results are presented for the total 
study period. Total cholesterol levels and the prevalence of hypercholesterolemia increased 
strongly with age in both men and women. In the age group 50-59 years mean TC levels 
in women exceeded those in men. Overall HDL-C decreased slightly with age, resulting 
in an increase of low HDL-C with age. Mean HDL-C was about 0.25 mmol/1 higher in 
women compared to men. The non-HDL-C/HDL-C ratio was lower in women at all ages. 
For all cholesterol parameters, age-adjusted levels were more favorable with increasing 
educational level. The differences between the different educational classes were larger 
in women than in men (figures la-c). 
Trends 
In table 3 age-standardized annual means and prevalences are given which, due to the 
standardization, represent the levels in the general population aged 20-59 in the 
Netherlands. Statistically significant differences between the annual means are indicated. 
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Table 1. Number of people examined in the Monitoring Project on Cardiovascular 
Disease Risk Factors 1987-1992, by 10-year age group, gender and educational status 
Educational Level 
Age Low Medium High 
Men 
20-29 1493 1416 560 
30-39 2354 1228 1435 
40-49 3435 934 1154 
50-59 3722 777 799 
Total 11004 4355 3948 
Women 
20-29 1594 1747 685 
30-39 3244 1088 1240 
40-49 4395 715 868 
50-59 5004 562 465 
Total 14237 4112 3258 
Table 2. Mean, standard deviation (SD) and prevalence of high-risk levels of total and 
HDL cholesterol and non-HDL-C/HDL-C ratio in men and women aged 20-59 by 10-
year age strata. Monitoring Project on Cardiovascular Disease Risk Factors, The 
Netherlands, 1987-1992 
Men Women 
20-29 30-39 40-49 50-59 20-29 30-39 40-49 50-59 
N 3531 5110 5622 5405 4070 5687 6062 6135 
Total cholesterol 
mean (mmol/l)a 4.75 5.35 5.82 5.98 4.87 5.03 5.50 6.23 
SD (mmol/1) 0.94 1.06 1.10 1.06 0.88 0.91 0.99 1.13 
% ä 6.5 mmol/1 4.5 13.6 24.1 29.2 4.2 6.2 14.5 37.7 
HDL cholesterol 
mean (mmol/1) 1.14 1.12 1.11 1.09 1.38 1.36 1.39 1.36 
SD (mmol/1) 0.25 0.26 0.28 0.28 0.30 0.31 0.33 0.34 
% <, 0.9 mmol/1 15.1 20.3 22.2 25.6 3.8 4.8 5.1 7.1 
non-HDL-C/HDL-•C ratio 
mean 3.37 4.06 4.56 4.82 2.68 2.90 3.21 3.88 
SD 1.37 1.77 2.02 1.85 1.03 1.21 1.40 1.60 
': 1 mmol/1 = 38.7 mg/dl 
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Men Women 
• low •medium • high education 
non-HDL/HDL ratio C 
Men Women 
I low B medium • high education 
Figure 1. Mean total cholesterol (a), HDL 
cholesterol (b), and non-HDL-C/HDL-C 
ratio (c) by educational level in men and 
women, adjusted for age. The Monitoring 
Project on Cardiovascular Disease Risk 
Factors 1987-1992. All differences between 
educational levels are statistically 
significant (p< 0.01), except the difference 
in total cholesterol between the medium and 
high educational level in men. 
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total cholesterol (mmol/1) 
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
87 I 88 I 89 I 90 I 91 I 92 
quarter year 
-""men + women 
HDL cholesterol (mmol/1) 
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 
87 I 88 I 89 I 90 I 91 I 92 
quarter year 
—men 4- women 
non-HDIVHDL ratio 
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
87 I 88 I 89 I 90 I 91 I 92 
quarter year 
— men + women 
Figure 2. Mean total 
cholesterol level (a), HDL 
cholesterol level (b) and 
non-HDL-C/HDL-C ratio (c) 
per quarter year in men and 
•women aged 20-59 in the 
period 1987-1992. Data are 
age-standardized to the age 
distribution of the Dutch 
population aged 20-59. The 
Monitoring Project on 
Cardiovascular Disease Risk 
Factors. 
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Table 3. Mean levels of total and HDL cholesterol and the non-HDL- C/HDL- C ratio and prevalence of high-risk levels of 
these per year for men and women aged 20-59 years. Data are age-standardized based on the age distribution of the Dutch 
population aged 20-59 years in the year 1990. Monitoring Project on Cardiovascular Disease Risk Factors, The 
Netherlands, 1987-1992 
Men Women 
Risk factor 1987 1988 1989 1990 1991 1992 1987 1988 1989 1990 1991 1992 
N 2979 3835 3477 3248 3515 2614 3227 4264 3924 3603 3919 3007 
Total cholesterol 
mean (mmol/l)a 5.44 5.39 5.37 5.40 5.31" 5.34 5.32 5.30 5.27 5.33 5.25 5.34 
% £ 6.5 mmol/1 17.6 16.1 16.1 16.2 14.6 14.3 14.0 13.2 12.9 13.1 11.7 14.0 
HDL cholesterol 
mean (mmol/1) 1.15 1.15 1.12 1.11° LOT* 1.11° 1.38 1.41 1.37 1.35 1.34c 1.41d 
% S 0.90 mmol/1 17.2 16.5 20.9 20.9 23.2* 22.1° 4.8 3.6 5.0 5.7 5.1 5.5 
non-HDL-C/HDL-C ratio 
mean 4.02 3.95 4.10 4.18c 4.19c 4.10c 3.06 2.98 3.07 3.16 3.15 3.03 
a : 1 mmol/1 = 38.7 mg/dl 
b : significantly different from 1987 
c: significantly different from 1988 
d: significantly different from 1991 
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Table 4. Regression coefficients for changes in cholesterol fractions over time, based 
on age-standardized data. Monitoring Project on Cardiovascular Disease Risk Factors, 
The Netherlands, 1987-1992 
Men Women 
Total cholesterol 
Mean intercept (mmol/l)a 
ß (mmol/l/year) 
95% CLb 
5.44 
-0.021*** 
(-0.032;-0.010) 
5.31 
-0.001 
(-0.014;+0.012) 
% 2: 6.5 mmol/1 intercept (%/year) 
ß (%/year) 
95% CL 
17.8 
-0.66*** 
(-1.02;-0.29) 
13.5 
-0.14 
(-0.46;+0.17) 
HDL cholesterol 
Mean intercept (mmol/1) 
ß (mmol/l/year) 
95% CL 
1.16 
-0.012*** 
(-0.016;-0.008) 
1.39 
-0.005 
(-0.012;+0.002) 
% S 0.90 mmol/1 intercept (%/year) 16.1 4.0 
B (%/year) 1.35*** 0.30* 
95% CL (+0.85;+1.84) (+0.05;+0.56) 
non-HDL-C/HDL-C ratio 
Mean intercept (mmol/1) 3.98 3.02 
B (mmol/l/year) 0.037** 0.019 
95% CL (+0.014;+0.060) (-0.002;+0.039) 
a: 1 mmol/1 = 38.7 mg/dl 
b: 95% CL = 95% confidence limits 
*: p<0.05, **: rxO.01, ***: p<0.001 
In the figures 2a-c the changes over time in TC, HDL-C and the non-HDL-C/HDL-C ratio 
in men and women are shown by plotting age-standardized means per quarter (January-
March, etc.). To establish a consistent upward or downward trend linear regression 
analysis was used (table 4). No differences in changes over time were found between the 
three educational levels, between study centers or between 10 year age groups, with the 
exception of women aged 50-59 (in whom the decrease in TC over time was stronger than 
for other age groups). Therefore only overall results are presented. 
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In men mean TC decreased statistically significantly by 0.02 mmol/1 per year, resulting 
in an increase of hypercholesterolemia of 0.7 percentage points per year. In women no 
statistically significant changes in TC were observed. HDL-C decreased in men by 0.01 
mmol/1 per year and the prevalence of low HDL-C levels increased by 1.4 percentage 
points per year. In women the decrease in mean HDL-C was not statistically significant, 
while the increase in the prevalence of low HDL-C by 0.3 percentage points per year did 
reach statistical significance. The non-HDL-C/HDL-C ratio increased in both men and 
women, although only in men statistically significantly. 
Discussion 
An advantage of the present study was the continuous measurement of plasma cholesterol 
levels in a standardized laboratory in a large number of persons during a 6-year period. 
The figures show that the range of variation in mean cholesterol levels per quarter can be 
of the order of magnitude of 0.1-0.2 mmol/1, even though each mean value is based on 
about 1,000 persons. Therefore, comparing just two points in time can lead to spurious 
conclusions. 
The overall response rate in our study was about 50% in men and about 57% in women. 
To assess possible selection bias that could have taken place, a non-response survey was 
carried out, in which education was considered an important variable for assessment of 
bias with regard to biological risk factors. In men the proportion of low, medium and high 
educational level was 56%, 23% and 22% respectively among respondents, and 52%, 27% 
and 21% respectively among non-respondents. For women the proportion of low, medium 
and high education was 63%, 20% and 17% respectively among respondents and 57%, 
26% and 17% respectively among non-respondents.9 Although we have no information on 
actual cholesterol levels of the non-respondents, the distribution with respect to education 
is an indication that the respondents of our study seem to be reasonably representative of 
the total group invited to participate in the study. It must also be noted that the non-
response survey revealed that about 10% of the addresses obtained from the municipal 
registries were outdated, thus contributing substantially to the observed non-response in 
our study. 
During the study the response rate dropped by about 5%. Because this percentage is small 
compared to the total non-response, and because the difference between respondents and 
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non-respondents in educational level was not striking, it seems unlikely that a decrease in 
response rate of this magnitude can explain the observed trends. 
Levels 
The results of the present study showed that, especially in middle age, 
hypercholesterolemia is a common risk factor in the Netherlands. When our data were 
standardized to the general population aged 20-59 years, about 1 out of 6 men and 1 out 
of 8 women had hypercholesterolemia. When our data are compared with data from other 
industrialized countries (obtained in the MONICA Project at the beginning of the 1980s), 
it shows that TC levels in Scandinavia (Denmark, Sweden, Finland and Iceland) and some 
eastern European countries (former Soviet Union, East Germany and Czechoslovakia) are 
on average about 0.5 mmol/1 higher than in the Netherlands.21 Levels in Spain, Italy, 
Canada and Australia are comparable to those in the Netherlands and TC levels in the 
United States are about 0.5 mmol/1 lower.21 This shows that in other industrialized 
countries (except for the United States) hypercholesterolemia is as prevalent or even more 
prevalent than in the Netherlands. 
Mean HDL-C levels in men were about 0.25 mmol/1 lower than in women. Consequently, 
about 1 in 5 men had low HDL-C levels compared to about 1 in 17 women. Compared 
with a recent study in 38 year old men in 6 European countries, in which HDL-C was 
measured in the same laboratory, HDL-C in Dutch men was similar to that in Polish men, 
but 0.10 to 0.15 mmol/1 lower than that in men from Sweden, Belgium and Italy.22 A 
similar study in 38 year old women showed that differences in HDL-C between women 
were less marked.23 
Trends 
In the period 1987-1992 mean TC levels declined in men by about 0.1 mmol/1 while in 
women no significant change was observed. A conclusion about the long term trend in TC 
levels in the general Dutch population is difficult, because data are scarce and concern a 
limited age range only. Previously we have analyzed data of two screening projects carried 
out between 1974-1980 (in men and women aged 37-43) and 1981-1986 (in men aged 33-
37).1 6 Between 1974 and 1980 a decrease in TC of 0.07 mmol/1 in men and 0.03 mmol/1 
in women was observed, followed by a decline of 0.2 mmol/1 in men between 1981-1986. 
Because there were indications that this decline was not generalizable to other age groups, 
it is difficult to make inferences for the general population during this period.24 So far, the 
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available data point into the direction of relatively stable TC levels over the past 17 years, 
with the exception of a decline in relatively young adult men in the early eighties, and a 
recent decline of 0.1 mmol/1 in 1991/1992 in men. 
This suggests that the marked decline in CHD mortality over the past decades, is not 
likely to be explained by changes in cholesterol levels. Of the major risk factors, the 
decline in the prevalence of cigarette smoking in the last decades probably has contributed 
most to the decline in CHD mortality. Furthermore, survival of acute myocardial infarction 
has increased, due to therapeutic improvements. When only survival rates increase without 
a decrease in the incidence of the disease the burden of illness in the population will 
increase. Unfortunately, data on the incidence of CHD are scarce. Data of a regional 
registration on the incidence of myocardial infarction did not indicate a decreasing 
incidence of CHD since the beginning of the 1970s.25 A study that compared hospital 
admission rates for acute CHD in the period 1971-1973 with that for 1985-1987 showed 
a decrease in hospital admission rates for persons below the age of 50 years, but an 
increase for those over 50 years.26 Therefore, there is no reason to diminish primary 
preventive efforts. 
In many industrialized countries efforts have been made to decrease cholesterol levels in 
the general population. In the United States a number of studies have shown that TC 
levels have decreased substantially over the last decades.27'30 Because of these changes, 
cholesterol levels in the US are now lower than in the Netherlands, while at the beginning 
of the 1960s cholesterol levels in middle-aged men in the US and the Netherlands were 
comparable.21,31 Also in Finland and Denmark TC levels decreased substantially between 
1972 and 1982, followed by a smaller or no decrease between 1982 and 1987.32"34 These 
data show that it is feasible to achieve a substantial change in cholesterol level in the 
general population. 
The decline in HDL-C in men is an unfavorable development. Data on trends in HDL-C 
in other countries and long term trend data for the Netherlands are to our knowledge not 
available. The observed changes in total and HDL cholesterol levels could not be 
explained by changes in BMI, smoking, alcohol consumption, physical activity and 
educational level over the study period. When these variables were included in the 
regression analyses the coefficients for the change in cholesterol over time hardly changed. 
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Over the study period the non-HDL-C/HDL-C ratio increased. If this ratio is interpreted 
as a measure of CHD risk that combines both the unfavorable effect of TC and the 
favorable effect of HDL, this would mean that over the total study period the lipid profile 
of Dutch men worsened, while it remained the same in Dutch women. 
The changes that occurred over the period 1987-1992 were comparable in different age, 
gender and educational strata. It could be expected that public health education about 
healthy lifestyles reaches higher educated people more easily than the less educated. 
However, also other studies have found that changes were similar in different socio-
economic strata.28 ,35 An explanation for the observed changes could be that certain lifestyle 
factors changed throughout the population. In this context, it would be interesting to 
examine changes in nutritional patterns in the Netherlands, for example with respect to 
fatty acid composition of the diet, concurrent with changes in TC levels. 
Recently, data have become available of the second National Food Consumption Survey, 
carried out in 1992. When these data were compared with the first survey carried out in 
1987/1988, it showed that consumption of saturated fat had decreased by about 2 
percentage points in both men and women.36 
In the spring of 1991 a campaign was launched to reduce fat intake in the Dutch 
population. For simplicity, it focused on a reduction in total fat intake. Evaluation of the 
campaign showed that in women the change in attitude towards products with a low 
(saturated) fat content was more pronounced than in men.3 7 These observations are 
however not compatible with the observation that the decline in TC was significant in men 
but not in women. 
The present study showed that, especially in middle age, prevalence of high TC (in men 
and women) and of low HDL-C (in men) is high in the Netherlands. Less educated 
respondents showed a more unfavorable risk profile than better educated respondents. 
Despite all the efforts of public health education over recent decades, TC levels did not 
change substantially in the Netherlands. It is disappointing to see that the most striking 
change over the past 5 years has been a decrease in HDL-C level. Based on the 
combination measure non-HDL-C/HDL-C ratio, it can be concluded that the lipid profile 
worsened in men and remained the same in women. 
Until now most primary prevention activities have been focused on TC levels. Because 
the evidence for the importance of HDL-C in the prevention of coronary heart disease is 
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increasing, lifestyle changes should be aimed at both lowering TC and increasing HDL-C. 
To achieve this, apart from dietary changes to lower TC levels, attention should be given 
to stimulating physical activity, prevention and treatment of obesity and discouraging of 
smoking. 
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4 Total and HDL cholesterol levels in premenopausal and postmenopausal women 
Abstract 
Background. In the Netherlands total cholesterol levels in women increase considerably 
around middle age. This led us to investigating the role of the menopause in levels of total 
and HDL cholesterol. 
Methods. The Netherlands Monitoring Project on Cardiovascular Disease Risk Factors was 
carried out between 1987 and 1991. To examine the effect of the menopause on 
cholesterol levels, women aged 45-54 who were either premenopausal (N=2,567) or who 
had had a naturally occurring menopause (N=1,657) were selected. 
Results. After adjustment for age, smoking and body mass index, non-smoking 
postmenopausal women were found to have a 0.45 mmol/1 higher total cholesterol level 
than non-smoking premenopausal women, while in smoking women this difference was 
0.28 mmol/1. HDL cholesterol levels were 0.04 mmol/1 higher in postmenopausal women 
compared to premenopausal women after adjustment for age, BMI, smoking, alcohol 
consumption and physical activity. No interaction with smoking was observed for HDL 
cholesterol levels. 
Conclusion. Menopause plays an important role in the marked increase in total cholesterol 
levels in middle-aged women, more so in non-smokers than in smokers. Menopause was 
associated with a small favorable effect on HDL cholesterol levels. 
Submitted as: 
Verschuren WMM, Kromhout D. Total and HDL cholesterol levels in premenopausal and 
postmenopausal women. The Netherlands Monitoring Project on Cardiovascular Disease Risk Factors. 
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Introduction 
It has been shown that total cholesterol is a major risk factor for coronary heart disease 
in men as well as in women.1"4 Total cholesterol increases markedly around middle-age. 
While in younger age groups total cholesterol is lower in women than in men, above age 
50 total cholesterol levels in women usually exceed those in men.5 In our study 
population, 45% of the women aged 55-59 had hypercholesterolemia, defined according 
to the classification of the Netherlands Cholesterol Consensus as a total cholesterol of 6.5 
mmol/1 or more.6 , 7 In aging populations therefore, hypercholesterolemia in women is a 
growing public health concern. 
Knowledge on factors influencing cholesterol levels in women are important with respect 
to prevention of hypercholesterolemia. Most women go through the menopause between 
age 45 and 55. It is known that the menopause influences total cholesterol levels although 
estimates of the magnitude of this effect differ.8"19 In studies that provide information on 
HDL cholesterol levels, no effect of menopause on HDL cholesterol levels is reported.8 , 1 0 , 1 9 
From 1987 to 1991 the Netherlands Monitoring Project on Cardiovascular Disease Risk 
Factors has been carried out.7 In this project over 36,000 men and women have been 
examined for cardiovascular risk factors such as plasma cholesterol, blood pressure, 
smoking and body mass index. These data provided the opportunity to investigate the 
relation between menopause, body mass index and cholesterol levels cross-sectionally in 
over 4,000 women aged 45-54 years. 
Materials and methods 
Study population 
The Monitoring Project on Cardiovascular Disease Risk Factors has been carried out in 
the Netherlands from 1987 to 1991. The aim of this project was to monitor major risk 
factors for cardiovascular diseases, e.g. plasma cholesterol, blood pressure and smoking 
habits. The project was carried out at the municipal health services in three towns in the 
Netherlands: Amsterdam, the capital city in the west, Doetinchem in the east and 
Maastricht in the south. Bach year a new random sample of men and women aged 20 to 
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59 is selected in each town. Because age and menopausal status are highly correlated, it 
is necessary to compare premenopausal and postmenopausal women in a narrow age 
range, to reduce the possibility of ascribing an effect of aging to the occurrence of 
menopause. Therefore, the analyses comparing premenopausal and postmenopausal women 
were restricted to women aged 45 to 54 years. The overall response rate for women in this 
age groups was 64%. 
Data collection 
The examination included measurement of weight, height and blood pressure, blood 
sampling and a questionnaire.7 The respondents were weighed without shoes, after 
emptying their pockets, with an accuracy of 0.1 kg. Height was measured with an 
accuracy of 0.5 cm, while the respondent stood upright against the wall with the feet at 
a 45° angle. Body mass index (BMI) was calculated as weightQcgyheighttm)2. Total and 
HDL cholesterol were determined in a non-fasting blood sample, at the Clinical Chemistry 
Laboratory of the University Hospital 'Dijkzigt' in Rotterdam. This laboratory takes part 
in the standardization program of the WHO through the WHO Regional Lipid Center for 
Europe in Prague, Czechoslovakia and the Centers for Disease Control (CDC), Atlanta, 
Georgia, USA.2 0 Plasma total cholesterol was determined enzymatically using a Boehringer 
testkit.21 HDL lipoproteins were isolated by precipitation of the apo-B-containing lipopro-
teins with magnesium phosphotungstate.22 Subsequently the cholesterol content of the HDL 
lipoproteins was determined, as described for total cholesterol. 
The questionnaire provided information about demographic variables, presence and family 
history of cardiovascular and a number of other chronic diseases, medication, smoking 
habits, physical activity, psycho-social factors and reproductive history. Menopausal status 
was evaluated by means of a question about regularity of menstruation. Response 
categories to this question were: regular, irregular, not applicable because of pregnancy, 
not applicable because of the menopause and not applicable due to surgery. The first two 
categories were classified as premenopausal. Women reporting that they no longer 
menstruated because of the menopause were classified as postmenopausal. Women 
reporting they did not menstruate due to surgery were excluded from the analysis because 
the type of operation (hysterectomy and/or oophorectomy) was not known, and therefore 
hormonal status could not be determined. 
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In the analyses present cigarette use was dichotomized into non-smoker versus smoker (> 
1 cigarette per day). Alcohol consumption (glasses/day) was used as a continuous variable. 
One question about physical activity at work and one about leisure time was asked. 
Physical activity during leisure time was used in the analyses. Answering categories were: 
no activity, exercise for at least four hours per week, regular exercise, heavy exercise. The 
first category was classified as inactive, the others as active. 
Statistical analyses 
The analyses were carried out on a personal computer using the statistical package SAS.2 3 
Regression analyses were performed using plasma total and HDL cholesterol as dependent 
variables. The total cholesterol difference between premenopausal and postmenopausal 
women was estimated in a regression model in which menopausal status, age, BMI and 
smoking were included as independent variables. For HDL cholesterol also alcohol 
consumption and physical activity were included in the regression model. It was tested 
whether the difference in total cholesterol between premenopausal and postmenopausal 
women was modified by cigarette smoking, body mass index (kg/m2) and age (45 to 49 
years versus 50 to 54 years). For HDL cholesterol also interaction with physical activity 
or alcohol consumption was examined. By including interaction terms in the model 
(menopausal status*smoking, menopausal status*body mass index, etc.) it was tested 
whether the interaction terms significantly increased the explained variance (tested with 
an F-statistic). 
Results 
In table 1 some basic characteristics of premenopausal and postmenopausal women are 
given. The postmenopausal women were on average 3 years older than the premenopausal 
women. Total cholesterol levels were higher in postmenopausal women than in 
premenopausal women, cigarette smoking was more prevalent in postmenopausal women 
while consumption of alcohol was more prevalent in premenopausal women. No difference 
between the two groups was observed in HDL cholesterol level, body mass index and 
physical activity. 
In table 2 results of the multivariate regression model are presented. The coefficient for 
menopause from this model can be interpreted as the difference in total or HDL 
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cholesterol between premenopausal and postmenopausal women, adjusted for the other 
variables in the model. The effect of menopause on total cholesterol levels was different 
in non-smokers compared to smokers, while no significant interactions of menopause with 
body mass index and age were observed. The estimated increase in total cholesterol due 
to menopause was 0.45 mmol/1 in non-smokers and 0.28 mmol/1 in smokers (0.448 minus 
0.166). The increase in total cholesterol with age was 0.047 mmol/1 per year, while the 
increase in total cholesterol per unit increase in BMI amounted to 0.026 mmol/1. The 
difference in total cholesterol between smokers and non-smokers was 0.28 mmol/1. In 
figure 1 the difference in total cholesterol between premenopausal and postmenopausal 
women according to smoking status is shown, estimated from the regression equation. 
Table 1. Basic characteristics (mean (SD)) of premenopausal and postmenopausal 
women aged 45-54 years. The Netherlands Monitoring Project on Cardiovascular 
Disease Risk Factors, 1987-1991 
Premenopausal Postmenopausal 
N=2,567 N=l,657 
mean SD mean SD 
Age (years) 48.7 2.40 51.71 2.23 
Total cholesterol (mmol/1) 5.63 1.03 6.18' 1.08 
HDL cholesterol (mmol/1) 1.37 0.32 1.37 0.33 
Body Mass Index (kg/m2) 25.96 4.39 26.02 4.22 
Smokers (%) 32.1 46.7 41.2a 49.2 
Alcohol users (%) 54.5 49.8 47.5" 50.0 
Physically active (%) 62.8 51.6 65.6 52.5 
a: significantly different from premenopausal (p<U.U01) 
Table 2. Menopause and lifestyle factors in relation to total and HDL cholesterol 
levels in 4,224 women aged 45-54 years. The Netherlands Monitoring Project on 
Cardiovascular Disease Risk Factors, 1987-1991 
Total cholesterol HDL cholesterol 
(rhmol/1) (mmol/1) 
ß a SE" ß SE 
Menopause (no/yes) 0.448 0.047 0.040 0.011 
Menopause*smoking -0.166 0.015 - -
Age (years) 0.047 0.007 -0.003 0.002 
Body Mass Index (kg/m2) 0.026 0.004 -0.020 0.001 
Cigarette smoking (no/yes) 0.284 0.044 -0.140 0.010 
Alcohol consumption (glass/day) - - 0.069 0.004 
Physical activity (no/yes) - - 0.030 0.010 
a: regression coefficient 
b: standard error 
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total cholesterol (mmol/1) 
non-smokers smokers 
I premenopausal H postmenopausal 
Figure 1. Total cholesterol level in premenopausal and postmenopausal women according to smoking 
status. Estimated from the regression equation (table 2) for a woman aged 50 with a BMI of 26 kg/m2. 
After multivariate analysis, HDL cholesterol was 0.04 mmol/1 higher in postmenopausal 
compared to premenopausal women. HDL cholesterol was not associated with age. BMI 
was inversely related to HDL cholesterol: HDL cholesterol was 0.025 mmol/1 lower for 
each unit increase in BMI. Smoking was associated with a 0.140 mmol/1 lower HDL 
cholesterol level. Per glass of alcohol consumed an increase of 0.069 mmol/1 in HDL 
cholesterol was observed. Physically inactive women had a 0.03 mmol/1 lower HDL 
cholesterol level than physically active women. No interaction of menopause with age, 
smoking, body mass index, alcohol consumption and physical activity was observed for 
HDL cholesterol levels. 
Discussion 
Some limitations of the present study must be kept in mind when interpreting the results. 
Menopausal status was self-reported in our study, which might give rise to 
misclassification. Bonithon-Kopp et al. validated self-reported menopause against serum 
concentrations of folhcle-stimulating hormone and estradiol.12 The menopause was 
confirmed for 94% of the women who reported a natural menopause, but only for 70% 
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of the women who had had a hysterectomy. In our study, women with a surgical 
menopause (hysterectomy or oophorectomy) were excluded because of unknown hormonal 
status. Mean total cholesterol levels for these women were intermediate between those for 
premenopausal and naturally postmenopausal women, confirming the heterogeneous 
hormonal status of this group (results not shown). 
No information on the use of hormones was obtained in the present study, but at the time 
of the study hormone replacement therapy was only used by a small proportion of the 
postmenopausal women in the Netherlands. A study of about 12,000 women (aged 40-73 
years) attending a routine breast cancer screening in the Netherlands, showed that three 
percent of all postmenopausal women used estrogens. Estrogen use was highest among 
perimenopausal women: about 10%.13 An American study showed that in 1989/1990 about 
3.5% of all women who had had a natural menopause used estrogens as opposed to over 
20% of the women with a surgical menopause.24 These results show that it is not likely 
that the results of the present study, in women with a natural menopause, are strongly 
biased due to lack of information on estrogen use. Since estrogen use is associated with 
lower total cholesterol levels, any bias that would occur leads to an underestimation of the 
cholesterol increase due to menopause. 
In the present cross-sectional study, the estimated increase in total cholesterol due to 
menopause amounted to 0.45 mmol/1 in non-smokers and 0.28 mmol/1 in smokers after 
adjustment for age, smoking and body mass index. We know of no other study that 
reported the effect of menopause stratified by cigarette smoking status. However, 
interaction between cigarette smoking and hormonal status has been suggested by the fact 
that smokers have an earlier menopause than non-smokers.25"26 It has been proposed that 
smokers may metabolize estrogen at a different rate from non-smokers.27 Our results are 
compatible with this hypothesis: due to the fact that the estrogen concentration is much 
lower after menopause, the difference in total cholesterol between non-smokers and 
smoker diminishes. 
In a number of other cross-sectional studies higher total cholesterol levels for 
postmenopausal compared to premenopausal women were reported. However, the reported 
magnitude of the effect of menopause differs. Bonithon-Kopp and co-workers reported an 
increase in total cholesterol due to menopause of 0.36 mmol/1 in women aged 45 to 54 
years.8 In the Evans County Study, an increase of 0.65 mmol/1 was found for white 
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women.9 In both studies adjustment for smoking, age and body mass index was made. In 
studies that did not adjust for differences in BMI or smoking, differences in total 
cholesterol between premenopausal and postmenopausal women ranged from 0.09 to 0.62 
mmol/1.10"14 
Smoking and BMI are associated with menopausal age: smoking is inversely and BMI is 
positively associated with age at menopause.25,26 Therefore, differences in BMI and 
smoking prevalence influence the observed difference in total cholesterol between 
premenopausal and postmenopausal women in different age strata. The fact that smoking 
women have an earlier menopause is reflected in the present study by the higher 
percentage of smokers in the group of postmenopausal women compared to the group of 
premenopausal women. 
It can be argued that comparing premenopausal and postmenopausal women in a cross-
sectional study can not prove that menopause precedes the cholesterol increase. Data from 
the Frarningham Study indicate that the effect of menopause on total cholesterol is a more 
or less 'immediate' effect, taking place within 1 to 2 years.16 In the Frarningham Study 
the longitudinal increase in total cholesterol in women who had become postmenopausal 
was about 0.30 mmol/1 higher than the increase in controls who remained 
premenopausal.16 Because of its longitudinal design, the Frarningham Study is one of the 
few studies able to show convincingly that menopause precedes the rise in serum total 
cholesterol. Lindquist observed an increase of about 0.40 mmol/1 over a 6-year period for 
women whose menopausal status changed during that period.15 The results of these 
longitudinal studies are well in range with most cross-sectional studies. A Dutch study 
reported a total cholesterol increase of 1.1 mmol/1 over an 8-year period in women who 
became postmenopausal during that period.17 From the present study it can be estimated 
that the increase in total cholesterol over an 8-year period, based on an effect of 
menopause of 0.45 mmol/1 in non-smokers and 0.28 mmol/1 in smokers and an increase 
of 0.048 mmol/1 per life-year, would be 0.83 mmol/1 in non-smokers and 0.66 in smokers. 
HDL cholesterol does not change much with age. Our results indicated a small positive 
effect of menopause on HDL cholesterol in multivariate but not in univariate analyses. 
This was due to the fact that smoking is inversely related to HDL cholesterol levels, and 
the percentage of smokers was higher in postmenopausal women while HDL cholesterol 
levels were similar. Therefore, after adjustment for smoking, HDL cholesterol levels were 
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higher in postmenopausal women. No interaction with age, body mass index, smoking, 
alcohol consumption or physical activity was observed. Also in the Minnesota Heart Study 
HDL cholesterol levels were higher in women with a natural menopause compared to 
premenopausal women after adjustment for age, smoking, body mass index, physical 
activity and alcohol consumption, but this difference (0.07 mmol/1) was not statistically 
significant.19 Other studies that examined HDL cholesterol levels, however, did not find 
an effect of menopause on HDL cholesterol levels. 8 1 0 
It can be concluded that menopause plays an important role in the marked increase in total 
cholesterol levels in middle-aged women. In the present study, menopause was associated 
with a small increase in HDL cholesterol levels. 
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5 Gender differences in total and HDL cholesterol: the role of lifestyle factors, body mass index, menopause and aging 
Abstract 
Background. We wanted to examine to what extent the gender differences in total (TC) 
and HDL cholesterol (HDL-C) are explained by differences in body mass index (BMI), 
cigarette smoking, drinking and physical activity (PA) and to what extent the TC increase 
with age can be Umited through a healthy lifestyle. 
Methods. Between 1987 and 1991, about 36,000 men and women aged 20-59 were 
examined for cardiovascular disease risk factors. The association of BMI, smoking, alcohol 
consumption, PA, age and menopause with TC and HDL-C was estimated in a regression 
model. From this model, it was estimated what the gender difference in total and HDL 
cholesterol would be if men and women had equal levels of BMI, smoking, alcohol 
consumption and physical activity. Furthermore, the total cholesterol increase with age was 
compared to the predicted increase based on a low-risk lifestyle (BMI=22.5 kg/m2, no 
smoking, moderate alcohol consumption, physically active). 
Results. Between age 30 and 50, 19-38% of the gender difference in TC was explained 
by differences in BMI and smoking. After age 50, the higher TC in women was to a large 
extent due to the effect of the menopause. The difference in HDL-C between men and 
women would be 0.02-0.04 mmol/1 larger if levels of BMI, smoking, alcohol consumption 
and PA had been similar. A low-risk lifestyle would, in men, lead to a 0.3 mmol/1 less 
increase in total cholesterol between age 20 and 59 and in women to a 0.15 mmol/1 less 
increase. 
Conclusion. Between age 30 and 50 38%, at most, of the gender difference in TC is 
explained by differences in risk factor levels. After age 50, the gender difference in TC 
is mainly due to the occurrence of menopause in women. Differences in risk factor levels 
do not account for the gender difference in HDL cholesterol. A low-risk lifestyle can to 
some extent limit the cholesterol increase with age. 
submitted as: 
Verschuren WMM, Kromhout D. Gender differences in total and HDL cholesterol: the role of lifestyle 
factors, body mass index, menopause and aging. 
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Introduction 
In western countries, coronary heart disease (CHD) is a major cause of death, and the 
incidence increases with age. A high total cholesterol and a low HDL cholesterol level are 
important risk factors for coronary heart disease.1"5 Plasma total cholesterol levels increase 
with age, but the pattern of increase is different in men and women. In men there is a 
strong increase until about age 45, while in women the increase is especially strong after 
that age.6 This different relation with age can be due to a different effect of aging in men 
and women, but could also be the result of different levels of the determinants of total 
cholesterol in men and women at various ages. Determinants that are positively associated 
with total cholesterol levels are body mass index (BMI) (kg/m2), cigarette smoking and, 
for women, the menopause.7"10 HDL cholesterol shows almost no relation with age, but the 
difference in HDL cholesterol between men and women is striking: women have 
consistently higher HDL cholesterol levels than men.11 A number of lifestyle factors 
influence HDL cholesterol levels: alcohol consumption and physical activity are positively 
associated with HDL cholesterol12"13 and smoking and BMI negatively.8,16 
With data from the Dutch Monitoring Project on Cardiovascular Disease Risk Factors17 
we tried to gain insight in the extent to which cigarette smoking, alcohol consumption, 
physical activity, BMI and menopause can explain the gender differences in total and HDL 
cholesterol at various ages. Furthermore, the extent to which the increase in total 
cholesterol with age in men and women can be prevented by keeping modifiable determi-
nants of total cholesterol at a desirable level was evaluated. 
Methods 
Study population 
The Monitoring Project on Cardiovascular Disease Risk Factors has been carried out in 
the Netherlands from 1987 to 1991.1 7 The aim of the project was to monitor the major risk 
factors for cardiovascular diseases: plasma cholesterol, blood pressure and smoking habits. 
The project was carried out at the municipal health services in three towns in the 
Netherlands: Amsterdam, the capital city in the west, Doetinchem in the east and 
Maastricht in the south. Each year a new random sample of men and women aged 20 to 
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59 years was selected in each town. In the years 1987-1991 over 36,000 men and women 
have been examined. The overall response rate was 51% in men and 58% in women.18 
Data collection 
The examination included measurement of weight, height and blood pressure, blood 
sampling and a questionnaire. The respondents were weighed without shoes, after 
emptying their pockets, with an accuracy of 0.1 kg. Height was measured with an 
accuracy of 0.5 cm, while the respondent stood upright against the wall with the feet at 
a 45° angle. Body mass index (BMT) was calculated as weightfkg^eightCm)2. Total and 
HDL cholesterol were determined in a non-fasting blood sample at the Clinical Chemistry 
Laboratory of the University Hospital 'Dijkzigt' in Rotterdam. This laboratory takes part 
in the standardization program of the WHO through the WHO Regional Lipid Center for 
Europe in Prague, Czechoslovakia and the Centers for Disease Control (CDC), Atlanta, 
USA.1 9 Plasma total cholesterol was determined enzymatically using a Boehringer testkit 2 0 
HDL lipoproteins were isolated by precipitation of the apo-B-containing lipoproteins with 
magnesium phosphotungstate.21 Subsequently the cholesterol content of the HDL 
lipoproteins was determined, as described for total cholesterol. 
The questionnaire provided information about demographic variables, presence and family 
history of cardiovascular and a number of other chronic diseases, medication, smoking 
habits, alcohol consumption, physical activity, psycho-social factors and, for women, 
reproductive history. 
In the analyses cigarette smoking was dichotomized into non-smoking and smoking (£ 1 
cigarette/day). Alcohol consumption was used as a continuous variable (glasses/day). Two 
questions about physical activity were asked: one about work and one about leisure time. 
Since most people had sedentary jobs, physical activity during leisure time was used in 
the analyses. There were four answering categories: no activity, exercise for at least four 
hours per week, regular exercise, heavy exercise. The first category was classified as 
inactive, the others as active. 
Menopausal status was based on a question about regularity of menstruation. The response 
categories were: regular, irregular, not applicable because of pregnancy, not applicable 
because of menopause and not applicable due to surgery. The first two categories were 
classified as premenopausal. All pregnant women (N=306) were excluded from the 
analyses. All women who reported that they no longer menstruated because of the 
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menopause were classified as postmenopausal. All women who did not menstruate due to 
surgery were excluded from the analysis because the type of operation (hysterectomy 
and/or oophorectomy) was not known, and therefore hormonal status could not be 
determined. 
Statistical methods 
The analyses were carried out using the statistical package SAS 6.07.22 All analyses were 
performed with plasma total and HDL cholesterol as dependent variables. Regression 
models were built using the following strategy. Gender, menopausal status, age and the 
known determinants (BMI and smoking for total cholesterol and BMI, smoking, alcohol 
consumption and physical activity for HDL cholesterol) were entered into the regression 
model. Only variables that are known to be causally related to total and HDL cholesterol 
levels were entered into the model, to prevent the entry in the model of factors that are 
merely markers for other (causative) factors. Because the increase with age was not linear, 
the term age2 was introduced. Differences in the coefficients between men and women 
were assessed by including interaction terms in the regression model of gender with the 
other variables. It was tested whether the interaction terms increased the explained 
variance with an F-statistic. The most parsimonious model was used. Separate regression 
coefficients for men and women were calculated from the interaction terms. 
The regression equations were used to estimate the extent to which differences in levels 
of these factors explain the difference in total and HDL cholesterol between men and 
women. It was calculated what the mean total and HDL cholesterol levels of the male 
respondents would have been if they would have had the same average risk factor profile 
as females of the same age. This was done by calculating the mean levels of BMI and 
percentage of smokers, drinkers and physically active persons for women for each one 
year age group. Subsequently, the male regression coefficients were applied to this female 
risk factor profile to obtain the simulated values for men. These values were then 
compared with the predicted values from the regression equation for men and women. 
Cholesterol levels associated with a low-risk and high-risk lifestyle were also calculated 
based on the regression equations. 
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Results 
Basic characteristics of men and women are given in table 1. Mean age, total cholesterol, 
BMI, percentage of smokers and the number of cigarettes smoked were somewhat higher 
in men compared to women. HDL cholesterol was 0.25 mmol/1 higher in women than in 
men. Alcohol consumption was more frequent in men and the amount of alcohol 
consumed per day was about twice as high in men. About two thirds of the men and 
women were physically active. 
Table 1. Basic characteristics" (mean (SD)) of men and women aged 20-59. The 
Netherlands Monitoring Project on Cardiovascular Disease Risk Factors, 1987-1991 
Men Women 
N=17,143" N=17,168b 
Age (years) 41.5 (10.9) 40.3 (11.0) 
Total cholesterol (mmol/1) 5.55 (1.15) 5.49 (1.11) 
HDL cholesterol (mmol/1) 1.12 (0.27) 1.37 (0.32) 
BMI (kg/m2) 25.3 (3.4) 24.6 (4.2) 
Smokers (%) 40.6 (49.5) 39.6 (49.4) 
Cigarettes/day0 16.4 (9.1) 14.6 (8.3) 
Drinkers (%) 76.7 (42.3) 50.2 (50.0) 
Drinks/dayd 2.2 (1.9) 1.2 (1.2) 
Physically active (%)' 66.2 (47.3) 63.0 (48.3) 
a : Men and women differ statistically significantly at p < 0.001 for all variables, for % smokers 
the difference is statistically significant at p < 0.05. 
b : minimum N 
c : mean is based on smokers only 
d : mean is based on drinkers only 
e : physically active during leisure time 
Gender differences in total and HDL cholesterol 
In figure 1 and 2 total and HDL cholesterol levels by age are shown. Under the age of 25 
years women had a higher mean total cholesterol than men, between the ages 25 to 50 
total cholesterol was higher in men, and after about age 50 women had again higher 
values. HDL cholesterol was fairly constant at all ages and was about 0.25 mmol/1 higher 
in women than in men. 
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Table 2. Regression equations" for total and HDL cholesterol for men and women 
Total cholesterol (mmol/1) 
Men = 0.73 + 0.060*BMJb + 0.132*Smokingc + 0.128*Age - 0.001 l*Age2 
Women = 4.21 + 0.029*BMI + 0.179*Smoking - 0.022*Age + 0.0007*Age* + 
0.356*Menopausal status11 
HDL cholesterol (mmol/1) 
Men = 1.646 - 0.023*BMI - 0.097*Smoking + 0.036*Alcohole + 
0.038*Activityf 
Women = 1.786 - 0.018*BMI - 0.131*Smoking + 0.073*Alcohol + 
0.038*Activity + 0.024*Menopausal status 
a: If coefficients differ between men and women this difference is statistically significant (p<0.01) 
b: BMI: Body Mass Index (kg/m2) 
c: Smoking : no/yes 
d: Menopausal status: O=premenopausal, l=postmenopausal 
e: Alcohol consumption (glasses/day) 
f: Physical activity during leisure time: 0=inactive, l=active 
Table 3. Difference in total and HDL cholesterol (mmol/l) between men and women as 
predicted from the regression equations shown in table 2, and as predicted from the 
same regression equations when simulated that men had the same levels of BMI and 
lifestyle factors as women 
Total cholesterol HDL cholesterol 
if BMI, smoking 
from if BMI and from alcohol and 
regression smoking regression physical activity 
Age group model were similar model were similar 
20-24 -0.30 -0.37 -0.23 -0.25 
25-29 0.02 -0.06 -0.23 -0.25 
30-34 0.26 0.16 -0.25 -0.27 
35-39 0.37 0.29 -0.25 -0.27 
40-44 0.42 0.33 -0.26 -0.28 
45-49 0.31 0.25 -0.27 -0.29 
50-54 -0.03 -0.06 -0.26 -0.29 
55-59 -0.42 -0.40 -0.26 -0.30 
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total cholesterol (mmol/1) 
age (years) 
-*-men + women 
Figure 1. Mean plasma total cholesterol according to age (yrs) in 36,000 men and 
women. The Netherlands Monitoring Project on Cardiovascular Disease Risk Factors 
1987-1991. 
HDL cholesterol (mmol/1) 
1.6 I 
1.4-r, 
1.2 
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age (years) 
-•-men + women 
Figure 2. Mean HDL cholesterol level according to age (yrs) in 36,000 men and 
women. The Netherlands Monitoring Project on Cardiovascular Disease Risk Factors 
1987-1991. 
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total cholesterol (mmol/1) 
Figure 3. Predicted total cholesterol values for men and women, and simulated for 
men with the same risk factor profile (BMI and smoking) as women of the same age. 
HDL cholesterol (mmol/1) 
1.5 
1-4 
1.3 h 
0.9 i i I I 
20 25 30 50 55 35 40 45 
age (years) 
— predicted men + predicted women - -simulated men 
Figure 4. Predicted HDL cholesterol values for men and women, and simulated for 
men with the same risk factor profile (BMI and lifstyle factors) as women of the same 
age. 
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In table 2 the associations of BMI, smoking, alcohol consumption, physical activity and 
menopause with total and HDL cholesterol levels in men, premenopausal and 
postmenopausal women are shown. From these equations the predicted total and HDL 
cholesterol levels for men and women (based on their own level of BMI and lifestyle 
factors) and the simulated values for men (assuming the same average level of BMI and 
lifestyle factors as females of the same age) were calculated (figure 3 and 4). In table 3 
the gender difference in total and HDL cholesterol is summarized per 5-year age category 
based on the predicted level for men and the simulated level for men. Until about age 55 
the total cholesterol level in men would be lower if they would have the same BMI and 
smoking level as their female contemporaries. Between age 30 and 50 about 19-38% of 
the total cholesterol difference was explained by differences in BMI and smoking. Above 
age 50, mean total cholesterol levels in women exceed those in men, and BMI and 
lifestyle factors hardly explain the difference between men and women. The sharp increase 
in women around age 50 is to a great extent the result of the occurrence of the 
menopause. The difference in HDL cholesterol between men and women was not 
explained by differences in BMI and lifestyle factors. On the contrary, if men would have 
the same levels of BMI, smoking, drinking and PA as women, the difference in HDL 
cholesterol between men and women would be about 0.02-0.04 mmol/l larger. 
Cholesterol difference between a low-risk and high-risk lifestyle 
To examine the extent to which the increase with age can be prevented through lifestyle 
factors, two situations were simulated: a 'low-risk' scenario (BMI=22.5 kg/m2 (mean level 
at age 20) and no cigarette smoking) and a 'high-risk' scenario (BMI=30 kg/m2 (cutoff 
point for grade II obesity) and cigarette smoking (£ 1 cigarette/day)). Mean observed, 
predicted, low-risk and high-risk total cholesterol values by age are presented in figures 
5 and 6 for men and women respectively. The low-risk line gives an indication to what 
level the rise with age can be restrained on average, by keeping BMI constant at a low 
level and abstaining from smoking. From figure 5 and 6 it can be seen that the total 
cholesterol level for the low-risk scenario at age 55-59 is about 0.3 mmol/l lower than the 
observed average level in men, and in women about 0.15 mmol/l lower. The difference 
between the low and high-risk lines gives an indication of the impact of a 'low-risk' 
versus a 'high-risk' lifestyle. This difference was greater in men (0.58 mmol/l) than in wo-
men (0.40 mmol/l). 
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total cholesterol (mmol/l) 
35 40 45 50 
age (years) 
— observed + predicted - •low-risk ""high-risk 
Figure 5. Mean observed", predicted1', minimum predicted', and maximum predicted1 total cholesterol 
according to age (years) in men. The Netherlands Monitoring Project on Cardiovascular Disease Risk 
Factors 1987-1991. 
": as measured 
b: as predicted from a regression model with age, BMI and cigarette smoking 
': predicted value, based on the assumptions: BMI=22.S kg/m2; no smoking 
d : predicted values based on the assumptions: BMI=30 kg/m2; cigarette smoking 
total cholesterol (mmol/l) 
45 50 35 40 
age (year) 
— observed + predicted - "low-risk •"high-risk 
Figure 6. Mean observed', predicted2, minimum predicted3, and maximum predicted4 total cholesterol 
according to age (years) in women. The Netherlands Monitoring Project on Cardiovascular Disease 
Risk Factors 1987-1991. 
°,b,c,d: footnotes, see figure 5 
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For HDL cholesterol the low-risk scenario was based on a BMI of 22.5 kg/m2, no cigarette 
smoking, 2 alcoholic consumptions per day and a physically active lifestyle; the high-risk 
scenario was based on a BMI of 30 kg/m2, cigarette smoking (S 1 cigarette/day), no 
alcohol consumption and a physically inactive lifestyle. For men, the HDL cholesterol 
level for the low and high-risk scenarios were 1.24 and 0.86 mmol/1 respectively (not 
shown). The HDL-C from the low-risk scenario was about 0.1 mmol/1 higher than the 
average observed HDL-C. In women, menopause was associated with a small increase in 
HDL cholesterol. Due to the increasing proportion of postmenopausal women with age, 
the HDL scenario lines increased slightly with age in women. The level of the scenarios 
was about 1.57 mmol/1 in the low-risk scenario and about 1.12 mmol/1 in the high-risk 
scenario (not shown). For women the low-risk scenario was associated with a 0.2 mmol/1 
higher HDL-C than the observed HDL-C. The difference in HDL-C between the low-risk 
and the high-risk scenario was 0.38 mmol/1 in men and 0.45 mmol/1 in women. 
Discussion 
One of the advantages of the present study was, that a large number of men and women 
(both premenopausal and postmenopausal) in a broad age range were examined in a 
standardized way. Therefore, this study could give reliable estimates of the relations 
between lifestyle habits and cholesterol levels in men and women. The figures in which 
both the observed and predicted values are plotted suggest that the models fitted the data 
well. 
With respect to the explanation of the cholesterol rise with age, it is important to note that 
our data are cross-sectional. In a number of both cross-sectional and longitudinal studies 
the observed pattern of the total cholesterol rise with age was similar, suggesting that 
cross-sectional studies give a fairly accurate picture of the total cholesterol changes with 
age.6 , 2 3"2 6 
Another issue in relation to generalizability of the results is possible selection bias due to 
non-response. A non-response survey was carried out among all non-respondents in the 
period August-December 1991 (N=1600). They were approached by telephone or, if no 
telephone number could be obtained, by mailed questionnaire. Educational level was 
considered an important indicator variable because it is known to be associated with risk 
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factor levels.27 2 9 For men the percentage of low, medium and high educational level was 
56%, 23% and 22% respectively among respondents, and among non-respondents 52%, 
27% and 21% respectively. For women these percentages were 63%, 20% and 17% 
respectively among respondents and 57%, 26% and 17% respectively among non-
respondents. Therefore we concluded that the participants in our study seemed to be 
representative of the total group invited to participate in the study.18 
The associations between BMI and lifestyle factors and total and HDL cholesterol levels 
differed between men and women. The stronger unfavorable effect of smoking in women, 
and the stronger unfavorable effect of BMI in men is in accordance with other studies.7,24" 
26,30,31 j j j e s t r o n g e r effect of BMI on total cholesterol in men compared to women can be 
explained by the fact that men have more abdominal fat than women, and this is known 
to be more atherogenic.32"33 Differences in fat distribution between men and women were 
however not measured in the present study. Alcohol consumption is known to increase 
HDL cholesterol levels. 1 2 , 1 3 A stronger effect in women than in men, as was observed in 
the present study, has also been observed in the Framingham Study and the LRC 
Prevalence Study.2 6 , 1 3 
The difference in total cholesterol between men and women at different ages is an 
intriguing phenomenon. With our data we tried to gain insight into factors that can explain 
this difference. Until about age 50, on average BMI was lower in women than in men, and 
therefore until this age men would have lower total cholesterol levels if they would have 
the same BMI as women. Because total cholesterol before age 25-30 is higher in women 
than in men, this lower TC would lead to an increased gender difference. From age 50 
onwards BMI is similar in men and women, and therefore around this age the gender 
difference is mainly explained by the occurrence of the menopause in women. Other 
factors, that were not measured in the present study, might also play a role. We had no 
detailed information to analyze differences in for example saturated fat intake, but a recent 
survey in the Netherlands did not show substantial differences in saturated fat intake 
between men and women, nor between younger and older adults.34 
The difference in HDL cholesterol between men and women was not explained by 
differences in BMI and the lifestyle factors studied (figure 4). If men would have the same 
risk factor levels as women, the difference in HDL cholesterol between men and women 
would be even 0.02-0.04 mmol/1 larger, due to the lower level of alcohol consumption in 
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women compared to men. Gender was the most important determinant of the difference 
in HDL cholesterol. During puberty, HDL cholesterol levels drop in boys due to the effect 
of male sex hormones, while in girls the levels remain constant.35 From puberty onwards 
men have lower HDL cholesterol levels than women. Recent publications suggest that 
differences in fat distribution (waist-to-hip ratio) between men and women, play an 
important role in explaining the gender difference in HDL cholesterol.3336-37 
The different scenarios (figure 5 and 6) gave an indication of the predicted mean total 
cholesterol levels at different ages, resulting from a low-risk lifestyle (BMI=22.5 kg/m2, 
no smoking) and a high-risk lifestyle (BMI=30 kg/m2, smoking) in comparison to average 
levels that were observed in the general population. The increase between age 20 and 60 
in average cholesterol levels in the general population amounts to about 1.7 mmol/1 in men 
and 1.6 mmol/1 in women. It was estimated that the average cholesterol level at age 55-59 
resulting from the low-risk scenario compared to the observed level would be about 0.3 
mmol/1 lower in men and about 0.15 mmol/1 lower in women. Therefore, a substantial part 
of the increase of total cholesterol with age remained unexplained. Part of this increase 
may be explained by factors not included in the analyses, or it may be an 'unpreventable' 
aging effect, due to changes in cholesterol metabolism. Grundy and coworkers showed that 
with aging the clearance rate of LDL diminishes and the production rate increases, result-
ing in an increase of LDL levels with age.38 Miller however only found a decrease in 
clearance rate with aging, and no change in production rate.3 9 
For total cholesterol the difference between a 'low-risk' and a 'high-risk' lifestyle was 
larger in men (0.58 mmol/1) than in women (0.40 mmol/1), due to the fact that the 
unfavorable effect of BMI was twice as strong in men compared to women. For HDL 
cholesterol the difference between the two scenarios is 0.38 mmol/1 for men and 0.45 
mmol/1 for women. The larger difference between the two scenarios in women compared 
to men is due to the stronger HDL cholesterol raising effect of alcohol in women. 
It can be concluded that the effects of lifestyle factors on total and HDL cholesterol are 
different in men and women. Between age 30 and 50, about 19-38% of the difference in 
total cholesterol is explained by differences in levels of body mass index and smoking. 
After age 50, the difference is largely due to the effect of menopause. The difference in 
HDL between men and women would be even slightly larger if men had the same levels 
of body mass index, smoking, alcohol consumption and physical activity as women. A 
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low-risk lifestyle can diminish the cholesterol increase with age on average with about 0.3 
mmol/1 in men and with about 0.15 mmol/1 in women. Women have the disadvantage that 
menopause, an unpreventable life event, has a strong cholesterol raising effect. 
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Abstract 
Background. The relation between total cholesterol (TC) and mortality from coronary heart 
disease (CHD), cardiovascular disease (CVD), cancer, non-cardiovascular/non-cancer and 
all causes in men and women was investigated. 
Methods. Between 1974 and 1980 about 23,000 men and 26,000 women aged 30-54 were 
examined and followed for mortality for on average 12 years. Mortality rates for the above 
mentioned endpoints for cholesterol quintiles were calculated and relative risks were 
estimated using Cox' proportional hazard (survival) analysis. Adjustment was made for 
age, smoking, systolic blood pressure and body mass index. 
Results. Mortality rates for all endpoints were higher in men than in women. A strong 
positive association between total cholesterol and CHD and CVD mortality was observed 
in both men and women. The relative risk for the highest compared to the lowest quintile 
for CHD mortality was 3.0 (95% confidence interval 1.8 to 5.1) in men and 3.8 (95% 
confidence interval 1.1 to 13.1) in women, and for CVD mortality 2.8 (95% confidence 
interval 1.8 to 4.2) in men and 2.9 (95% confidence interval 1.4 to 6.0) in women. No 
increase in non-cardiovascular mortality at low cholesterol levels was observed. All-cause 
mortality was significantly elevated in the highest cholesterol quintile compared to the 
lowest, relative risk 1.6 (95% confidence interval 1.3 to 2.0) in men and 1.5 (95% 
confidence interval 1.1 to 1.9) in women. 
Conclusion. Total cholesterol was a strong predictor of CHD, CVD and all-cause mortality 
in women as well as in men. It was estimated that a cholesterol reduction of 0.6 mmol/1 
was associated with a reduction of about 20% in CHD mortality, 15% in CVD mortality 
and 6% in all-cause mortality. 
In press as: 
Verschuren WMM, Kromhout D. Total cholesterol and mortality at a relatively young age: do men 
and women differ? The Netherlands Consultation Bureau Heart Project. BMJ 1995; 
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Introduction 
There is growing awareness that cardiovascular diseases are not only an important public 
health problem in men but also in women.1,2 In the Netherlands, about 40% of total 
mortality is caused by cardiovascular diseases, both in men and women.3 
Because research on cardiovascular diseases has been carried out mostly in middle-aged 
men, longitudinal data on women are still relatively scarce. In the Netherlands, a screening 
project on cardiovascular disease risk factors has been carried out between 1974 and 1980 
in which 50,000 men and women aged 30-54 were examined.4 Mortality follow-up of this 
cohort has recently been completed, and to our knowledge, this is one of the largest 
cohorts that provides information on total cholesterol in relation to mortality in women. 
Although it has been shown in men that the relationship between total cholesterol and 
coronary heart disease mortality is strong and graded,5,6 the risk of low cholesterol levels 
is debated.7 There are indications that the benefit with respect to coronary heart disease 
mortality at low cholesterol levels would be offset by an increase in mortality from cancer 
and other diseases.7,8 Therefore, we also investigated the associations between total 
cholesterol and non-cardiovascular mortality. 
Methods 
Study population 
The Consultation Bureau Heart Project was carried out from 1974 to 1980 in five towns 
in the Netherlands: Amsterdam, Doetinchem, Maastricht, Leiden and Tilburg.4 The 
response rate varied from 70% to 80%. The project was aimed primarily at the age group 
of around 40 years, but in some towns a wider age range was taken. The age range of the 
population examined was 30 to 54, with about 75% of the respondents aged 35 to 45. 
Examination 
Questionnaire information about smoking habits, cardiovascular complaints and the 
respondents history of myocardial infarction, stroke, hypertension and diabetes mellitus 
was obtained. Blood pressure, weight and height were measured. A non-fasting blood 
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sample was taken in which total cholesterol was measured at the Central Clinical 
Chemistry Laboratory of the University Hospital Dijkzigt in Rotterdam. This laboratory 
participated in the standardization program of the World Health Organization (WHO). 
Total cholesterol was determined according to a direct Liebermann-Burchard method.9 In 
more recent projects, cholesterol has been determined enzymatically, and cutoff points for 
hypercholesterolemia according to the Netherlands Cholesterol Consensus are based on 
enzymatic values.10 Therefore, cholesterol values were converted based on a comparison 
study carried out in 1981 in which cholesterol was measured with both methods in over 
5,000 serum samples. The following equation for conversion from Huang to enzymatic 
values was obtained11: 
total cholesterol,,^^ = 1.004* total cholesterolHlia i lg - 0.299 mmol/1. 
Mortality follow-up 
Mortality follow-up was started in 1986 and completed in 1993. The administration cards 
of the project were retrieved from the archives and computerized. The vital status was 
checked through the municipal registries. Censor date was the date at which the 
information was obtained from the municipal registry (for the living) or date of death. If 
a person had moved with unknown destination, the date at which the person was dropped 
from the municipal registry was used as censor date. For 49,202 of the 50,887 persons 
examined, the administration card was still present in the archive. For 49,018 persons 
(96.3%) mortality follow-up was successfully completed, for 48,949 persons a total 
cholesterol value was obtained. A total of 1319 persons had died. From 1289 subjects the 
cause of death was obtained from the Central Bureau of Statistics, while for 30 persons 
who died outside the Netherlands, such information could not be obtained. Causes of death 
were coded according to the 9th revision of the International Classification of Diseases 
(ICD-9).12 For deaths that had occurred before January 1st 1979 (n=89), the 8th revision 
(ICD-8) had been used. For the endpoints used in the present analyses, all codes from 
ICD-8 remained in the same category when defined according to ICD-9. Cause-specific 
endpoints used in the analyses were coronary heart disease (ICD 410-414), cardiovascular 
disease (ICD 390-459), cancer (ICD 140-239) and non-cardiovascular/non-cancer diseases 
(ICD 0-139, 240-389, 460-999). 
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Statistical methods 
SAS statistical programs were used for the analyses.13 Cholesterol was divided into gender 
specific quintiles and into categories of 0.5 mmol/1 width. Cox proportional hazards 
(survival) analysis was used to estimate relative risks (RR). Adjustment for smoking was 
made based on a dichotomous variable 'current smoking yes/no', while age, systolic blood 
pressure and body mass index (weight(kg)/height(m)2) were entered into the model as 
continuous variables. For cause-specific analyses subjects with an unknown cause of death 
were excluded. Two deceased subjects did not have a cholesterol measurement. Excluding 
prevalent cases of angina, stroke and myocardial infarction (N=1349) did not substantially 
alter the results and therefore they were included in the analyses. 
Results 
Mean age was 39 years, mean total cholesterol level was 5.55 mmol/1 in men and 5.19 
mmol/1 in women. For all cardiovascular risk factors levels were higher in men than in 
women (table 1). In men, cardiovascular diseases (CVD), cancer and non-cancer/non-
cardiovascular diseases each contributed for about 1/3 to total mortality. In women cancer 
was the predominant cause of death (table 2). 
Table 1. Characteristics of 49,018 men and women aged 30-54 years at baseline. 
The Netherlands Consultation Bureau Project on Cardiovascular Diseases, 1974-1980 
Men Women 
N=23,389a N=25,629a 
mean SDb mean SDb 
Age (years) 39.2 4.3 39.4 4.4 
Total cholesterol (mmol/1) 5.55 1.10 5.19 1.00 
Systolic blood pressure (mmHg) 132.8 16.2 126.7 17.6 
Diastolic blood pressure (mmHg) 81.1 11.2 77.8 11.0 
Body Mass Index (kg/m2) 24.9 3.0 24.3 3.7 
Smoking (%) 65.6 47.5 47.0 49.9 
a: maximum number of valid observations 
b: SD = standard deviation 
Mean total cholesterol level per quintile ranged from 4.18 mmol/1 in the lowest to 7.14 
mmol/1 in the highest quintile in men, and from 3.94 mmol/1 to 6.69 mmol/1 in women 
(table 3). For men the total number of person-years was over 275,000 (mean 11.8 years) 
and for women over 300,000 (mean 12.0 years). 
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For coronary heart disease, the highest compared to the lowest quintile showed a three-
fold higher risk in men, and an almost four-fold higher risk in women after adjustment for 
age, smoking, blood pressure and body mass index (table 4). For cardiovascular diseases, 
the highest compared to the lowest quintile showed an almost three-fold higher risk in 
both men and women. For both coronary heart disease and cardiovascular diseases, the 
RR's for men were statistically significantly elevated in the fourth and fifth quintile, for 
women only in the fifth quintile. 
Table 2. Main causes of death in 49,018 men and -women aged 30-54 years at baseline, after 
(on average) 12 years of follow-up. The Netherlands Consultation Bureau Project on 
Cardiovascular Diseases, 1974-1980 
Men Women 
Cause of death ICD-9 codes N % N % 
Cardiovascular diseases 390-459 290 35.5 92 18.4 
Coronary heart disease 410-414 194 23.7 38 7.6 
Cerebrovascular disease 430-439 38 4.6 35 7.0 
Other cardiovascular diseases 390-409, 415- 58 7.1 19 3.8 
429, 440-459 
Cancer 140-239 276 33.7 292 58.3 
Digestive 150-159 66 8.1 66 13.2 
Respiratory8 160-169 116 14.2 27 5.4 
Breast 175 - - 95 19.0 
Other cancers 140-149, 170- 73 8.9 31 6.2 
173, 175-239 
Non-Cardiovascular/non-cancer 0-139, 240- 232 28.4 107 21.4 
389,459-999 
Respiratory diseases 460-519 15 1.8 10 2.0 
Digestive diseases 520-570 32 3.9 7 1.4 
Accidentsb 800-999 112 13.7 59 11.8 
Other non-CVD/non-cancer 0-139, 240- 73 8.9 31 6.2 
389, 580-799 
Unknown 20 2.4 10 2.0 
Total 0-999 818 100.0 501100.0 
a: predominantly lung cancer n=lU8 in men and n=2b in women 
b: including suicide: n=54 in men and n=30 in women 
87 
Chapter 6 
Table 3. Total number examined, mean age (years) and total cholesterol level (mmoUl) by 
cholesterol quintile and gender 
Men Women 
Total cholesterol Total cholesterol 
Quintile N range mean SD1 N range mean SD 
1 4,904 S 4.62 4.18 0.40 5,185 5 4.32 3.94 0.35 
2 4,114 4.63 - 5.12 4.90 0.14 5,165 4.33 - 4.82 4.63 0.14 
3 5,405 5.13 - 5.73 5.45 0.17 5,403 4.83 - 5.32 5.12 0.14 
4 4,060 5.74 - 6.33 6.00 0.17 4,826 5.33 - 5.93 5.65 0.17 
5 4,868 £6.34 7.41 0.76 4,988 2:5.94 6.69 0.73 
Total 23,351 2.1 - 17.8 5.55 1.10 25,567 1.91 - 16.3 5.19 1.00 
I: SD = standard deviation 
In both men and women, no associations between cholesterol quintiles and mortality from 
cancer or non-cardiovascular/non-cancer causes were observed (table 4). Also no 
associations with site-specific cancers nor with subgroups of non-cardiovascular/non-
cancer causes mentioned in table 2 were observed (results not shown). 
All-cause mortality was significantly elevated in the highest cholesterol quintile, by 60% 
in men and by 46% in women (table 4). To explore the shape of the relation between total 
cholesterol level and all-cause mortality in more detail, cholesterol was divided into 9 
categories, with 0.5 mmol/1 steps (figure 1). The middle category (5.5-5.99 mmol/1) was 
used as the reference category. A total cholesterol level of 7.5 mmol/1 or more, gave in 
men a relative risk of 2.3 (95% confidence interval 1.8 to 3.0) and in women a relative 
risk of 1.8 (95% confidence interval 1.2 to 2.8) (table 5). Risk increased continuously with 
increasing cholesterol level in women. In men the lowest all-cause mortality was observed 
in the category 4.5-4.99 mmol/1. The relative risk for total cholesterol below 4.0 mmol/1 
compared to a level of 5.5-5.99 mmol/1 in men was 1.18 (95% confidence interval 0.81 
to 1.71). 
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Table 4. Relative risks (RR) for mortality from coronary heart disease (CHD), total 
cardiovascular diseases (CVD), cancer, non-CVD/non-cancer and all causes according to serum 
total cholesterol quintiles in men and women 
Men Women 
Cholesterol quintiles Cholesterol quintiles 
Ql Q2 Q3 04 Q5 Ql Q2 Q3 Q4 Q5 
low high low high 
Coronary heart dis ease 
rate8 2.77 3.30 3.77 9.84 15.64 0.48 0.64 0.62 1.20 3.32 
RRb 1.0 1.14 1.29 3.37 5.32 1.0 1.34 1.28 2.50 6.86 
RRC 1.0 0.93 0.94 2.29 3.03 1.0 1.16 1.00 1.65 3.80 
CÍ 0.47- 0.50- 1.31- 1.79- - 0.26- 0.22- 0.42- 1.10-
1.84 1.75 4.01 5.14 5.21 4.48 6.45 13.1 
Cardiovascular dis eases 
rate 4.85 5.57 6.91 12.35 22.77 1.45 2.09 2.15 2.75 6.65 
RR 1.0 1.12 1.39 2.48 4.53 1.0 1.45 1.50 1.91 4.60 
RR 1.0 0.93 1.05 1.76 2.77 1.0 1.30 1.23 1.38 2.85 
CI 0.55- 0.65- 1.13- 1.84- . 0.56- 0.53- 0.61- 1.36-
1.58 1.68 2.76 4.18 3.05 2.85 3.16 5.99 
Cancer 
rate 8.83 10.52 7.86 10.89 12.51 8.05 8.68 7.38 11.86 11.63 
RR 1.0 1.20 0.89 1.24 1.41 1.0 1.06 0.91 1.45 1.42 
RR 1.0 1.14 0.82 1.11 1.24 1.0 1.00 0.82 1.24 1.11 
CI 1.78- 0.52- 0.75- 0.86- - 0.68- 0.55- 0.86- 0.77-
1.69 1.22 1.65 1.80 1.47 1.21 1.79 1.62 
Non-cardiovascular/non-cancer 
rate 7.62 6.39 8.01 9.42 10.43 2.74 2.73 3.54 2.92 5.48 
RR 1.0 0.84 1.08 1.25 1.38 1.0 1.01 1.30 1.08 2.02 
RR 1.0 0.80 0.98 1.09 1.15 1.0 0.96 1.21 0.95 1.67 
CI 0.50- 0.65- 0.72- 0.72- - 0.49- 0.64- 0.48- 0.91-
1.26 1.47 1.67 1.72 1.88 2.27 1.88 3.06 
All-cause 
rate 21.30 22.48 22.94 32.66 45.71 12.24 13.50 13.07 17.53 23.77 
RR 1.0 1.06 1.08 1.53 2.13 1.0 1.10 1.06 1.42 1.92 
RR 1.0 0.95 0.90 1.24 1.60 1.0 1.01 0.93 1.17 1.46 
CI 0.74- 0.71- 0.98- 1.29- - 0.74- 0.69- 0.87- 1.10-
1.23 1.15 1.56 1.99 1.37 1.27 1.57 1.94 
a: crude mortality rate per 10,000 person-years 
b: RR unadjusted 
c: RR adjusted for age, smoking, systolic blood pressure and body mass index 
d: 95% confidence interval 
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all-cause mortality rate/10,000 person-years 
total cholesterol (mmol/1) 
• m e n Xwomen 
Figure 1. All-cause mortality rates (/10.000 person-years) according to serum total cholesterol 
category in men and women aged 30-54, after (on average) 12 years of follow-up, adjusted for age, 
smoking, blood pressure and body mass index. 
Table 5. All-cause mortality according to cholesterol categories of 0.5 mmol/l width in men and 
women: number of persons, adjusted" mortality rates, adjusted" relative risks and 95% 
confidence interval per category. Fifth quintile is used as the reference category 
Men Women 
Range 
(mmol/1) N Rate RR 95% CI N Rate RR 95% CI 
<4.0 1,269 31.14 1.18 0.81-1.71 2,311 14.09 0.78 0.52-1.17 
4.0-4.49 2,288 26.39 1.00 0.73-1.6 3,812 15.54 0.86 0.62-1.20 
4.5-4.9 3,812 24.81 0.94 0.73-1.23 5,388 14.64 0.81 0.60-1.10 
5.0-5.49 4,380 25.33 0.96 0.75-1.23 5,174 15.90 0.88 0.65-1.18 
5.5-5.99 4,216 26.39 1.00 - 3,899 18.07 1.00 -
6.0-6.49 3,061 34.00 1.29 1.01-1.65 2,473 18.61 1.03 0.73-1.44 
6.5-6.99 2,054 32.20 1.22 0.93-1.61 1,327 24.39 1.35 0.94-1.95 
7.0-7.49 1,133 44.34 1.68 1.25-2.25 632 23.13 1.28 0.78-2.08 
£7.5 1,159 60.43 2.29 1.76-2.97 561 32.35 1.79 1.16-2.77 
Total 23,372 29.69 25,577 16.25 
a: mortality rate per 10,000 person-years adjusted for age, smoking, blood pressure and body mass index. 
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Discussion 
During the follow-up period only 38 women died of coronary heart disease compared to 
194 men, showing that at middle-age, coronary heart disease is already a prominent cause 
of death in men, but not yet in women. The association between total cholesterol and 
coronary heart disease mortality was comparable in men and women: risk was higher in 
the fourth and fifth quintile, although in women only the estimate for the fifth quintile was 
statistically significant. The relative risk for the highest compared to the lowest quintile 
was 3.0 in men and 3.8 in women. A slightly higher relative risk for women compared to 
men has been observed in other studies as well.1 , 1 4 In all studies, however, absolute risk 
was lower in women than in men. 
In the present study a single measurement of total cholesterol was obtained, leading to 
underestimation of the relative risk, a phenomenon often referred to as regression dilution 
bias.16 Law et al. estimated the magnitude of the dilution factor to be 1.4.17 When we 
apply this dilution factor to the relative risk for the highest quintile in the present study, 
the observed ('diluted') relative risk of 3.03 for men would correspond to an undiluted 
relative risk of 4.7 (3.031 4), and the relative risk for the highest quintile in women would 
increase from 3.8 to 6.5. 
The relative risk's for coronary heart disease in women in the present study were high 
compared to other studies, even after adjustment for age, smoking, blood pressure and 
body mass index. 1 1 4 This might be due to the fact that the respondents were relatively 
young at the time of examination: three-quarters of the respondents were aged 35-45 years. 
A number of studies have shown that the relative risk is higher, the younger the age at 
examination.18"20 Law et al. estimated that after 13 years of follow-up, a 0.6 mmol/1 
decrease in total cholesterol level was associated with a 31 % decrease in coronary heart 
disease mortality in men aged 35-44 at baseline, while in men aged 55-64 this decrease 
was only 12 %.17 
The Dutch Cholesterol Consensus applies the same cutoff point for hypercholesterolemia 
(total cholesterol > 6.5 mmol/1) to men and women.10 Because HDL cholesterol levels are 
on average 0.25 mmol/1 higher in women than in men15, this cutoff point is in fact more 
strict for women. In the present study coronary heart disease risk in women with 
cholesterol levels above 5.9 mmol/1 was almost four times that of women with levels 
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below 4.3 mmol/1. Therefore, the Consensus criteria seem justified. However, since 
absolute risk is much lower in women compared to men, the decision to treat 
hypercholesterolemia in women has to take the absolute risk (and therefore also other 
coronary heart disease risk factors besides total cholesterol) into account. 
Recently, concern has been raised about an increased mortality risk at the lower end of 
the cholesterol distribution.7 A number of studies reported an increased risk of non-
cardiovascular mortality at a low cholesterol level, or even inverse associations over the 
entire cholesterol range.8 ,21"26 In many studies these associations remained after exclusion 
of the first few years of follow-up, contradicting the hypothesis that the associations were 
due to pre-existing diseases at baseline.8 ,21'24"26 In most studies in which these observations 
were found, study subjects were middle-aged men. It has been suggested that in 'healthy' 
cohorts, consisting of working persons27 or relatively young persons28, these associations 
are not present. In the present study of relatively young persons, no association was 
observed between total cholesterol levels and mortality from cancer and non-
cardiovascular/non-cancer causes. Also for site specific cancers (digestive, respiratory and 
breast) and for subgroups of non-cardiovascular/non-cancer mortality (respiratory diseases, 
digestive diseases and accidents) no association with total cholesterol level was observed. 
Our data thus support the healthy cohort hypothesis. 
In both men and women, all-cause mortality was increased by 60% and 46% respectively 
in the highest compared to the lowest cholesterol quintile. To examine the possibility of 
an increase in all-cause mortality at the lower end of the cholesterol distribution in more 
detail, smaller categories than quintiles were used. In women all-cause mortality increased 
continuously with increasing cholesterol level. In men all-cause mortality was lowest at 
a cholesterol level of 4.5-4.9 mmol/1, but the difference with mortality rates at cholesterol 
levels below 4.5 mmol/1 was not statistically significant. In the MRFTT Study all-cause 
mortality at cholesterol levels below 4.1 mmol/1 was increased in men.8 In a recent meta-
analysis all-cause mortality was increased at low cholesterol levels in men but not in 
women.7 In the NHANESI Epidemiological Follow-up Study (NHEFS) all-cause mortality 
at low cholesterol levels was increased in both men and women, but this increase was only 
statistically significant in persons aged over 60 at baseline.28 Our results support the 
hypothesis that the relation between total cholesterol and mortality is dependent on age 
at baseline. 
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With respect to public health an important question is how much of the mortality could 
be avoided by lowering cholesterol levels. Based on the cholesterol distribution and the 
RR's, it was calculated29 that a decrease in total cholesterol of 0.6 mmol/1 in this 
population would reduce coronary heart disease mortality by 19% in men and 20% in 
women and all-cause mortality by 7% in men and 5% in women. This stresses the 
importance of cholesterol lowering in the primary prevention of cardiovascular and all-
cause mortality. Due to the lower mortality rates in women, these percentages correspond 
with lower absolute numbers of lives saved in women compared to men. 
The present study showed that total cholesterol is a strong risk factor for coronary heart 
disease and all-cause mortality in men as well as in women. No significant increase in all-
cause mortality at low cholesterol levels was observed. Our results add to the evidence 
that increased non-cardiovascular mortality at low cholesterol levels is limited to subjects 
who are middle-aged or older at baseline. 
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Serum total cholesterol and long-term coronary 
heart disease mortality in the Seven Countries 
Study 
Abstract 
Background. The relationship between serum total cholesterol and long-term mortality 
from coronary heart disease (CHD) was compared in different cultures. 
Methods. Total cholesterol was measured at baseline (1958-1964) and at 5- and 10-year 
follow-up in 12,467 men aged 40-59 years in 16 cohorts located in seven countries in 
Europe, the United States, and Japan. To increase statistical power six cohorts were 
formed, based on similarities in culture and cholesterol changes during the first 10 years 
of follow-up. Relative risks (RRs) were estimated with Cox proportional hazards (survival) 
analysis, for 25-year CHD mortality for cholesterol quartiles and per 0.50 mmol/1 
cholesterol increase. Adjustment was made for age, smoking and systolic blood pressure. 
Results: The age-adjusted CHD mortality rates in the six cohorts ranged from 3% to 20%. 
The RR's for the highest compared with the lowest cholesterol quartile ranged from 1.5 
to 2.3, except for Japan's RR of 1.1. For a cholesterol level of around 5.45 mmol/1, CHD 
mortality rates varied from 4% to 5% in Japan and Mediterranean Southern Europe to 
about 15% in Northern Europe. However, the relative increase in CHD mortality due to 
a given cholesterol increase was similar in all cultures except Japan. Using a linear 
approximation, a 0.50 mmol/1 increase in total cholesterol corresponded to an increase in 
CHD mortality risk of 12% (17% after adjustment for regression dilution bias). 
Conclusion: Across cultures, cholesterol is linearly related to CHD mortality and the 
relative increase in CHD mortality rates with a given cholesterol increase is the same. The 
large difference in absolute CHD mortality rates at a given cholesterol level however, 
indicates that other factors, such as diet, that are typical for cultures with a low CHD risk 
are also important with respect to primary prevention. 
Published as: 
WMM Verschuren, DR Jacobs, BPM Bloemberg, D Kromhout, A Menotti, C Aravanis, H Blackburn, 
R Buzina, AS Dontas, F Fidanza, MJ Karvonen, S Nedeljkovic, A Nissinen, H Toshima. Serum total 
cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five year 
follow-up of the Seven Countries Study. JAMA 1995;274:131-136. Copyright 1995 Am Med Assoc 
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Introduction 
The purpose of the Seven Countries Study was to study associations between risk factors 
and CHD mortality both at the population and at the individual level. After 5 years of 
follow-up, Keys et al. had already reported a strong ecological correlation between serum 
total cholesterol and mortality from CHD in the 16 cohorts of the Seven Countries Study1. 
On the individual level the 5 and 10-year follow-up data suggested strong associations 
between serum total cholesterol and CHD mortality in the United States and Northern 
Europe, but much weaker associations in Southern Europe and Japan.1-2 This could have 
resulted partly from small numbers of CHD deaths in these cultures. 
Recently, the 25-year mortality follow-up of the cohorts of the Seven Countries Study has 
been completed, and some preliminary data on the extent of CHD differences among 
cohorts have been reported.3 These data provided a unique opportunity to examine in 
detail the relationship between serum total cholesterol level and CHD mortality in different 
cultures. It is known that a single measurement may not accurately classify individuals 
with respect to cholesterol levels, which leads to a weakening of the observed relationship 
often referred to as regression dilution bias.4 In the current study, total cholesterol was 
measured not only at baseline but also during follow-up. The relationship between serum 
total cholesterol level and 25-year mortality from CHD in different cultures will be 
reported herein, and the effect of regression dilution bias will be discussed. 
Materials and methods 
Study population 
Between 1958 and 1964,12,763 men aged 40 through 59 years from seven countries were 
enrolled in the study.5 A total of 16 cohorts were examined in the following countries: the 
United States (US Railroad), Finland (East and West), the Netherlands (Zutphen), Italy 
(Rome Railroad, Crevalcore, and Montegiorgio), Greece (Crete and Corfu), Croatia and 
Serbia (the former Yugoslavia) (Zrenjanin, Velika Krsna, Belgrade, Dalmatia, and 
Slavonia), and Japan (Tanushimaru and Ushibuka). In 11 rural cohorts all men aged 40 
through 59 from official registries were invited. In the town of Zutphen, for every nine 
men, four were invited. In the United States and Rome, railroad personnel was recruited. 
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In Serbia, workers from a large cooperative in Zrenjanin and professors from the 
University of Belgrade were invited. Overall the participation rate was over 90%, with 
several cohorts reaching almost 100%. 
For the analyses the cohorts were pooled into six groups to obtain more statistical power: 
Northern Europe (East and West Finland and Zutphen), Inland Southern Europe (Rome, 
Crevalcore, Slavonia and Belgrade), Mediterranean Southern Europe (Crete, Corfu, 
Montegiorgio and Dalmatia), Serbia (Velika Krsna and Zrenjanin), the United States and 
Japan (Ushibuka and Tanushimaru). The criteria for pooling were similarities in baseline 
cholesterol level, cultural resemblance, and homogeneity with respect to cholesterol 
changes during the first 10 years of follow-up. In the Northern European cohort, 
cholesterol remained more or less stable during the first 10 years of follow-up. The 
American cohort was measured only after 5 years, and cholesterol levels were stable. In 
the Southern European cohorts, both Inland and Mediterranean, cholesterol levels 
increased by about 10%. Two Serbian cohorts (Velika Krsna and Zrenjanin) formed a 
separate group because they showed a dramatic cholesterol increase of about 30%. 
Cholesterol levels in Japan were more or less stable. 
Measurements 
In all cohorts the major cardiovascular risk factors were measured in a standardized way 
at baseline. In most cohorts this examination was repeated after 5 and 10 years, but in 
Japan cholesterol was not measured 5 years after baseline and in the United States not 
after 10 years. Details of the methods used have been extensively described elsewhere.1,3 
Total cholesterol was measured in a non-fasting blood sample, according to the Abell-
Kendall method, modified by Anderson and Keys, in standardized laboratories.6 Blood 
pressure was measured twice with a mercury sphygmomanometer at the end of the 
physical examination with the subject in supine position, following the methods later 
described in the World Health Organization (WHO) manual Cardiovascular Survey 
Methods? The mean of the two measurements was used in the analyses. Cigarette smoking 
was established by means of a standardized questionnaire. For the present analyses 
smoking was dichotomized into current smoking or non-smoking. 
Mortality follow-up 
All men were followed up for mortality for 25 years. Only 56 men (0.4%) were lost to 
follow-up. The underlying cause of death was coded in a standardized way, by two 
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reviewers (H.B. and A.M.), using the eighth revision of the WHO International 
Classification of Diseases*. The final cause of death was adjudicated on the basis of 
information from the official death certificate, in combination with information from 
medical and hospital records. The coder of the causes of death was blinded to the risk 
factor status of the subject. In the case of multiple causes of death, priority was given to 
unintentional injuries, followed by cancer in advanced stages, CHD, and stroke. For the 
current analyses CHD was defined as 'fatal coronary events manifested as myocardial 
infarction or sudden death of probable coronary origin occurring within 2 hours from the 
onset of symptoms, after the reasonable exclusion of other conditions'. This included ICD-
8 codes 410-413, 427.2, 427.6 and 795, the latter code only when the above mentioned 
definition was met. 
Statistical methods 
Cohort-specific, age-standardized 25-year CHD mortality rates were computed by 
weighing cohort-specific CHD mortality rates for 5-year age categories to the age 
distribution of the total study population. Cox proportional hazards (survival) analysis was 
used to estimate relative risks (RRs) (SAS statistical package, release 6.07, procedure 
PHREG)9. Cholesterol was analyzed continuously, or as quartiles, with the lowest quartile 
as the reference category. In all analyses adjustment was made for age (years), cigarette 
smoking (no/yes) and systolic blood pressure (rrnriHg). A possible interaction effect of 
cholesterol with smoking or blood pressure was tested by adding interaction terms to the 
model and testing (by means of an F-statistic) whether the explained variance was 
significantly increased.10 Analyses were carried out with and without respondents with 
CHD at entry examination. Since results were not different, in this article the analyses 
based on all respondents are presented. 
Respondents were categorized into quartiles based on their baseline cholesterol level. A 
single baseline cholesterol measurement is subject to random fluctuations, due to both 
laboratory measurement error and biological day-to-day fluctuations. When subjects are 
categorized according to their cholesterol level, the bottom category contains 
disproportionately many persons whose baseline cholesterol was underestimated and the 
top category has disproportionately many persons whose baseline cholesterol was 
overestimated4. Therefore, the observed cholesterol difference between the bottom and top 
categories is larger than the 'true' difference. This weakens the estimate of the relationship 
between cholesterol and mortality. This phenomenon is often referred to as regression 
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dilution bias4. In this study the dilution factor was calculated by dividing the difference 
in mean cholesterol between the lowest and highest quartiles based on the baseline 
cholesterol level by the same difference based on the cholesterol level of the survivors at 
5-year follow-up. Correction for the regression dilution bias was made by multiplying the 
coefficients from the survival analysis by the dilution factor and subsequently calculating 
RRs. 
Results 
In table 1 mean serum total cholesterol level at baseline and age-standardized 25-year 
CHD mortality rates are shown, together with some other baseline characteristics. Mean 
cholesterol levels ranged from around 4.15 to 4.40 mmol/1 in the Serbian and Japanese 
cohorts, to around 5.15 mmol/1 in the Southern European cohorts and around 6.20 to 6.70 
mmol/1 in the American and Northern European cohorts. Average systolic blood pressure 
ranged from 132.5 mmHg in Serbia to 144.0 mmHg in Northern Europe, and body mass 
index, expressed as weight in kilograms divided by height in meters, squared, ranged from 
22.0 kg/m2 in Japan to 25.5 kg/m2 in the United States and Inland Southern Europe. The 
prevalence of smoking varied between 56% in Serbia and 74% in Japan. Prevalence of 
CHD at baseline ranged from less than 1% in Mediterranean Southern Europe and Japan 
to 4.6% in the United States. Mortality rates for CHD ranged from 3% in the Japanese 
cohort to 20% in the Northern European cohort. 
In table 2 the cutoff points for the serum cholesterol quartiles are shown together with the 
mean cholesterol level for each quartile based on the baseline measurements as well as 
on the cholesterol measurement 5 years after baseline. The ratio of the difference in mean 
cholesterol between highest and lowest quartiles, baseline value divided by 5 year value, 
gives an estimate of the magnitude of the regression dilution bias. The regression dilution 
factor was comparable between the cohorts, and was on average 1.4. 
Table 3 shows the RR's per quartile for each of the cohorts, before and after adjustment 
for age, smoking and systolic blood pressure. In all cohorts except the Japanese one, CHD 
mortality increased with increasing cholesterol quartile, with an adjusted RR between 1.5 
and 2.3 for the highest compared with the lowest cholesterol quartile. 
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Table 1. Baseline characteristics of men aged 40-59 at baseline and age-standardized 25-year mortality (%)for the cohorts of the Seven 
Countries Study 
Age 
(years) 
Cholesterol 
(mmol/1) 
Systolic 
blood pres-
sure (mmHg) 
Body Mass 
Index 
(kg/m2) 
Cigarette 
smoking 
(%) 
Prevalence 
of CHD at 
baseline 
(%) 
Age-adjusted 
25-year CHD 
mortality rate 
(%) N" mean SD mean SD mean SD mean SD 
Northern Europe 2555 49.4 5.5 6.55 1.35 144.0 20.4 23.8 3.1 66.8 2.8 20.3 
United States 2571 49.4 5.8 6.20 1.15 139.2 20.8 25.5 3.2 59.0 4.6 16.0 
Southern Europe 
Inland 
2993 48.8 5.5 5.25 1.10 141.3 20.7 25.5 3.7 59.3 1.1 9.1 
Southern Europe 
Mediterranean 
2605 49.4 5.3 5.15 1.10 137.0 19.4 23.4 3.4 59.2 0.5 4.7 
Serbia 1027 49.3 5.8 4.25 0.85 132.5 18.8 23.6 3.5 56.3 1.5 7.7 
Japan 1010 49.8 5.7 4.25 0.90 135.0 25.0 22.0 2.4 74.3 0.6 3.2 
a: maximum number of valid observations 
Table 2. Cutoff points and mean serum total cholesterol level (mmol/l) (SD) to baseline cholesterol quartile per cohort, and calculated 
dilution factor 
Cholesterol quartile 
Northern 
Europe 
United 
States 
Southern 
Europe 
Inland 
Southern 
Europe 
Mediterranean Serbia Japan 
1 range 
mean baseline (SD) 
mean 5-yr follow-up (SD) 
<5.60 
5.00 (0.50) 
5.55 (0.95) 
<5.40 
4.85 (0.50) 
5.15 (0.80) 
<4.55 
4.00 (0.45) 
4.75 (0.85) 
<4.40 
3.95 (0.40) 
4.60 (0.80) 
<3.65 
3.30 (0.35) 
4.10 (0.80) 
<3.65 
3.20 (0.35) 
n.a." 
2 range 
mean baseline (SD) 
mean 5-yr follow-up (SD) 
5.60-6.40 
6.00 (0.25) 
6.25 (0.75) 
5.40-6.05 
5.75 (0.20) 
5.85 (0.70) 
4.55-5.15 
4.90 (0.20) 
5.45 (0.80) 
4.40-5.05 
4.75 (0.20) 
5.15 (0.70) 
3.65-4.15 
3.95 (0.15) 
4.70 (0.85) 
3.65-4.15 
3.90 (0.15) 
n.a. 
3 range 
mean baseline (SD) 
mean 5-yr follow-up (SD) 
6.45-7.30 
6.90 (0.45) 
6.80 (0.85) 
6.10-6.90 
6.50 (0.25) 
6.40 (0.70) 
5.20-5.90 
5.55 (0.20) 
5.90 (0.85) 
5.10-5.80 
5.45 (0.20) 
5.60 (0.75) 
4.15-4.75 
4.45 (0.20) 
5.10 (0.80) 
4.20-4.85 
4.50 (0.20) 
n.a. 
4 range 
mean baseline (SD) 
mean 5-yr follow-up (SD) 
>7.30 
8.30 (0.95) 
7.80 (1.15) 
>6.90 
7.75 (0.85) 
7.20 (1.05) 
>5.90 
6.70 (0.70) 
6.70 (1.10) 
>5.80 
6.60 (0.75) 
6.55 (1.05) 
>4.75 
5.35 (0.60) 
5.80 (1.00) 
>4.85 
5.50 (0.55) 
n.a. 
Cholesterol difference between the lowest and 
highest quartiles 
baseline 3.30 
5-yr follow-up 2.25 
2.90 
2.05 
2.70 
2.00 
2.70 
1.95 
2.05 
1.70 
2.25 
n.a. 
Dilution factor 1.45 1.43 1.36 1.39 1.23 n.a. 
a: n.a. = not available 
Table 3. Crude and adjusted relative risks (95% confidence interval) per cholesterol quartile for each cohort 
^ Cholesterol quartile p-value 
Cohort X2-trend 
1 (low) 2 3 4 (high) 
Northern Europe crude 1.0 1.18 (0.90-1.55) 1.45 (1.12-1.89) 2.16 (1.69-2.76) < 0.001 
adjusted" 1.0 1.11 (0.84-1.45) 1.34 (1.03-1.74) 2.03 (1.59-2.59) < 0.001 
United States crude 1.0 1.22 (0.89-1.68) 1.50 (1.11-2.04) 2.74 (2.07-3.63) < 0.001 
adjusted 1.0 1,09 (0.79-1.51) 1.39 (1.03-1.89) 2.34 (1.77-3.11) < 0.001 
Southern Europe crude 1.0 1.24 (0.86-1.79) 1.55 (1.10-2.18) 1.65 (1.17-2.33) <0.01 
Inland adjusted 1.0 1.21 (0.84-1.74) 1.50 (1.06-2.12) 1.52 (1.07-2.15) <0.01 
Southern Europe crude 1.0 1.12 (0.62-2.00) 1.51 (0.87-2.61) 2.30 (1.38-3.82) < 0.001 
Mediterranean adjusted 1.0 1.03 (0.57-1.85) 1.35 (0.78-2.33) 1.66 (0.98-2.80) <0.05 
Serbia crude 1.0 1.57 (0.76-3.27) 2.17 (1.10-4.30) 2.17 (1.07-4.38) <0.05 
adjusted 1.0 1.43 (0.69-2.96) 1.88 (0.94-3.73) 1.86 (0.92-3.76) £0.05 
Japan crude 1.0 1.46 (0.61-3.50) 0.82 (0.30-2.26) 1.13 (0.45-2.86) ¿0.05 
adjusted 1.0 1.51 (0.60-3.84) 0.89 (0.31-2.57) 1.13 (0.42-3.02) £0.05 
a : adjusted for age, systolic blood pressure and cigarette smoking 
Cholesterol and CHD mortality, Seven Countries Study 
CHD mortality (%) 
3.9 4.55 5.2 5.85 6.5 7.15 
total cholesterol (mmol/1) 
•*• Northern Europe + United States * Inland Southern Europe 
* Medit. Southern Europe X Serbia • Japan 
Figure 1. 25-year CHD mortality rates per baseline cholesterol quartile, adjusted for age, 
cigarette smoking and systolic blood pressure. 
Table 4. Relative risks (95% confidence intervals) per 0.50 mmol/l cholesterol 
increase, before and after correction for regression dilution. Adjusted for age, smoking 
and systolic blood pressure 
Cohort 
Unadjusted for 
regression dilution 
Adjusted for 
regression 
dilution 
Northern Europe 1.12 (1.08-1.15) 1.18 
United States 1.15 (1.10-1.19) 1.21 
Southern Europe Inland 1.10 (1.04-1.16) 1.14 
Southern Europe 
Mediterranean 
1.12 (1.04-1.22) 1.18 
Serbia 1.11 (0.97-1.28) 1.14 
Japan 0.96 (0.77-1.18) not available 
Overall 1.12 (1.09-1.16) LIT 
a: Based on the average regression dilution factor of 1.4 (see table 2) 
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In figure 1, mortality rates for all cohorts for each quartile, adjusted for age, smoking and 
systolic blood pressure, are plotted against the mean cholesterol level of that quartile. 
From this figure it becomes clear that the absolute level of risk is strikingly different 
among the cohorts. For example, for a cholesterol level of around 5.45 mmol/1 there is a 
threefold range in mortality rates, varying from 4% to 5% in Japan and the Mediterranean 
to 10% in Inland Southern Europe, 12% in the United States and 15% in Northern Europe. 
A little less than half the CHD mortality occurred in the first 15 years of follow-up, and 
a little more than half occurred in the last 10 years of follow-up. The relationships of 
CHD to baseline cholesterol level appeared to be similar in the early and late follow-up 
periods (data not shown). Death rates were lower in the United States but higher in all 
other cohorts in the late than in the early follow-up period, with a particularly large 
increase in Serbia. 
Although the absolute levels of CHD mortality are different, the slopes of the curves for 
the different cohorts are comparable. Based on the approximation of a linear regression 
analysis, for each of the cohorts the increase in risk was estimated for a 0.50 mmol/1 
increase in total cholesterol (table 4). An overall estimate for all cohorts combined was 
also made, adjusting for cohort with dummy variables. Only the RR for Japan did not 
differ from 1.0; in the other five cohorts the estimated increase for a 0.50 mmol/1 
cholesterol increase ranged from 1.10 to 1.15. These estimates did not significantly differ 
from the combined estimate of 1.12. When this combined estimate was corrected for 
regression dilution bias, it was calculated that a 0.50 mmol/1 increase in total serum 
cholesterol corresponded with an RR of 1.17. 
Discussion 
No statistically significant differences were observed between the different cohorts with 
respect to the regression coefficients for the relationship between serum total cholesterol 
and long-term CHD mortality. For the Japanese cohort the regression coefficient was not 
statistically significantly different from 1.0. However, for several reasons, power to detect 
an association in the Japanese cohort was low: the Japanese cohort was relatively small, 
the number of CHD cases was small (N=22), and cholesterol levels were extremely low. 
A considerably larger study in China reported a significant positive linear relationship 
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between total cholesterol and CHD mortality, even at very low cholesterol levels of about 
2.95 mmol/Ln Baseline cholesterol levels in Serbia were about the same as in Japan, but 
long-term CHD mortality in this, cohort was much higher, probably because total 
cholesterol increased dramatically (by about 30%) during the first 10 years of follow-up. 
This and the relatively small size of the Serbian cohort may explain why in this cohort the 
regression coefficient was positive, although not statistically significant. 
It is often reported that the predictive power of a baseline cholesterol measurement 
decreases over long follow-up periods12. A comparison of early and late follow-up in our 
study, however, showed only a slight reduction in RR's for the late versus early follow-up. 
From our study it was estimated that an increase in total cholesterol of 0.50 mmol/1 
corresponds to a 12% increase in long-term CHD mortality and, when corrected for 
regression dilution bias, even to a 17% increase. Although these estimates are based on 
an approximate linearity assumption, they correspond with a recent estimate of Law et al.1 3 
In their analyses the estimated decrease in CHD mortality per 0.6 mmol/1 decrease in total 
cholesterol was 17% for men aged 45 through 54 years (adjusted for regression dilution, 
24%) and 12% for men aged 55 through 64 years (adjusted for regression dilution, 17%). 
The dilution factors in our study were about 1.4 in Northern Europe, Southern Europe 
(Inland and Mediterranean) and the United States, and about 1.2 in Serbia. The smaller 
dilution factor in Serbia can be explained by the fact that during the first 5 years serum 
cholesterol levels were increasing strongly. The magnitude of the regression dilution bias 
seems to be universal: apart from similarities in the different cultures of the Seven 
Countries Study, Law et al. 1 3 obtained a similar estimate, and also other studies in which 
cholesterol was remeasured after several years found estimates of around 1.4 (see 
reference 13). This means that the weakening of observed associations between cholesterol 
and mortality due to a single cholesterol measurements is the same in different cultures, 
as long as cholesterol levels are relatively stable. However, the dilution factor, if estimated 
several years later, would be biased by coexisting time trends. 
No interaction was observed between smoking or blood pressure and cholesterol, 
indicating that RRs were the same in smokers and non-smokers and not dependent on 
blood pressure levels. However, when an RR of 1.1 is translated into excess mortality, the 
absolute CHD risk is also important. Since absolute CHD risk is higher in smokers 
compared with non-smokers, a 10% increase in risk will be translated into a larger number 
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of excess deaths in smokers than in non-smokers. More generally, with respect to primary 
prevention, a 10% risk reduction in populations with high cholesterol levels will translate 
into a larger number of lives saved than a 10% risk reduction in populations with low 
cholesterol levels. 
Our data showed that the relation between serum total cholesterol level and CHD risk was 
similar in different cultures, but the absolute levels of CHD mortality were strikingly 
different. Within cultures the RR for the highest cholesterol quartile compared with the 
lowest was about 1.5 to 2.3. Between cultures, this range was larger, even at the same 
level of serum total cholesterol. At a cholesterol level of about 5.45 mmol/1, CHD 
mortality rates varied from 4% to 5% in Japan and Mediterranean Southern Europe to 
10% in Inland Southern Europe, 12% in the United States, and 15% in Northern Europe. 
Because of these differences in mortality rates, the lowest cholesterol quartile for Northern 
Europe, with a mean level of about 4.90 mmol/1, had about a two-fold higher risk than the 
highest cholesterol quartile for Mediterranean Southern Europe, with a mean cholesterol 
level of about 6.45 mmol/1. These differences in risk were not explained by differences 
in age, smoking, or systolic blood pressure, because the rates were adjusted for these 
factors. However, because all measurements are subject to measurement error, it is never 
possible to completely remove the effect of these confounders, so there may be some 
residual corrfounding. The public health implication of this difference is important: it may 
be impossible to achieve a reduction of CHD mortality rates in Northern Europe and the 
United States to the Mediterranean level by a cholesterol reduction alone; the reduction 
in cholesterol must be accompanied by changes in other factors to achieve a profile more 
typical of the 'low-risk' countries. 
Other factors that explain these differences have to be considered. First, methodological 
differences can play a role, such as biases in the coding of the death certificates. However, 
the study was designed to investigate CHD mortality and its determinants in different 
cultures, and coding of the causes of death was done by two reviewers using standard 
criteria to ensure comparability among the countries. Differences in medical care can 
result in different survival rates that would lead to differences in mortality rates. However, 
to cause the observed difference in mortality rates, medical care would have to be of lower 
quality in Northern Europe and the United States than in the Mediterranean countries. It 
is unlikely that this is the case. 
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It has been postulated that the oxidized form of low density lipoprotein (ox-LDL) is more 
atherogenic than native LDL.1 4 The amount of ox-LDL is the result of the balance between 
the amount of oxidative stress (eg, smoking) and the antioxidant capacity.15 Susceptibility 
of LDL particles to oxidation is related to their fatty acid composition: polyunsaturated 
fatty acids increase susceptibility to oxidation compared with monounsaturated fatty 
acids.16 Antioxidant capacity is influenced by the amount of antioxidants in the diet (eg, 
vitamins C and E, 8-carotene and flavonoids).17 A given level of serum total cholesterol 
will represent different levels of ox-LDL in different cultures because of differences in the 
above mentioned factors. 
Differences in nutritional factors may play an important role because dietary patterns differ 
greatly between the cohorts.1 1 8 In the present study, dietary information has been collected 
in a small subsample of men within each cohort, to characterize the dietary pattern of the 
cohorts. Compared with the Northern European and American diet, the Mediterranean diet 
contained less meat but more fish, fruits, vegetables, and ethanol.18 The fatty acids 
consumed in Northern Europe and the United States were predominantly saturated but in 
the Mediterranean predominantly mono-unsaturated.19 Intake of the anti-oxidant vitamins 
B-carotene and a-tocopherol was highest in Mediterranean Southern Europe.20 Flavonoid 
intake was twice as high in Southern Europe (Inland and Mediterranean) as in Northern 
Europe and the United States, but was highest in Japan.21 Intake of flavonoids, 
polyphenolic substances with antioxidant properties, has been shown to protect against 
CHD.2 2 In an ecological analysis of the Seven Countries Study data, it was shown that, 
at the cohort level, mean intake of saturated fat and flavonoids and current smoking were 
strongly correlated (r=0.95) with the CHD mortality rate.21 This means that at the cohort 
level the occurrence of CHD was almost completely explained by saturated fatty acids, 
flavonoids, and smoking. However, because of strong correlations between dietary 
variables, it is possible that dietary variables strongly correlated with saturated fatty acids 
and flavonoids also play a role. 
The effect of a Mediterranean diet was studied in a secondary prevention trial on CHD.2 3 
Although no difference in total cholesterol levels between the experimental and control 
group occurred, after 27 months both cardiac and all-cause mortality were significantly 
lower in the experimental group. The fact that the beneficial effect of the experimental 
diet was already apparent in the first months suggests an effect of this Mediterranean diet 
on thrombogenesis. 
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These results indicate that the relationship between diet and cholesterol explains only a 
part of the relationship between diet and coronary heart disease. Dietary factors that 
influence LDL oxidation and thrombotic factors are also of great importance. 
Besides differences in diet, differences in biological risk factors (other than total 
cholesterol) and genetic factors may play a role in explaining differences in absolute risk. 
Differences in high density lipoprotein (HDL) cholesterol and post-prandial lipoproteins 
can be present, and are not accounted for by the total cholesterol level.24 Furthermore, the 
effect of genetic differences among cultures that would influence atherogenicity of 
cholesterol (due to differences in LDL-subclasses or HDL cholesterol) can not be ruled 
out.25 
In conclusion, our study showed that the relative increase in CHD risk with an increase 
in serum total cholesterol was comparable in different cultures. However, the absolute 
increase was quite different from culture to culture, since the absolute level of CHD risk 
differed substantially among cultures. Therefore, from a public health perspective it is not 
enough to focus solely on serum cholesterol levels to decrease the burden of CHD in 
populations. It appears that reductions in serum total cholesterol levels are not likely to 
bring cultures with a high CHD risk, such as the United States and Northern Europe, back 
to a CHD mortality level characteristic for the Mediterranean and Japanese cultures unless 
other factors are also changed. The Mediterranean and Japanese diets, low in saturated fat 
and rich in antioxidants, may have beneficial effects both on the oxidizability of LDL 
particles and on thrombogenesis, apart from an effect on LDL levels per se. This stresses 
the importance of factors other than serum cholesterol, blood pressure and smoking status, 
such as diet, in CHD prevention. 
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Abstract 
Background: The association of low total cholesterol levels with non-cardiovascular 
mortality is still in debate. This led us to investigating the association between serum total 
cholesterol level (TC) and 25-year non-cardiovascular and all-cause mortality in the Seven 
Countries Study. 
Methods: TC was measured between 1958 and 1964 in 12,467 men aged 40-59 in 16 
cohorts located in seven countries in Europe, the USA and Japan. Relative risks (RR) were 
estimated using Cox proportional hazards (survival) analysis for continuous cholesterol 
levels and for the TC categories <4.15, 5.16-6.20 and >6.20 rnmol/1 using the category 
4.15-5.15 rnmol/1 as the reference. Adjustment was made for age, smoking, systolic blood 
pressure and cohort. Smoking strata were also examined. 
Results: Cancer mortality was inversely associated with TC category only in smokers. 
Non-cardiovascular/non-cancer mortality was inversely associated with TC category in 
smokers, and elevated in non-smokers only at TC <4.15 mmol/1. For subgroups of diseases 
(infections and respiratory diseases) inverse associations were observed both in smokers 
and non-smokers. Total mortality in non-smokers showed a J-shaped relation with TC 
(lowest mortality for TC of 4.15-5.15 mmol/1), while no association with TC was observed 
in smokers. Exclusion of deaths during the first 10 years of follow-up did not alter the 
results. There were indications that alcohol abuse was more prevalent at low TC levels. 
Conclusion: The inverse association of TC with non-cardiovascular mortality was most 
prominent among smokers. The associations observed were, at least partly, explained by 
confounding. For non-smokers the lowest total mortality rate was observed for TC levels 
of 4.15-5.15 mmol/1. 
Submitted as: 
Verschuren WMM, Jacobs DR, Bloemberg BPM, Kromhout D, Menotti A, Aravanis C, Blackburn H, 
Buzina R, Dontas AS, Fidanza F, Nedeljkovic S, Nissinen A, Toshima H. Serum total cholesterol and 
long-term non-cardiovascular and all-cause mortality. Twenty-five year follow-up of the Seven 
Countries Study. 
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Introduction 
The strong positive relation between serum total cholesterol and risk of mortality from 
coronary heart disease has been shown in many prospective studies in the last decades.1"3 
The relation has been shown to be positive and graded, even at lower cholesterol levels, 
which means that the lower the cholesterol level, the lower the coronary heart disease 
mortality risk.4 
However, questions have been raised about an increased mortality risk at the lower end 
of the cholesterol distribution.5 A number of studies have reported an increased risk for 
cancer mortality at a low cholesterol level, thus off-setting the lower cardiovascular 
mortality risk.6"16 Apart from an increased cancer risk, a number of studies have also 
reported an increased mortality risk for non-cardiovascular/non-cancer diseases at lower 
cholesterol levels. 5 , 1 5 , 1 7 After 15 years of follow-up in the Seven Countries Study, excess 
cancer mortality was reported at low cholesterol levels.18 Recently, the 25-year mortality 
follow-up of all cohorts of the Seven Countries Study was completed, and we are now 
able to exclude up to ten years of follow-up in order to exclude early mortality due to pre-
existing diseases. 
From a public health point of view it is important to know whether the inverse association 
of total cholesterol and non-cardiovascular mortality is causal. If causal, this would imply 
that there is an optimum cholesterol level, and that cholesterol lowering below that level 
would not be desirable. Furthermore, because lipids are important in many body processes, 
it is important to shed additional light on possible roles of lipids in disease etiology. In 
this paper, the emphasis will be on the associations of total cholesterol with cancer, non-
cardiovascular/non-cancer and all-cause mortality. For comparative purposes also the 
association between total cholesterol and cardiovascular mortality will be reported. 
Materials and methods. 
Study population 
Between 1958 and 1964, 12,763 men aged 40-59 from seven different countries were 
enrolled in the study (Keys, 1967). A total of 16 cohorts were examined in the following 
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countries: USA (US Railroad), Finland (East and West), the Netherlands (Zutphen), Italy 
(Rome Railroad, Crevalcore and Montegiorgio), Greece (Crete and Corfu), Croatia and 
Serbia (the former Yugoslavia: Dalmatia, Slavonia, Zrenjanin, Velika Krsna, Belgrade) and 
Japan (Tanushimaru and Ushibuka). In 11 rural cohorts all men aged 40-59 from official 
registries were invited. In the town of Zutphen (Netherlands) a four-nineth sample of these 
men was invited. In the USA and Rome (Italy), railroad personnel was recruited. In Serbia 
(former Yugoslavia) workers from a large cooperative in Zrenjanin and professors from 
the University of Belgrade were invited. Overall the participation rate was over 90%, with 
several cohorts reaching almost 100%. 
Measurements 
The major cardiovascular risk factors were measured in a standardized way at baseline 
and, in most cohorts, at 5 and 10 years after baseline. In Japan cholesterol was not 
measured 5 years after baseline and in the USA not after 10 years. Details of the methods 
used have been extensively described elsewhere.19,20 Total cholesterol was measured in a 
non-fasting blood sample, according to the Abell-Kendall method, modified by Anderson 
and Keys, in standardized laboratories.21 Blood pressure was measured twice at the end 
of the physical examination with the subject in supine position, with a mercury 
sphygmomanometer following the methodology later described in the WHO manual 
'Cardiovascular Survey Methods'.22 The mean of the two measurements was used in the 
analyses. Cigarette smoking was established by means of a standardized questionnaire, 
and, for the present analyses, dichotomized into current smoking or non-smoking. 
Mortality follow-up 
All men were followed for mortality during 25 years. Only 56 men (0.4%) were lost to 
follow-up. The underlying cause of death was coded in a standardized way, by two re-
viewers (H.B. and A.M.) using the 8th revision of the WHO International Classification 
of Diseases.23 The final cause of death was adjudicated on the basis of information from 
the official death certificate, in combination with information from medical and hospital 
records. The coder of the causes of death was blind to the risk factor status of the subject. 
In the case of multiple causes of death, priority was given to accidents, followed by cancer 
in advanced stages, coronary heart disease and stroke. Only the primary cause of death 
was used in the analyses. 
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Statistical analyses 
For the cohort-specific analyses the cohorts were pooled into six cohorts based on 
sirnilarities in baseline cholesterol level, cultural resemblance and homogeneity with 
respect to cholesterol changes during the first ten years of follow-up: Northern Europe 
(East and West Finland, the Netherlands), the United States, Inland Southern Europe 
(Rome, Crevalcore, Slavonia, Belgrade), Mediterranean Southern Europe (Dalmatia, 
Montegorgio, Crete and Corfu), Serbia (Velika Krsna, Zrenjanin), and Japan (Tanushimaru 
and Ushibuka). In this way, statistical power was increased within each cohort, but 
adjustment for cultural differences could still be made. In the American, Northern 
European and Japanese cohorts, cholesterol remained more or less stable during the first 
5 respectively 10 years of follow-up. In the Southern European cohorts, both inland and 
mediterranean, cholesterol levels increased by about 10% while two Serbian cohorts 
(Zrenjanin and Velika Krsna) showed a dramatic increase of about 30%. A total of 343 
men were excluded from the analyses due to missing values of cholesterol, blood pressure 
or smoking status at baseline, or unknown vital status. 
Cox' proportional hazards (survival) analysis was used to estimate relative risks (RR), 
using the SAS statistical package (release 6.07, procedure PHREG).24 Cholesterol was 
entered as a continuous linear term or categorized into four categories (less than 4.15 
mmol/1, 4.15-5.15 mmol/1, 5.16-6.20 mmol/1 and 6.20 mmol/1 or more. Due to small 
numbers in the lowest category for some cohorts the second cholesterol category (4.15-
5.15 mmol/1) was used as the reference category. Adjustment was made for age (years), 
cigarette smoking (no/yes) and systolic blood pressure (rnmHg). Furthermore, to adjust for 
differences in mortality between the different cohorts, dummy variables for cohort were 
entered into the model, Northern Europe being the reference. To exclude the effect of 
early mortality, analyses were repeated with exclusion of the first ten years of follow-up. 
Main end-points were cardiovascular diseases, cancer, non-cardiovascular/non-cancer and 
all-cause mortality. These large, heterogeneous groups of diseases were broken down into 
smaller, more specific, disease categories if there were 100 cases or more, leading to the 
following subdivision (for ICD-8 codes see table 2): cardiovascular disease (CVD) was 
divided into coronary heart disease (CHD), cerebrovascular disease (CVA) and other 
CVD; cancer was divided into digestive cancer, (which was further subdivided into 
stomach cancer, colon/rectum cancer, and other digestive cancers (two-thirds of which 
were liver cancers)), lung cancer, lymphatic/hematopoietic cancers, and other cancers; non-
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cardiovascular/non-cancer causes were divided into infections, respiratory diseases (which 
was subdivided into chronic obstructive pulmonary diseases (COPD) and 'other' 
respiratory diseases), digestive diseases (subdivided into liver cirrhosis and 'other' 
digestive diseases), accidents and 'other' non-cardiovascular/non-cancer causes. Mortality 
from liver cirrhosis and alcohol dependency syndrome combined was defined as 'alcohol 
related diseases'. 
Results 
In table 1 some characteristics of the cholesterol distribution in the six cohorts are given. 
Mean cholesterol levels ranged from about 4.25 mmol/1 in Japan and Serbia to about 5.16 
mmol/1 in the inland and mediterranean Southern European cohorts and about 5.45 mmol/1 
in Northern Europe and the United-States. The percentage of respondents with a 
cholesterol level below 4.15 mmol/1 ranged from 2% to 48%. During twenty-five years 
of follow-up 5974 men died, for 5830 of these men a baseline cholesterol measurement 
was available. About half of all deaths could be attributed to cardiovascular diseases, 
while cancer and non-cardiovascular/non-cancer causes each contributed about 25% to 
total mortality (table 2). 
Mortality from cardiovascular diseases (CVD) increased with increasing cholesterol 
category, mainly due to the strong positive relation between total cholesterol and coronary 
heart disease mortality (table 3). In analyses with linear cholesterol, a 1.0 mmol/1 increase 
in total cholesterol was associated with a RR of 1.16 for CVD mortality. In the cohort-
specific analysis a positive relation between total cholesterol and cardiovascular disease 
mortality was not observed in Southern Europe and Japan (table 4). 
Mortality from cancer was elevated in the lowest cholesterol category compared to the 
second category (4.15-5.15 mmol/1), and decreased further in the highest cholesterol 
category. The estimated RR per 1.0 mmol/1 cholesterol increase was 0.92 (table 3). A 
significant inverse association with total cholesterol (continuous) was observed for 
digestive and lung cancer. The association was borderline significant (p<0.10) for 
lymphatic and hematopoietic cancers. Within the group of digestive cancers, the inverse 
association was strongest for the group of 'other digestive cancers' compared to stomach 
and colon/rectum cancers. No association with the remaining cancers was observed. 
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Table 1. The serum total cholesterol distribution at baseline in men aged 40 to 59 years, according to cohort. 
The Seven Countries Study 
< 4.15 mmol/1 
4.15-5.15 
mmol/1 
5.16-6.20 
mmol/1 
>6.20 
mmol/1 
Cohort N mean SD N % N % N % N % 
Northern Europe 2489 6.54 1.34 38 2 295 12 754 30 1402 56 
United States 2555 6.21 1.16 61 2 369 14 906 35 1219 48 
Southern Europe 
Inland 
2933 5.28 1.09 379 13 1039 35 971 33 544 19 
Southern Europe 
Mediterranean 
2548 5.17 1.09 392 15 958 38 778 31 420 16 
Serbia 1025 4.25 0.83 475 46 415 40 111 11 24 2 
Japan 917 4.27 0.91 441 48 329 36 128 14 19 2 
Total 12467 5.53 1.37 1786 14 3405 27 3648 29 3628 29 
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Table 2. Frequency of causes of death after 25-years of follow-up" 
Cause of death ICD-8 code(s) N of cases 
Cardiovascular 390-459 2901 
Coronary heart disease 410-414, 795 1472 
Cerebrovascular disease 430-438 778 
Other cardiovascular diseases 390-409, 415-429, 440-459 651 
Cancer 140-239 1551 
Digestive 150-159 582 
Stomach 151 255 
Colon and rectum 153,154 158 
Other digestive 152,155-159 134 
Lung 162 418 
Lymphatic/Hematopoietic 200-209 110 
Other cancers 140-149, 160, 161, 163-199, 210-239 441 
Non-cardiovascular/Non-cancer 0-139, 240-389, 459-794, 796-999 1378 
Infections 0-139 140 
Respiratory 460-519 366 
Chronic obstructive pulmonary 490-492 230 
disease 
Other respiratory 460-489, 493-519 136 
Digestive 520-579 267 
Liver cirrhosis 571 148 
Other digestive 520-570, 575-578 119 
Accidents 800-999 297 
Other non-cardiovascular/non-cancer 240-389, 580-794, 796-799 308 
All causes 0-999 5830 
a: based on men with a baseline cholesterol measurement 
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Table 3. Adjusted" relative risks (95% confidence interval) for selected causes of death for different total cholesterol levels using 
4.15-5.15 mmol/l as reference and relative risk (95% confidence interval) per 1.0 mmol/l cholesterol increase 
Cholesterol level (mmol/l) p-value 
X2-trend 
RR per 1.0 
mmol/l increaseb S 4.15 4.15-5.15 5.16-6.20 >6.20 
Cardiovascular disease 0.98 (0.85-1.14) 1.0 1.12 (1.00-126) L38 (1.23-1.55) <0.001 1.16 (1.13-L21) 
Coronary heart disease 0.91 (0.72-1.17) 1.0 1.19 (1.02-1.40) 1.65 (1.41-1.93) <0.001 1.26 (1.21-1.31) 
Cerebrovascular disease 1.09 (0.87-1.37) 1.0 1.37 (1.13-1.66) 1.22 (0.98-1.52) 0.08 1.03 (0.96-1.10) 
Other CVD 0.92 (0.71-1.19) 1.0 0.85 (0.68-1.05) 0.99 (0.80-1.24) 0.87 1.07 (0.99-1.14) 
Cancer total 1.16 (0.98-136) 1.0 1.00 (0.87-1.14) 0.89 (0.76-1.03) 0.01 0.92 (0.88-0.97) 
Digestive 1.25 (0.98-1.61) 1.0 1.09 (0.87-1.36) 0.79 (0.61-1.02) 0.01 0.89 (0.82-0.96) 
Stomach 1.01 (0.70-1.44) 1.0 0.77 (0.55-1.08) 0.79 (0.54-1.15) 0.16 0.94 (0.84-1.06) 
Colon/rectum 1.23 (0.71-2.13) 1.0 1.50 (0.97-2.32) 0.90 (0.54-1.49) 0.52 0.87 (0.75-1.02) 
Other digestive 1.91 (1.16-3.15) 1.0 1.35 (0.84-2.18) 0.70 (0.39-1.25) 0.01 0.80 (0.67-0.95) 
Lung 1.16 (0.81-1.66) 1.0 0.85 (0.65-1.12) 0.82 (0.62-1.08) 0.06 0.88 (0.81-0.97) 
Lymph/hemato0 1.54 (0.81-2.91) 1.0 0.91 (0.55-1.53) 0.76 (0.44-1.32) 0.07 0.88 (0.73-1.05) 
Other 0.98 (0.72-1.34) 1.0 1.07 (0.83-1.37) 1.11 (0.84-1.47) 0.40 1.03 (0.94-1.12) 
Non-CVD/non-cancer 1.23 (1.05-L45) 1.0 1.00 (0.87-1.16) 0.86 (0.73-1.01) 0.001 0.91 (0.87-0.96) 
Infections 1.72(1.12-2.64) 1.0 0.81 (0.51-1.28) 0.43 (0.23-0.82) <0.001 0.68 (0.57-0.82) 
Respiratory 0.93 (0.67-1.27) 1.0 0.82 (0.62-1.08) 0.65 (0.48-0.90) 0.03 0.88 (0.79-0.97) 
COPD" 0.82 (0.54-1.24) 1.0 0.98 (0.70-1.38) 0.70 (0.47-1.05) 0.40 0.93 (0.81-1.05) 
Other respiratory 1.13 (0.68-1.85) 1.0 0.61 (0.38-0.97) 0.60 (0.36-0.99) 0.01 0.80 (0.68-0.95) 
Digestive 1.87 (1.29-2.69) 1.0 1.26 (0.90-1.76) 1.27 (0.88-1.84) 0.32 0.94 (0.84-1.06) 
Liver cirrhosis 1.78 (1.11-2.87) 1.0 1.05 (0.68-1.63) 1.16 (0.72-1.87) 0.25 0.87 (0.74-1.02) 
Other digestive 2.01 (1.13-3.58) 1.0 1.60 (0.95-2.71) 1.47 (0.82-2.63) 0.84 1.03 (0.87-1.22) 
Accidents 1.05 (0.72-1.53) 1.0 1.21 (0.83-1.68) 1.18 (0.83-1.68) 0.39 1.06 (0.95-1.18) 
Other non-CVD/non-cancer 1.09 (0.77-1.56) 1.0 0.99 (0.73-1.33) 0.79 (0.56-1.10) 0.12 0.90 (0.81-1.00) 
Total mortality 1.10 (1.01-1.21) 1.0 1.06 (0.98-1.14) 1.10 (1.02-1.19) 0.27 1.04 (1.01-1.06) 
H : Adjusted for age, cigarette smoking, systolic blood pressure and cohort 
b : Estimated from a separate analysis with cholesterol as a continuous variable 
c : Lymphatic/hematopoietic 
d : Chronic Obstructive Pulmonary Disease 
Table 4. Relative risk (95% confidence interval) per 1.0 mmol/l total cholesterol increase in the cohorts separately, adjusted for age, 
cigarette smoking, systolic blood pressure and cohort 
Non-cardiovascular 
Cardiovascular Cancer Non-cancer All-cause mortality 
Northern Europe 1.21 (1.14-1.28) 0.88 (0.81-0.96) 0.92 (0.82-1.03) 1.06 (1.01-1.10) 
United States 1.25 (1.17-1.33) 0.95 (0.85-1.06) 0.89 (0.80-1.02) 1.11 (1.05-1.17) 
Southern Europe 
Inland 
1.10 (1.02-1.19) 1.01 (0.92-1.12) 0.89 (0.80-0.99) 1.03 (0.97-1.08) 
Southern Europe 
Mediterranean 
1.02 (0.93-1.13) 0.83 (0.74-0.94) 0.89 (0.80-1.00) 0.94 (0.89-1.00) 
Serbia 1.19 (1.02-1.39) 0.88 (0.69-1.11) 1.12 (0.92-1.36) 1.07 (0.97-1.20) 
Japan 0.88 (0.72-1.07) 0.99 (0.82-1.19) 0.88 (0.71-1.07) 0.92 (0.82-1.02) 
Overall" 1.16 (1.13-1.21) 0.92 (0.88-0.97) 0.91 (0.87-0.96) 1.04 (1.01-1.06) 
a: adjusted tor cohort 
Table 5. Adjusted' relative risks (95% confidence interval) for smokers (N-7,637) and non-smokers (N=4,781), for different total 
cholesterol levels, using a cholesterol level of 4.15-5.15 mmol/l as reference, and relative risks (95% confidence interval) per 
1.0 mmol/l cholesterol increase!' 
Cholesterol level (mmol/l) 
<4.15 4.15-5.15 5.16-6.20 > 6.20 RR per 1.0 
mmol/l increase 
Cancer (total) 
Non-smokers 1.13 (0.80-1.58) 1.0 1.22 (0.94-1.59) 1.08 (0.81-1.44) 0.97 (0.89-1.07) 
Smokers 1.16 (0.96-1.40) 1.0 0.93 (0.80-1.10) 0.82(0.69-0.98) 0.90 (0.85-0.96) 
Digestive cancers 
Non-smokers 1.13 (0.69-1.85) 1.0 1.69 (1.14-2.51) 1.07 (0.68-1.69) 0.97 (0.85-1.11) 
Smokers 1.29 (0.96-1.72) 1.0 0.87 (0.66-1.15) 0.69 (0.50-0.96) 0.85 (0.76-0.94) 
Lung cancer 
Non-smokers 1.34 (0.51-3.50) 1.0 0.99 (0.47-2.08) 0.97 (0.45-2.10) 0.86 (0.67-1.10) 
Smokers 1.14 (0.77-1.68) 1.0 0.83 (0.62-1.11) 0.80(0.59-1.07) 0.89 (0.81-0.98) 
Lymphatic/hematopoietic cancers 
Non-smokers 2.17 (0.83-5.68) 1.0 0.89 (0.38-2.11) 1.25 (0.54-2.87) 0.93 (0.71-1.21) 
Smokers 1.19 (0.50-2.84) 1.0 0.92 (0.49-1.76) 0.50 (0.24-1.07) 0.84 (0.66-1.07) 
Other cancers 
Non-smokers 0.85 (0.45-1.61) 1.0 0.90(0.56-1.45) 1.09 (0.67-1.78) 1.06 (0.90-1.24) 
Smokers 1.02(0.71-1.46) 1.0 1.14(0.85-1.54) 1.11 (0.79-1.55) 1.01 (0.91-1.13) 
Continued on next page 
Table 5. Continued 
Cholesterol level (rnmol/1) 
<4.15 4.15-5.15 5.16-6.20 >6.20 RR per 1.0 mmol/1 increase2 
Non-CVD/Non-Cancer 
Non-smokers 
Smokers 
Infections 
Non-smokers 
Smokers 
Respiratory 
Non-smokers 
Smokers 
Digestive 
Non-smokers 
Smokers 
Accidents 
Non-smokers 
Smokers 
Other non-CVD/non-Cancer 
Non-smokers 
Smokers 
1.35 (1.01-1.80) 
1.18 (0.97-1.44) 
2.63 (1.12-6.22) 
1.48 (0.90-2.44) 
1.20 (0.64-2.25) 
0.86 (0.59-1.24) 
1.58 (0.84-2.98) 
2.02 (1.29-3.18) 
1.08 (0.56-2.08) 
1.07 (0.67-1.70) 
1.15 (0.63-2.09) 
1.05 (0.68-1.64) 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.14 (0.89-1.47) 
0.94 (0.78-1.12) 
0.79 (0.30-2.05) 
0.82 (0.48-1.40) 
0.76 (0.44-1.31) 
0.85 (0.62-1.17) 
1.23 (0.70-2.18) 
1.25 (0.83-1.90) 
1.57 (0.93-2.65) 
1.03 (0.69-1.54) 
1.24 (0.78-2.00) 
0.84 (0.57-1.24) 
1.04 (0.79-1.38) 
0.77 (0.63-0.94) 
0.45 (0.13-1.54) 
0.43 (0.20-0.92) 
0.65 (0.35-1.19) 
0.66 (0.45-0.95) 
1.64 (0.90-2.96) 
1.07 (0.67-1.72) 
1.37 (0.76-2.47) 
1.08 (0.70-1.67) 
1.04 (0.62-1.77) 
0.63 (0.40-0.99) 
0.97 (0.89-1.06) 
0.88 (0.83-0.94) 
0.69 (0.49-0.97) 
0.68 (0.55-0.85) 
0.82 (0.67-1.00) 
0.90 (0.80-1.01) 
0.98 (0.81-1.19) 
0.91 (0.79-1.06) 
1.17 (1.00-1.38) 
0.98 (0.85-1.13) 
0.99 (0.84-1.17) 
0.83 (0.72-0.97) 
Total mortality 
Non-smokers 
Smokers 
1.17 (1.00-1.38) 
1.08 (0.97-1.20) 
1.0 
1.0 
1.24(1.09-1.41) 
0.98 (0.90-1.07) 
1.32 (1.16-1.51) 
1.01 (0.92-1.11) 
1.09 (1.04-1.13) 
1.01 (0.98-1.04) 
a : adjusted for age, systolic blood pressure and cohort. 
b : estimated from a separate analysis with cholesterol as a continuous variable. 
Chapter 8 
Exclusion of the first ten years of follow-up did not decrease the excess cancer risk at 
cholesterol levels below 4.15 mmol/1 (results not shown). In the cohort-specific analysis, 
the RR for a 1.0 mmol/1 increase was less than one in five of the six cohorts, but 
statistical significance was reached only in the Northern European and Mediterranean 
Southern European cohorts (table 4). 
Mortality from non-cardiovascular/non-cancer causes was elevated at cholesterol levels of 
less than 4.15 mmol/1, and reduced at levels above 6.20 mmol/1 (table 3). Within this 
heterogeneous group of diseases, a strong inverse relation was observed for mortality from 
infections. Mortality from respiratory diseases was not elevated in the lowest cholesterol 
category, but was reduced in the higher cholesterol categories and was inversely associated 
with total cholesterol when taken continuously. This inverse association was not so much 
determined by a relation with COPD, but more by a strong inverse relation with the 
remainder of respiratory diseases. Mortality from digestive diseases was elevated at 
cholesterol levels less than 4.15 mmol/1, but did not decrease at higher cholesterol levels. 
No association with mortality from accidents was observed, and an inverse association 
with the remainder of non-cardiovascular/non-cancer diseases was observed. Exclusion of 
the first ten years of follow-up did not decrease the excess risk at cholesterol levels below 
4.15 mmol/1. In the cohort-specific analysis, the RR per 1.0 mmol/1 cholesterol increase 
was about 0.9 in all cohorts except Serbia (table 4). 
Total mortality was lowest for cholesterol levels of 4.15-5.15 mmol/1, and was statistically 
significantly elevated at a level below 4.15 mmol/1 and at levels of 6.20 mmol/1 or above 
(table 3). The cohort-specific analysis showed that the RR for total mortality for a 1.0 
mmol/1 cholesterol increase was greater than one in four of the six cohorts (statistically 
significant in two) (table 4). In cohorts with a low rate of cardiovascular disease mortality 
(Mediterranean Southern Europe and Japan) the RR was less than one. 
Stratification by smoking status revealed that the associations between cholesterol and 
mortality differed between smokers and non-smokers (table 5, figure 1). The association 
of cholesterol with CVD mortality was weaker in smokers than in non-smokers (figure 1). 
The inverse association of cholesterol with cancer mortality was concentrated in smokers, 
and was observed for lung, digestive and lymphatic/hematopoietic cancers, while no 
associations with the remainder of cancers was observed. 
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mortality rate/1,000 person-years 
0' 1 1 1 
<4.15 4.15-5.15 5.16-6.20 > 6.20 
total cholesterol (mmol/1) 
~ non-smokers -'-smokers 
A Cardiovascular diseases 
mortality rate/1,000 person-years 
<4.15 4.15-5.15 5.16-6.20 > 6.20 
total cholesterol (mmol/1) 
— non-smokers -"-smokers 
B Cancer 
mortality rate/1,000 person-years mortality rate/1,000 person-years 
total cholesterol (mmol/1) total cholesterol (mmol/1) 
— non-smokers smokers —non-smokers smokers 
C Non-cardiovascular/non-cancer D All causes 
Figure 1. Mortality rates (per 1,000 person-years) by cholesterol level, adjusted for age, blood 
pressure and cohort, in smokers and non-smokers. 
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Non-CVD/non-cancer mortality was inversely associated with cholesterol in smokers, in 
non-smokers it was only elevated at cholesterol levels less than 4.15 mmol/1 compared to 
levels of 4.15-5.15 mmol/1, but no further decrease at cholesterol levels above 5.16 mmol/1 
was observed. For both smokers and non-smokers inverse associations with infections 
(p<0.01) and respiratory diseases (p<0.10) were present. Mortality from digestive diseases 
was elevated at cholesterol levels below 4.15 mmol/1 in smokers, and accidents seemed 
to be positively associated with total cholesterol in non-smokers. In smokers, but not in 
non-smokers, an inverse association with mortality from 'other' non-CVD/non-cancer 
causes was present. Due to these differential associations, total cholesterol showed a J-
shaped association with total mortality in non-smokers, while in smokers total cholesterol 
was unrelated to total mortality. 
Discussion 
In smokers, a significant inverse association of total cholesterol with mortality from cancer 
and non-cardiovascular/non-cancer causes was observed. In non-smokers no association 
with cancer mortality was observed, while non-CVD/non-cancer mortality was increased 
at cholesterol levels less than 4.15 mmol/1 compared to 4.15-5.15 mmol/1, but did not 
decrease further with increasing cholesterol levels. Total cholesterol was positively 
associated with mortality from cardiovascular diseases. Due to the differential associations 
with non-cardiovascular mortality, total mortality showed a J-shaped association with total 
cholesterol in non-smokers, while in smokers there was no significant association. 
Mortality rates for all endpoints were higher in smokers than non-smokers. 
A meta-analysis of 19 studies, including the MRFTT Study, showed a significant inverse 
association between total cholesterol level and cancer mortality, also after excluding the 
first five years of follow-up.5 However, it was not concluded that this observation implied 
causality. In the present study, the inverse association with cancer mortality was observed 
only in smokers. The inverse association in smokers was due to inverse associations for 
lung, hematopoietic and digestive cancers. Not all studies have analyzed their data by 
smoking strata, but a number of studies have observed that the inverse association between 
total cholesterol and cancer mortality was strongest with smoking-related cancers. 1 1 1 5 , 1 6 
Inverse associations with lung and hematopoietic cancers have been consistently observed 
in a number of studies. 8 1 1 , 1 2 , 1 5 The MRFIT study, a study with over 350,000 study subjects, 
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is possibly the only one with enough power to analyze a large number of specific cancer 
sites.15 They observed inverse associations with lung, digestive, nervous system, lymphatic 
and hematopoietic cancers. 
In the present study, for most subgroups of non-CVD/non-cancer mortality associations 
were comparable in smokers and non-smokers: infections and respiratory diseases were 
inversely associated with total cholesterol, while accidents and digestive diseases were 
unrelated to total cholesterol. The remainder of non-CVD/non-cancer causes was inversely 
associated with total cholesterol only in smokers. A number of other studies have shown 
consistent inverse association between cholesterol and mortality from non-CVD/non-cancer 
diseases 5 1 2 1 5, especially respiratory and digestive diseases. In the present study, especially 
infections (two-thirds of which were tuberculosis) were strongly inversely related with 
total cholesterol. Most other studies did not analyze this group of diseases separately. It 
is known that lipid-soluble toxins bind to blood lipoproteins and are transported to the 
liver for detoxification.25 Consequently, defence against infections might be impaired when 
TC is low, leading more often to a fatal outcome. It seems logical, that this effect would 
be more pronounced in physiologically 'weaker' persons, such as the diseased or elderly. 
Accidents were unrelated to low cholesterol levels, as found in other longiradinal studies. 
The issue of excess mortality from accidents has emerged from intervention trials, and 
may therefore have more to do with drugs used to lower an initially high cholesterol level, 
than with 'naturally' low cholesterol levels.2 5 , 2 6 
The question remains, whether the associations between low cholesterol levels and 
increased non-cardiovascular mortality are causal. A mechanism by which a low 
cholesterol would cause excess mortality would be one of relative cholesterol deficiency. 
It has been shown, however, that cell membranes maintain cholesterol homeostasis 
exposed to plasma cholesterol levels as low as about 1.5 mmol/128, so cholesterol 
'deficiency' is unlikely. It has been suggested that persons who have a low cholesterol 
level at baseline differ in other respects from persons with higher cholesterol levels. They 
might be genetically different, with a predisposition to non-cardiovascular diseases. 
Another explanation could be the presence of preclinical diseases at baseline that cause 
both a low cholesterol level and an increased risk of non-cardiovascular mortality. In some 
studies, the inverse association disappeared when early mortality (often defined as deaths 
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in the first five years of follow-up) was excluded6 ,8"1013, but in a number of other studies 
this was not the case. 7 1 1 , 1 2 , 1 4" 1 6 There is evidence that cholesterol lowering due to pre-
existing cancer is manifested from about two to four years prior to diagnosis29, even up 
to ten years.30 In the present study exclusion of the first ten years of follow-up did not 
abolish the observed excess risk for cancer and non-cancer/non-cardiovascular mortality 
at cholesterol levels below 4.15 mmol/1. It can not be excluded however, that other 
diseases such as chronic lung diseases might lower cholesterol many years before death. 
An indication that pre-existing diseases play a role is the observation that inverse 
associations with non-cardiovascular mortality were not observed in a 'healthy* cohort, 
consisting of working persons31, but were present in a general population cohort in the 
same region.32 Also, inverse associations were not observed in cohorts with a relatively 
young age at baseline.33"33 In a middle-aged population, the low cholesterol category would 
not only contain persons with a 'naturally' low cholesterol level, but also persons who 
have a 'lowered' cholesterol level due to pre-existing diseases. 
A number of correlates of low cholesterol levels have been proposed as confounders in 
the observed associations. One is excessive alcohol consumption which is often associated 
with poor nutritional status and liver damage, thus influencing cholesterol metabolism and 
predisposing to a number of diseases. In a recent meta-analysis relations were the same 
within strata of alcohol consumption5, suggesting that this does not play a role. In the 
MRFTT Study a strong inverse association of cholesterol was observed with death 
attributed to alcohol dependency.15 In the present study, a total of 168 deaths could be 
defined as 'alcohol-related' (ICD-8 codes 303 alcoholism and 571 liver cirrhosis). Two-
thirds of these occurred among smokers. RR for alcohol-related mortality for the lowest 
cholesterol category compared to the cholesterol category of 4.15-5.15 mmol/1 was 1.9 in 
non-smokers (p>0.1) and 2.2 in smokers (p<0.01). This indicates that excessive alcohol 
use was more prevalent in the low cholesterol group, and might explain part of the 
observed excess risk. 
From a public health viewpoint it is important to note that mortality rates in smokers were 
higher for all disease groups. The inverse associations between serum total cholesterol and 
mortality from cancer were restricted to smokers, possibly due to a decreased anti-oxidant 
potential in smokers.3 6 , 3 7 For non-smokers, total mortality risk was lowest in the cholesterol 
range 4.15-5.15 mmol/1. There were indications that alcohol abuse was more prevalent in 
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the low cholesterol group. Therefore, it seems likely that the low cholesterol-mortality 
association is at least partly explained by confounding factors. 
In western countries, few middle-aged persons have blood cholesterol levels below 4.14 
mmol/1. Moreover, in the treatment of persons with hypercholesterolemia (mostly defined 
as cholesterol above 6.19 mmol/1) levels of less than 4.14 mmol/1 will seldom be achieved. 
From a public health viewpoint, excess risk for a cholesterol level of less than 4.14 
mmol/1 is limited due to the small number of persons with these levels, the relatively low 
mortality rate for this group and the fact that at least part of the observed associations is 
due to confounding. Therefore, lowering of relatively high average population cholesterol 
levels remains a public health need. 
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General Discussion 
Introduction 
Results of descriptive and etiological epidemiological studies have been presented: 
descriptive studies have given insight into current levels of total and HDL cholesterol in 
the general population of the Netherlands and changes in cholesterol levels over the period 
1974-1992. The etiological studies have provided insight into the determinants of total and 
HDL cholesterol, and the effect of different levels of total cholesterol on mortality from 
coronary heart disease and all-cause mortality. The effect of cholesterol on mortality was 
studied in different cultures and in men as opposed to women. Combining the results of 
these studies, conclusions can be drawn on the public health impact of cholesterol levels 
in the Netherlands and the reduction in mortality that can theoretically be achieved by 
lowering cholesterol levels. 
Measuring cholesterol 
Trends in total cholesterol levels and the relation between total cholesterol levels and 
subsequent mortality were studied using a single cholesterol measurement for each 
individual. It is important to realize that a single cholesterol measurement will contain an 
error component due to biological variation of cholesterol levels in individuals (within-
person variation) and within-laboratory variation. The effect of these two sources of 
measurement error varies with the purposes of the study (e.g. studying trends or studying 
cholesterol-mortality relations). 
Within-person variation 
The effect of within-person variation is an important source of error for classification of 
individuals and for studying cholesterol-mortality relations, however, it is less important 
when groups are studied and is unimportant for studying trends. Cholesterol levels in 
humans vary from day to day around a mean level. For individuals a single cholesterol 
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measurement is not enough to reliably establish their individual mean cholesterol level. 
A guideline for clinicians is to measure cholesterol on at least three occasions to obtain 
a reliable mean.1 On the group level, however, a single measurement can be enough to 
characterize the group mean accurately because overestimation of the cholesterol level in 
one subject will be compensated by underestimation of the cholesterol level in another 
subject. When repeated measurements per individual are used, the group mean will remain 
similar, but the standard deviation of the distribution will diminish. Therefore, although 
the mean level will be estimated correctly by a single measurement, the estimated 
prevalence of the percentage of persons above a given cutoff point will be overestimated. 
When studying cholesterol-disease associations prospectively, it is known that a single 
cholesterol measurement leads to dilution of the observed strength of the association, the 
so-called regression dilution effect, as described in the methods and discussion sections 
of Chapter 7. If repeated measurements are available on at least a subsample of the study 
population, it is possible to correct the observed associations for this dilution effect.2 In 
the Seven Countries Study correction for the regression dilution effect increased the 
relative risk estimates by approximately 40%. 
Laboratory drift 
Since laboratory drift influences the group mean and the estimated prevalence of 
hypercholesterolemia over time, it is an important problem in studying trends in 
cholesterol levels over time. All laboratory measurements have some imprecision. Certified 
laboratories take part in standardization programs that constantly monitor the accuracy and 
precision of the measurements. A maximum deviation from the "true" level of plus or 
minus 5% is allowed.3 However, within this range drifts are possible. For the individual 
a small deviation from the true level is not so important, but when studying trends in 
cholesterol a drift from the maximum allowed overestimation to the maximum allowed 
underestimation can result in a spurious trend. When the control sera measurements, 
included in all measurement runs in the laboratory, are available for analysis, small drifts 
can be detected and trend analyses can be corrected for these. 
Table 1 summarizes the effect of within-person variation and laboratory drift for different 
study purposes. 
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Table 1. Importance of within-person and laboratory drift for different study purposes 
Purpose of the study Within-person Laboratory 
variation drift 
Individual level + 
Group • mean level - + 
• prevalence of elevated levels + + 
Trends - ++ 
Mortality associations + 
++ = of strong influence 
+ = of influence 
- = not of (much) influence 
Trends in plasma cholesterol levels in the Netherlands from 1974-1992 
Studying trends in total and HDL cholesterol is important because changes which take 
place at present will have an impact on morbidity and mortality from coronary heart 
disease in the near future. Furthermore, monitoring can contribute to evaluating the 
effectiveness of public health campaigns aimed at reducing cholesterol levels in the 
general population. 
Trends 
Drawing a conclusion on the long-term trend in total cholesterol levels in the Netherlands 
is hampered by the fact that for the period 1974-1986 only information on a limited age 
range was available and the fact that for women over the period 1981-1986 no information 
at all was available. In men, a decline in total cholesterol levels was observed in all three 
study periods, the largest (0.2 mmol/1) in the period 1981-1986. However, data from the 
Zutphen Study indicated that the decline in 35-year-olds over the period 1981-1986 was 
not generalizable to older men.4 For the period 1987-1992 the decline in total cholesterol 
levels in men aged 20-59 took place mainly in 1991 and remained at this lower level in 
1992. Elderly Dutch men showed also a decline in total cholesterol levels between 1990 
and 19935, so the cholesterol decline in recent years in men does seem to be generalizable 
to the general population. In women a decline in cholesterol levels was observed in 1991; 
however, it was not maintained in 1992, resulting in no net change over the period 1987-
1992. 
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In Table 2, the changes that occurred over the three study periods are expressed as a 
percentage of the cholesterol level at the beginning of the study period. In men, a total 
decline of about 6.5% over three study periods was observed. It must, however, be noted 
that the largest decline was observed from 1981-1986 in men aged 33-37 and that this 
decline was not generalizable to other age groups. In women, no net change in total 
cholesterol level was observed in the study periods 1974-1980 and 1987-1992. 
Table 2. Changes in mean total cholesterol levels over the three study periods 
expressed as a percentage of the cholesterol level at the beginning of the study period 
Study Period Study population 
Change in total cholesterol 
Men Women 
CB Project 1974-1980 o" and ?, 37-43 years -1.2 % -0.6 % 
RIFOH Project 1981-1986 o" 33-37 years -3.5 % n.a." 
Monitoring Project 1987-1992 d" and ?, 20-59 years -1.9 % -0.1 % 
a: n.a. = not available 
During the period 1987-1992 not only total cholesterol was measured but also HDL 
cholesterol. During this period HDL cholesterol levels declined by about 7% in men and 
did not change significantly in women. Comparing the changes in total and HDL 
cholesterol by looking at the change in the non-HDL/HDL cholesterol ratio showed that 
this ratio increased in men and remained unchanged in women. The favorable change in 
total cholesterol levels in men was thus counteracted by unfavorable changes in HDL 
cholesterol levels. In the Zutphen Study, however, no change in HDL cholesterol levels 
was observed in middle-aged and elderly men when five measurements were analyzed 
over the period 1977-1993.5 Since it has become increasingly clear that HDL cholesterol 
is inversely related to CHD mortality, it is important to focus not only on total cholesterol 
levels but also on the HDL cholesterol fraction. 
Prerequisites for monitoring cholesterol levels 
In order to accurately monitor cholesterol levels in the general population a number of 
conditions has to be met. Firstly, the cholesterol measurements have to be carefully 
standardized. Because the changes that take place in the population are relatively small, 
measurement error can easily disguise the real changes that are taking place. During the 
entire period 1974-1992 cholesterol measurements were performed in the Central Clinical 
Chemistry Laboratory of the University Hospital "Dijkzigt" in Rotterdam, which is the 
136 
General Discussion 
reference laboratory for cholesterol determinations in the Netherlands. During this whole 
period the laboratory variation was in the range allowed by the WHO standards for 
cholesterol measurements. However, a deviation of about 5% (too high or too low) from 
the "true" level is allowed. In the light of cholesterol changes of a few percent in the 
population, the range allowed in laboratory measurement error is large. Our analysis of 
the internal quality control of the laboratory showed that in some periods it was necessary 
to adjust for these small shifts in laboratory measurements when performing trend 
analyses. 
Secondly, measurements have to be carried out on a continuous basis over a sufficiently 
long period of time. In all three monitoring projects it was observed that despite the large 
number of persons examined, mean cholesterol levels (monthly or quarterly) showed 
fluctuations of as much as 0.1-0.2 rnmol/1, even when the same seasons were compared, 
so that seasonal change could excluded. When two points in time are compared, these 
fluctuations can lead to spurious conclusions about the changes in cholesterol levels that 
are taking place. This illustrates the need for continuous measurements. 
Thirdly, changes in the study protocol can affect the cholesterol measurements. A puzzling 
observation was the fact that although the changes in cholesterol levels were relatively 
small within one project, a slight shift in cholesterol levels became apparent between the 
projects. At the end of the CB Project in 1980 the mean cholesterol level in men aged 40 
was 5.70 mmol/1, while at the start of the RTFOH project in 1981 the mean cholesterol 
level in men aged 35 was 5.64 mmol/1. This happened despite the fact that the CB and 
RTFOH projects were carried out in the same locations, by the same personnel and with 
cholesterol measurements in the same laboratory. Taking into account the 5-year age 
difference, a larger cholesterol difference between the men in the CB Project and the 
RIFOH project would be expected (in the order of about 0.2 mmol/1). Apparently, a 
changing daily routine, with a possible slight impact on procedures pertaining to drawing 
or handling of the serum samples, can lead to small shifts in cholesterol levels. This 
further underlines the many pitfalls that comparing cholesterol levels over time has. 
On the basis of all these observations it can be concluded that for a good monitoring 
system it is important to have well standardized measurements with good quality-control 
data over a sufficiently long period of time without changes in the study protocol. Because 
this cannot always be attained, it is of great importance to collect quality-control data over 
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the study period to make it possible to adjust for any changes in the study protocol or 
laboratory drifts that have taken place during the study period. 
Cholesterol changes in relation to mortality changes 
Age-standardized CHD mortality in the Netherlands reached its peak in 1972 and has 
declined since then by 29% in men and 38% in women.6 The question as to what extent 
changes in risk factor levels have contributed to this decline is an interesting but difficult 
one. Firstly, no detailed information on changes in risk factor levels in large samples (with 
a broad age range) of the general population are available for the 1950s to the early 1980s. 
Secondly, there is a lag time of 5-10 years between changes in risk factors and changes 
in mortality. Thirdly, changes in medical care have taken place during the same period. 
From meta-analyses of a large number of intervention studies it has been estimated that 
a 1% decline in serum total cholesterol levels results in a 2% to 3% reduction in CHD 
mortality.7 Generalizing the changes observed in the three studies described above to the 
whole population (a "best case" scenario, since there were indications that the decline of 
3.5% from 1981-1986 was not generalizable), it could be estimated that the total 
cholesterol decline of 6.5% in men, would result in a decline in CHD mortality of 13% 
to 19.5%. In women total cholesterol levels declined by less than 1%, resulting in a 
predicted CHD mortality decline of at most 2% to 3%. Although for men it seems 
plausible that cholesterol changes have contributed to the decline in CHD mortality rates, 
this is not the case for women. With respect to the other major CHD risk factors, blood 
pressure levels have hardly changed in the last decades.8 Smoking has decreased 
substantially in men, from 90% in the 1950s to about 40% at present.9 Since smoking 
influences CHD mortality both directly (due to damage to the intima and the influence on 
thrombogenesis) and indirectly (by increasing levels and atherogenicity of cholesterol), this 
decline in smoking will have influenced CHD mortality rates. However, in women 
smoking prevalence increased from about 30% in 1958 to about 40% in 1975, followed 
by a slight decline in the late 1970s that came to standstill in the late 1980s.9 These 
changes in smoking habits of women are much smaller than those in men. Therefore, 
especially in women it is difficult to explain the observed decline in coronary heart disease 
mortality by changes in risk factor levels. With respect to improvements in medical care, 
the introduction of thrombolytic therapy in the mid-1980s has probably contributed 
substantially to the decline in CHD mortality since that time. 
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From a public health perspective, it is important to know to what extent the decline in 
CHD mortality has been caused by primary prevention, and thus by a concomitant decline 
in CHD incidence, and to what extent it is caused by a better chance of survival after a 
first event. If caused by a better survival rate only, the prevalence of the disease in the 
population will increase. In contrast to the national mortality statistics, no data on the 
incidence of the disease are available on a national level. The regional morbidity registry 
in the Nijmegen area has not, however, shown a decline in CHD incidence since the 
1970s.6 Hospital statistics showed that hospital admissions at younger ages have decreased, 
suggesting a decline in the incidence of the disease, while in middle-aged and older 
persons hospital admission rates have increased. To gain insight into developments that 
are taking place with respect to the burden of coronary heart disease on the population, 
a good incidence register for CHD is necessary. The combination of mortality and 
incidence data provide insight into the prevalence of the disease. This will complement 
the information from risk factor monitoring and mortality statistics, and yield valuable 
information on health-care costs and demands in the future. 
Plasma total and HDL cholesterol levels in the Netherlands and their 
determinants 
Total cholesterol and its determinants 
Most changes in total cholesterol levels that take place during a lifetime occur within the 
age range of 20 to 60. In men, total cholesterol levels increase greatly between age 20 and 
40, after age 40 the increase with age levels off and total cholesterol levels start to decline 
after age 60. In women total cholesterol levels start to increase around the age of 35 to 
40 years, and tend to decline after age 70. 1 0 Due to this increase in total cholesterol levels 
with age, prevalence of hypercholesterolemia in the Netherlands increases in men from 
about 1% at age 20 to 24 to about 30% at age 55 to 59, and in women from about 4% at 
age 20 to 24 to over 40% at age 55 to 59 (Chapter 3). 
In the Netherlands hypercholesterolemia is defined as a total cholesterol level of 6.5 
mmol/1 or above, according to the Cholesterol Consensus.11 This cutoff point has been 
chosen because above this level the relative risk for coronary heart disease tends to 
increase exponentially. When comparing prevalence figures for hypercholesterolemia, it 
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must be kept in mind that a small shift in cutoff point can result in a large increase in the 
prevalence of hypercholesterolemia. Standardized to the age distribution of the general 
population aged 20-59 in the Netherlands, the prevalence of hypercholesterolemia in 1992 
was 14% in both men and women. In comparison, if the United States cutoff point of 6.2 
mmol/1 is applied, the prevalence of hypercholesterolemia will be 22% in men and 19% 
in women (figures la and lb). Also for HDL cholesterol a small shift in cutoff point 
would have considerable impact on the prevalence of low cholesterol levels (figure lc). 
The prevalence figures from the present study represent a slight overestimation of the true 
prevalence, being based on a single measurement. 
It can be concluded that large parts of the general population are at increased risk of 
developing CHD on the basis of their cholesterol levels. Comparing age and gender-
specific mean cholesterol levels in the Netherlands to levels in other countries shows that 
levels in Scandinavian countries (Denmark, Sweden, Finland and Iceland) and some 
eastern European countries (former Soviet Union, East Germany and Czechoslovakia) are 
on average about 0.5 mmol/1 higher than in the Netherlands. Levels in Spain, Italy, 
Canada and Australia are comparable to those in the Netherlands and total cholesterol 
levels in the United States are on average about 0.5 mmol/1 lower.12 This shows that in 
most industrialized countries (except the United States) hypercholesterolemia is as 
prevalent or even more prevalent than in the Netherlands. 
When identifying subgroups of the general population in which the risk of coronary heart 
disease is increased due to an elevated total cholesterol level, it is clear that age and 
gender are the most prominent detenrunants. However, differences between social strata 
(defined by educational level) are also observed. Total cholesterol levels are inversely 
associated with educational level, while HDL cholesterol levels are positively associated 
with educational level (Chapter 3). More favorable risk profiles for most other risk factors 
that were measured in the Monitoring Project on Cardiovascular Disease Risk Factors are 
also observed for higher as opposed to lower educational levels.13 Therefore, in public 
health education campaigns special attention should be paid to lower educated groups. 
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Figure 1. The percentage of persons below a certain 
level of total cholesterol in different age categories in 
males (a) and females (b) and the percentage of 
persons below a certain level of HDL cholesterol (c) 
in the Netherlands. 
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The question is whether the increase in total cholesterol levels with age is physiological 
or caused by a "western" lifestyle. In almost all affluent countries an increase with age is 
observed. One hypothesis is that with aging the activity/turnover rate of the LDL receptors 
decreases, resulting in a reduced clearance rate of cholesterol from the blood, which leads 
to an increase in blood cholesterol concentrations. Part of the age-related increase in 
women is associated with the menopause. It was estimated that due to the menopause 
cholesterol increases by about 0.45 mmol/1 in non-smokers and 0.30 mmol/1 in smokers 
(Chapter 4). Although the menopause itself cannot be prevented, the effects of the 
menopause can be reduced by postmenopausal use of estrogens. A number of studies have 
shown that the increase in total cholesterol after the menopause is prevented by hormone 
replacement therapy.14 However, side-effects of this therapy are an increased risk for some 
forms of cancer (endometrium, breast).14 Therefore wide-scale and long-term use of 
hormone replacement therapy is still debated. Women have the advantage that the rise in 
cholesterol levels occurs later in life than in men, which makes their lifetime exposure to 
cholesterol lower. 
Another factor associated with the age-related total cholesterol increase is body mass 
index. A steady rise in body mass index takes place with increasing age. Each unit 
increase in body mass index is associated with a cholesterol increase of 0.06 mmol/1 in 
men and 0.03 mmol/1 in women. However, it was estimated that the increase in body mass 
index accounts for only a small part (about 10%) of the cholesterol increase with age. 
Other lifestyle factors that influence total cholesterol levels are smoking and diet. Since 
these factors do not show much change with age, they do not explain the cholesterol 
increase with age. The data from the Monitoring Project on Cardiovascular Disease Risk 
Factors showed that total cholesterol levels were higher in smokers than in non-smokers. 
After adjustment for body mass index, men who smoked had a 0.13 mmol/1 higher total 
cholesterol level than non-smokers. For women this figure was 0.18 mmol/1. Therefore, 
quitting smoking can contribute to maintaining cholesterol levels at a desirable level. 
Although not described in this thesis, dietary factors are important determinants of total 
cholesterol levels. As early as the 1950s, Keys showed that fat intake was the most 
important dietary factor with respect to cholesterol levels.15 Based on a number of studies 
performed in the 1950s and early 1960s, an equation was developed to predict change in 
total cholesterol due to changes in dietary fatty acid composition of the diet. 1 6 1 7 A meta-
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analysis of more recent trials has established the effect of dietary fatty acids on both total 
and HDL cholesterol.18 It was estimated that replacing 10% of energy from saturated fat 
by carbohydrates would lower LDL cholesterol by 0.33 mmol/1 but also HDL cholesterol 
by 0.12 mmol/1, replacement by monounsaturated fat would lower LDL cholesterol by 
0.39 mmol/1 and HDL cholesterol by 0.03 mmol/1, and replacement by polyunsaturated 
fat would lower LDL cholesterol by 0.47 mmol/1 and HDL cholesterol by 0.05 mmol/1. 
Due to the higher LDL lowering effect and the lower decrease in HDL cholesterol, it was 
concluded that replacement of saturated fat by unsaturated fat was more favorable with 
respect to the lipid profile than replacement by carbohydrate. However, this was only true 
assuming no effects on body mass index. Furthermore, effects of diet on platelets and 
oxidizability of LDL were not taken into account due to lack of data. 
The influence of genetic factors was not studied within the context of this thesis, but a 
number of genetic defects are known to lead to elevated cholesterol levels. For example, 
persons with the monozygous form of familiar hypercholesterolemia (FH) have no LDL 
cholesterol receptors, leading to extremely high cholesterol levels. This form is rare and 
only present in about 1:106 persons who have cholesterol levels of 15 mmol/1 or more. The 
more prevalent heterozygous form is estimated to be present in about 1:300-1:500 persons. 
Persons who are heterozygous for FH have only 50% of the LDL receptors of persons 
without this genetic trait and usually have cholesterol levels exceeding 8 mmol/1. 
However, even in these persons strict lifestyle rules can be effective in keeping serum 
cholesterol levels within an acceptable range.19 Genetic factors related to levels and 
atherogenicity of cholesterol are being studied more and more. With increasing 
technology, the number of genetic polymorphisms and mutations discovered will probably 
rapidly increase in the near future. This makes it all the more necessary to study 
gene—environment interactions because expression of genetic traits can be modified by 
environmental factors. It must, however, be noted that hypercholesterolemia in the general 
population is to a large extent multifactorial and adverse lifestyle habits play an important 
role. 
An individual's cholesterol level is the outcome of the balance between a great number 
of interacting factors. Genetics and lifestyle interact: given a genetic trait, the expression 
of this trait (and therefore the resulting deleterious consequences) can be modified by 
lifestyle factors. Furthermore, given a certain total cholesterol level, the atherogenicity of 
that cholesterol level depends on the amount of ox-LDL. This amount of ox-LDL is 
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dependent on the balance between the oxidizability of the LDL particles (dependent on 
the amount of polyunsaturated fatty acids), dietary anti-oxidants (e.g. carotenoids, vitamin 
E and flavonoids) and oxidants (e.g. smoking). 
HDL cholesterol and its determinants 
HDL cholesterol levels remain remarkably stable with age. The most important 
determinant of the HDL cholesterol level is gender. In women HDL cholesterol is on 
average 0.25 mmol/1 higher than in men. This gender difference in HDL cholesterol arises 
from the drop in HDL cholesterol levels in males during puberty due to increasing levels 
of testosterone.20 It has been established that a low HDL cholesterol level is an 
independent risk factor for developing coronary heart disease. It was estimated that an 
increase of 0.026 mmol/1 in HDL cholesterol was associated with a decrease in coronary 
heart disease mortality of 1.9% to 2.9%.21 When the internationally used cutoff point of 
0.9 mmol/1 was used to define low HDL cholesterol22, prevalence of low HDL cholesterol 
levels was 22% in men and 6% in women. 
Differences in HDL cholesterol between men and women were not explained by 
differences in factors such as body mass index, smoking, physical activity and alcohol 
consumption (Chapter 5). Assuming equal levels of these factors, the predicted HDL 
cholesterol difference between men and women was even slightly greater. Body mass 
index and cigarette smoking each have an adverse effect on HDL cholesterol levels. Each 
unit increase in body mass index was associated with a 0.02 mmol/1 lower HDL 
cholesterol in men and women. Cigarette smoking was associated with a 0.10 mmol/1 
lower HDL cholesterol in men and a 0.13 mmol/1 lower level in women. A physically 
active lifestyle was associated with a 0.04 mmol/1 higher HDL cholesterol level than for 
a physically inactive lifestyle in both men and women. For each glass of alcoholic 
beverage HDL cholesterol was higher by 0.04 mmol/1 in men and 0.07 mmol/1 in women. 
Thus although HDL cholesterol levels do not change with age and are largely determined 
by gender, a number of modifiable lifestyle factors are of influence. It can be calculated 
that a combination of obesity (BMI=30 kg/m2), cigarette smoking (>10 cigarettes/day) and 
a physically inactive lifestyle leads to a 0.26 mmol/1 (men) or 0.29 mmol/1 (women) lower 
HDL cholesterol level compared to a combination of "normal" weight (BMI=25 kg/m2), 
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no smoking and a physically active lifestyle. The amount of difference due to two 
different lifestyles is similar to that due to the gender difference. 
Total cholesterol and its relation with mortality 
Coronary heart disease 
When it became clear in the 1950s and 1960s that coronary heart disease mortality was 
reaching epidemic proportions, a number of large-scale studies were started to elucidate 
the etiology of this disease. Over the past decades the importance of cholesterol with 
respect to coronary heart disease mortality has been shown in these studies.23"26 These 
studies were mostly done in countries with high CHD mortality rates, such as the United 
States and Northern Europe, and involved subgroups of those populations that were known 
to be at high risk: mostly middle-aged men. Although it is known that middle-aged women 
suffer much less CHD mortality than men, the growing proportion of elderly women in 
the population makes CHD in women an important public health concern. However, there 
are few longitudinal studies in women and the question remains whether results from 
studies in males can be extrapolated to women. 
The Consultation Bureau Heart Project (CB Project) provided the opportunity to compare 
the relation between total cholesterol and coronary heart disease mortality in males and 
females. Data from the Seven Countries Study were used to compare this relation in 
countries with different CHD mortality rates. 
The most striking observation from these studies was the fact that the relative risk (RR) 
for the relation between serum total cholesterol and CHD mortality seemed to be more or 
less universal. For both men and women, the RR for those in the upper 20% of the 
cholesterol distribution was 3 to 4 fold higher than for those in the lower 20% of the 
distribution. In different cultures, whether it was one with a low CHD mortality such as 
Mediterranean Southern Europe or one with a high CHD mortality such as Northern 
Europe, CHD mortality risk increased by 12% for each 0.5 mmol/1 cholesterol increase. 
However, there were large differences in absolute risk for CHD mortality. In women, 
CHD mortality rates were five times lower compared to men at any cholesterol level. At 
a cholesterol level of 5.2 mmol/1, 25-year CHD mortality rates in the Seven Countries 
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Study, varied from 5% in Mediterranean Southern Europe and Japan, to 10% in Inland 
Southern Europe and 15% in Northern Europe. 
The large difference in CHD mortality rate between men and women (after adjustment for 
blood pressure, smoking and body mass index) is to a large extent explained by 
physiological (intrinsic) differences between men and women and not by differences in 
lifestyle. Women have a higher HDL cholesterol level, which protects them against CHD. 
It is generally assumed that estrogens protect women against CHD, not only through an 
effect on cholesterol levels but also through an effect on the susceptibility to CHD. 
The large differences in CHD mortality rates (after adjustment for age, blood pressure and 
smoking) that were observed at a given cholesterol level in the different cultures of the 
Seven Countries Study were, however, largely determined by differences in lifestyle. It 
is unlikely that intrinsic (genetic) differences played a role. For example, the Japanese in 
the Seven Countries Study had very low cholesterol levels, and CHD mortality was 
extremely low. However, it has been shown that when Japanese change their lifestyle to 
more American, their cholesterol levels and CHD mortality rates became similar to the 
American ones.27 This shows that these differences are unlikely to be explained by genetic 
differences between the cultures, but that lifestyle factors are the most important in 
explaining the differences between the cultures with respect to CHD mortality. Analyses 
of differences in dietary intake between the cultures showed that the Mediterranean and 
Japanese diets contained a high intake of antioxidant vitamins (e.g. E, C and carotenoids) 
and flavonoids, combined with a low intake of saturated fat. Since ox-LDL is the 
atherogenic lipoprotein fraction, a high intake of antioxidants is likely to reduce the 
amount of ox-LDL. Furthermore, it has been shown that an a-linolenic acid enriched 
Mediterranean diet has favorable effects on thrombogenesis.28 These results suggest that 
the effect of a given total cholesterol level on CHD mortality is modified by lifestyle 
factors such as diet. 
With respect to primary prevention, the difference with respect to relative versus absolute 
risk is important. For example, the cutoff points of the Netherlands Cholesterol Consensus 
are based on the observation that above the level of 6.5 mmol/1 RR for CHD increases 
exponentially. However, an exponential increase of a low baseline risk (e.g. in women) 
may still result in a low absolute risk, while a small increase in a high baseline risk (e.g. 
in men) may cause a large increase in absolute risk. Furthermore, with the results of the 
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Seven Countries Study in mind, it is important not to focus solely on total cholesterol 
levels per se. Attention should also be paid to factors that modify the atherogenicity of 
cholesterol, such as intake of antioxidants and saturated fat. 
Total mortality 
Total cholesterol levels show a continuous positive relation with coronary heart disease 
mortality. In the Netherlands coronary heart disease makes a large contribution to total 
(all-cause) mortality. If total cholesterol levels are unrelated to other diseases, a positive 
relation between total cholesterol levels and all-cause mortality is expected that is, 
however, weaker than the relation with CHD. A number of studies, however, show a J-
shaped relation between total cholesterol and all-cause mortality due to higher cancer and 
non-cardiovascular/non-cancer mortality at low cholesterol levels.29 
In both the CB Project (Chapter 6) and the Seven Countries Study (Chapter 8) the relation 
between total cholesterol level and all-cause mortality was studied. All-cause mortality can 
be divided into three large subgroups of diseases: cardiovascular diseases (including 
coronary heart disease), cancer and non-cardiovascular/non-cancer diseases. To understand 
the association between total cholesterol and all-cause mortality, associations between total 
cholesterol and these subgroups were studied. 
In the CB Project, a positive association between total cholesterol and all-cause mortality 
was observed in both men and women. No associations were observed with non-
cardiovascular mortality. Men and women in the upper 20% of the cholesterol distribution 
had a 60% and 46% higher mortality risk, respectively, than men and women in the lower 
20% of the distribution. In the Seven Countries Study however, total cholesterol was 
unrelated to total mortality due to the fact that inverse associations with cancer (in 
smokers only) and non-cardiovascular/non-cancer mortality (in both smokers and non-
smokers) were observed. Within the subgroups of non-cardiovascular/non-cancer mortality 
the inverse association was most prominent for infectious diseases. 
A recent meta-analysis of a number of longitudinal studies showed an excess all-cause 
mortality at low cholesterol levels, and a detailed analysis of the MRFTT Study showed 
inverse associations between total cholesterol and a number of diseases: cancers of 
different sites, respiratory and digestive diseases. The question on the causality of these 
findings is, however, still in debate. A number of explanations have been put forward.30 
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First, it is possible that low cholesterol is not the cause but the consequence of a disease 
(e.g. cancer). However, in many studies the association remained after exclusion of the 
first 5 to 10 years of follow-up. Also in the Seven Countries Study, excluding the first ten 
years of follow-up did not alter the results. Secondly, confounding factors or effect 
modifiers may be associated with low cholesterol levels. It has been shown that excess 
mortality was not observed in "healthy" cohorts such as young adult men31 and not in a 
cohort of employed men, contrary to a general population cohort from the same region.32 
This would indicate that in some studies the group with a low cholesterol level is 
"polluted" with people who have a low cholesterol level due to adverse health conditions. 
The effect of age may explain the different findings in the CB Project and the Seven 
Countries Study: the majority of men and women in the CB Project were between age 35 
and 45 at baseline, while the men in the Seven Countries were aged 40-60 at baseline. 
Several hypotheses for a causal mechanism by which low cholesterol levels could 
predispose to diseases have been put forward. One of them is that a low cholesterol 
concentration leads to unfavorable changes in the composition of cell membranes. A 
hypothesis on a causal mechanism by which low cholesterol levels increase mortality due 
to infectious diseases is that lipoproteins bind lipid-soluble toxins and subsequently take 
them to the liver for detoxification.33 The Seven Countries Study lends support to this 
hypothesis because a strong inverse association with mortality from infectious diseases 
was observed. 
From the point of CHD prevention cholesterol lowering is favorable, and in many 
countries programs have been launched to lower cholesterol levels in the general 
population. From a broader public health perspective, the relation with all-cause mortality 
is most important and therefore the issue of a possible higher non-cardiovascular mortality 
at low cholesterol levels raised a lot of concern. It seems most likely that some of the 
relations that have been observed between low cholesterol levels and mortality are due to 
corrfounding or effect modification by other factors, and that some of the relations 
observed may be causal. Looking at the cholesterol distribution in the Netherlands, less 
than 10% of all men and women aged 20-59 years have levels below 4.1 mmol/1 and only 
less than 5% of middle-aged men and women. Low cholesterol levels are not a major 
public health concern in the Netherlands because the prevalence of low cholesterol in the 
Netherlands is low and it is probable that the excess mortality at low cholesterol levels is 
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at the most only partly causal, while the burden of coronary heart disease in the population 
is high. 
Prevention 
It has been shown in the longitudinal studies described above that mortality risk differs 
greatly between persons with different cholesterol levels and different lifestyles. Still the 
question remains whether persons with a higher cholesterol level can acquire this lower 
level of risk when they lower their cholesterol levels and change their lifestyles. The final 
answer to this question can only be given by intervention studies. A number of cholesterol 
lowering trials has been carried out that have indeed shown that cholesterol-lowering leads 
to lowering of CUD mortality.7 However, most trials did not show an effect of cholesterol 
lowering on total mortality. Several meta-analyses of trials produced conflicting results.34"37 
The most recent meta-analysis showed that all-cause mortality was significantly reduced 
in secondary prevention trials and that excess mortality in the intervention group was only 
observed for drug intervention and not for dietary intervention.37 Furthermore it was 
concluded that the statistical power to detect an effect of cholesterol reduction on total 
mortality was small. A recent secondary prevention trial in which total cholesterol was 
reduced by 25% and HDL cholesterol increased by 8%, showed a reduction in both 
coronary heart disease mortality and all-cause mortality.38 It has also been shown that in 
secondary prevention, regression of the atherosclerotic lesions can be achieved.38"41 In a 
number of these trials CHD incidence was reduced, while only a small change in the 
degree of stenosis was achieved.39,40 It has been suggested that cholesterol lowering might 
reduce the cholesterol content in cholesterol-rich lesions.42 Because cholesterol-rich lesions 
are most vulnerable to rupture, cholesterol lowering might stabilize vulnerable plaques.43 
Therefore, also in already advanced coronary heart disease, cholesterol lowering can yield 
health benefits. 
The first choice in lowering cholesterol levels is through lifestyle changes that not only 
decrease the level of total cholesterol, but can also modify its atherogenicity. Furthermore, 
it will also have a favorable effect on other chronic diseases, such as cancer, because 
cardiovascular diseases and different types of cancer share a number of common risk 
factors (e.g. dietary antioxidants, smoking, physical activity). A diet rich in fruits and 
vegetables (and thus antioxidants and flavonoids), and low in saturated fat, in combination 
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with no smoking, enough physical activity and a desirable weight, will, for many people, 
lead to a lipid profile that does not need drug intervention. 
Main conclusions 
Cholesterol levels in the Netherlands are still relatively high, being higher in lower 
educated than in higher educated persons. Despite a long tradition of health education, a 
substantial shift towards lower cholesterol levels has, contrary to the United States, not 
been reached in the Netherlands. That a relatively high proportion of the Dutch population 
still smokes cigarettes, and the Dutch diet is still relatively high in saturated fat, show that 
the risk profile with respect to CHD leaves much to be desired. From the CB Project it 
was estimated that a cholesterol reduction of 0.6 mmol/1 was associated with a reduction 
of about 20% in CHD mortality, 15% in CVD mortality and 6% in all-cause mortality in 
this population. 
The atherogenicity of a given total cholesterol level is dependent on factors that detenrune 
the amount of oxidized LDL, such as the antioxidant content of the diet and cigarette 
smoking. To lower cholesterol levels and the amount of oxidized LDL a multifactorial 
approach should be followed. A diet low in saturated fat and high in fruits and vegetables 
and no cigarette smoking are recommended in combination with a physically active 
lifestyle (e.g. to increase HDL cholesterol levels). Because the proposed lifestyle to lower 
cholesterol has been proven to be favorable also for the prevention of other diseases, this 
multifactorial approach goes beyond prevention of CHD and will also lower risk of cancer 
and other chronic diseases such as diabetes and chronic non-specific lung disease. Given 
that the causality of the relation between low cholesterol levels and all-cause mortality has 
not been proven, and is at least partly explained by confounding and effect modification, 
the health consequences of a low cholesterol is not of public health importance in the 
Netherlands. 
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Summary 
Coronary heart disease mortality is a major public health problem in the Netherlands. Age-
standardized mortality rates for coronary heart disease have declined during the past two 
decades, but it is not yet clear to what extent this has been caused by primary prevention 
or better survival rates after a first event. Due to the aging of the population, coronary 
heart disease will remain an important public health burden. Serum total cholesterol is one 
of the major risk factors for coronary heart disease. With respect to primary prevention, 
it is essential to have information on cholesterol levels in the general population and 
changes that are taking place in these levels. Also information on factors that influence 
cholesterol levels and information on the strength of the relation between total cholesterol 
and coronary heart disease mortality is needed. Furthermore, it is important to know 
whether low cholesterol levels are associated with increased risk for non-cardiovascular 
diseases. 
Changes in total cholesterol levels over the period 1974-1986 were studied using data 
from the Consultation Bureau Heart Project (CB Project, 1974-1980) and the Risk Factor 
Project on Coronary Heart Disease (RTFOH Project, 1981-1986) (Chapter 2). Both projects 
were carried out in five different towns in the Netherlands: Amsterdam, Doetinchem, 
Maastricht, Tilburg and Leiden. Between 1974 and 1980 about 30,000 men and women 
aged 37-43 were examined. From 1981-1986 about 80,000 men aged 33-37 were 
examined; no women were examined during this period. In men and women aged 37-43, 
a decline in total cholesterol levels was observed between 1974 and the end of 1977, 
followed by an increase up to the end of 1980. Over the period 1974-1980 this resulted 
in a net decrease in mean total cholesterol levels of 0.07 mmol/1 in men and 0.03 mmol/1 
in women, while the prevalence of hypercholesterolemia (total cholesterol > 6.5 mmol/1) 
decreased by 3 percentage points in men and 2 in women. Between 1981 and 1986 a 
decrease in mean total cholesterol of 0.20 mmol/1 was observed in 80,000 men aged 33-
37, leading to a decrease in the prevalence of hypercholesterolemia of 4 percentage points. 
Over the period 1987-1992 levels of and changes in total and HDL cholesterol levels in 
over 40,000 men and women aged 20-59 were studied using data from the Monitoring 
Project on Cardiovascular Disease Risk Factors (Chapter 3). Mean total cholesterol levels 
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in men increased with age from 4.75 mmol/1 at age 20-29 to 5.98 mmol/1 at age 50-59 and 
in women from 4.87 mmol/1 at age 20-29 to 6.23 mmol/1 at age 50-59. The prevalence of 
hypercholesterolemia increased in men from 5% at age 20-29 to 29% at age 50-59 and in 
women from 4% at age 20-29 to 38% at age 50-59. Mean HDL cholesterol levels changed 
only slightly with age and were on average approximately 1.15 mmol/1 in men and 1.40 
mmol/1 in women. The prevalence of low HDL cholesterol levels (5 0.90 mmol/1) 
increased with age from 15% at age 20-29 to 26% at age 50-59 in men and from 4% to 
7% in women. The lipid profile of those with a higher educational level was more 
favorable than that of those with a lower educational level. Over the period 1987 to 1992, 
total cholesterol levels in men decreased by 0.12 mmol/1, HDL cholesterol levels 
decreased by 0.07 mmol/1 and the non-HDL/HDL cholesterol ratio increased by 0.22. In 
women no statistically significant changes were observed. Changes over time did not differ 
according to age and educational level. 
In women a large increase in the prevalence of hypercholesterolemia was observed after 
age 40. The extent to which this increase is attributable to the menopause was examined 
comparing about 2,600 premenopausal and 1,700 postmenopausal women in an age range 
in which most women go through menopause (45 to 54 years) (Chapter 4). After 
adjustment for age and body mass index (BMT), total cholesterol levels were 0.45 mmol/1 
higher in non-smoking postmenopausal women than in non-smoking premenopausal 
women. For smoking women this difference amounted to 0.28 mmol/1. HDL cholesterol 
levels were 0.04 mmol/1 higher in postmenopausal women compared to premenopausal 
women after adjustment for age, smoking, body mass index, alcohol consumption and 
physical activity. It was concluded that menopause plays an important role in the total 
cholesterol increase in women around middle-age. 
The effect of lifestyle and biological factors on the difference in total and HDL cholesterol 
levels in men and women was evaluated in 36,000 men and women aged 20-59 who 
participated in the Monitoring Project on Cardiovascular Disease Risk Factors between 
1987-1991 (Chapter 5). Between age 30 and 50, when total cholesterol is higher in men 
than in women, 19-38% of the gender difference was explained by differences in body 
mass index and smoking. After age 50, when total cholesterol is higher in women than in 
men, the difference was no longer partly explained by differences in BMI and smoking, 
but was to a large extent due to the cholesterol-increasing effect of menopause in women. 
The difference in HDL cholesterol between men and women would be about 0.02-0.04 
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mmol/1 larger if the levels of BMI and lifestyle factors (cigarette smoking, alcohol 
consumption and physical activity) had been similar. The effect of a "low-risk" versus 
"high-risk" lifestyle on changes of total and HDL cholesterol with age were also estimated. 
The difference in mean total cholesterol between a "low-risk" (BMI=22.5 kg/m2, no 
smoking) versus a "high-risk" (BMI=30 kg/m2, smoking) lifestyle was 0.58 mmol/1 in men 
and 0.40 mmol/1 in women. For HDL-C the difference between a "low-risk" (BMI=22.5 
kg/m2, no smoking, 2 alcoholic rlrinks per day, physically active) and a "high-risk" 
(BMI=30 kg/m2, smoking, no alcohol, physically inactive) lifestyle was about 0.38 mmol/1 
in men and about 0.45 mmol/1 in women. Between age 20 and 60 total cholesterol levels 
increase on average by 1.7 mmol/1 in men and by 1.6 mmol/1 in women. It was estimated 
that a "low-risk" lifestyle would lead to a 0.3 mmol/1 less increase in men and a 0.15 
mmol/1 less increase in women. 
The predictive value of total cholesterol with respect to mortality from coronary heart 
disease was examined in 50,000 Dutch men and women aged 30 to 54 years at baseline 
(CB Project) (Chapter 6) and in over 12,000 men from seven different countries who were 
40 to 59 years old at baseline (Seven Countries Study) (Chapter 7). 
In the CB Project after an average 12 years of follow-up, 818 men and 501 women had 
died, of whom 194 men and 38 women from coronary heart disease (Chapter 6). After 
adjustment for age, cigarette smoking, blood pressure and body mass index the relative 
risk (RR) for CHD mortality was 3.0 (95% confidence interval 1.8-5.1) for men in the 
highest gender-specific quintile compared to men in the lowest quintile, while for women 
the relative risk for the highest quintile compared to the lowest was 3.8 (95% confidence 
interval 1.1-13.1). Although relative risks for CHD mortality were comparable in men and 
women, the absolute risk was five times higher in men than in women. It was calculated 
that in this study population a cholesterol reduction of 0.6 mmol/1 would be associated 
with a 20% reduction in CHD mortality in both men and women. 
Data from the Seven Countries Study were used to compare the association of cholesterol 
and CHD mortality in different cultures. Six different groups of cohorts were formed for 
the analyses on the basis of cholesterol levels, similarities in culture and changes in 
cholesterol levels during the first ten years of follow-up (Chapter 7). The age-adjusted 
CHD mortality rates in the six cohorts ranged from 3% to 20%. The relative risks for 
CHD mortality for the highest compared to the lowest cholesterol quartile ranged from 1.5 
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to 2.3, except for Japan where it was 1.1. Using a linear approximation, a 0.5 mmol/1 
increase in total cholesterol corresponded to an increase in CHD mortality risk of 12%. 
When the regression dilution bias was taken into account this increase in risk was 17%. 
However, the absolute CHD mortality risk was strikingly different in the different cultures. 
For a cholesterol level of around 5.4 mmol/1, CHD mortality rates varied from 4% to 5% 
in Japan and Mediterranean Southern Europe to about 15% in Northern Europe. We 
concluded that CHD mortality across cultures increases continuously with increasing total 
cholesterol levels; the relative increase in CHD mortality rates with a given cholesterol 
increase is similar. The large difference in absolute CHD mortality rates at a given 
cholesterol level, however, indicates that other factors, such as diet, typical for cultures 
with a low CHD risk are also important with respect to primary prevention. 
The association of (low levels of) total cholesterol with non-cardiovascular and all-cause 
mortality was examined in the CB Project and the Seven Countries Study. In the CB 
Project (Chapter 6), no increase of non-cardiovascular mortality (divided into cancer and 
non-cardiovascular/non-cancer mortality) was observed at low cholesterol levels after an 
average 12 years of follow-up. Total cholesterol was positively related to all-cause 
mortality. After adjustment for age, cigarette smoking, blood pressure and body mass 
index, all-cause mortality was 60* and 46% higher in the highest compared to the lowest 
cholesterol quintile in men and women respectively. In the Seven Countries Study 
(Chapter 8), a possible association of low cholesterol levels and 25-year non-
cardiovascular mortality was examined by comparing non-cardiovascular mortality in four 
cholesterol categories: < 4.15 mmol/1, 4.15-5.15 mmol/1, 5.16-6.20 mmol/1 and > 6.20 
mmol/1. After adjustment for age, cigarette smoking, blood pressure and cohort, total 
cancer mortality was inversely associated with cholesterol only in smokers. Non-
cardiovascular/non-cancer mortality was inversely associated with cholesterol in smokers, 
and elevated in non-smokers in the lowest cholesterol category (< 4.15 mmol/1) only. For 
subgroups of diseases (infection and respiratory diseases) inverse associations were 
observed both in smokers and non-smokers. Total mortality in non-smokers showed a J-
shaped relation with total cholesterol (lowest mortality for the cholesterol category of 4.15-
5.15 mmol/1), while no association with cholesterol was observed in smokers. It was 
investigated to what extent confounding played a role in these associations. Exclusion of 
deaths occurring in the first ten years of follow-up did not alter the results. To examine 
the effect of confounding by alcohol consumption, the association of low cholesterol levels 
with alcohol-related cancers was examined (because there was no information on actual 
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alcohol consumption). In the lowest cholesterol category, the relative risk of mortality 
from alcohol-related cancers was about 2. These results suggest that the associations 
observed were at least partly explained by confounding. For non-smokers the lowest total 
mortality rate was observed for cholesterol levels of 4.15-5.15 mmol/1. 
It was concluded that cholesterol levels in the Netherlands are still relatively high. Despite 
a long tradition in health education, a substantial shift towards lower cholesterol levels has 
not been reached in the Netherlands, contrary to, for example, the United States. It was 
shown that in both men and women total cholesterol is an important predictor of CHD 
mortality. The strength of the relation between total cholesterol levels and CHD mortality 
was comparable for different cultures. However, the observation that absolute levels of 
CHD mortality were strikingly different in these cultures emphasizes the importance of 
other factors, such as diet, in this context. The fact that the association between low 
cholesterol levels and non-cardiovascular mortality was not observed in the CB Project 
(men and women with a relatively young age at baseline) contrary to the Seven Countries 
Study (men who were middle-age at baseline) provides support to the hypothesis that this 
association is dependent on age at baseline. This suggests that this association is at least 
partly explained by pre-existing diseases at baseline. The low prevalence of low 
cholesterol levels in the Netherlands, together with the probability that the excess mortality 
at low cholesterol levels is at most partly causal, coupled with the high burden of coronary 
heart disease in the population, result in low cholesterol not being a major public health 
concern in the Netherlands. A cholesterol reduction in the general population remains a 
desirable aim in reducing the burden of coronary heart disease in the population. This 
reduction should preferably be achieved by means of changes in lifestyle (a diet low in 
saturated fat and high in fruits and vegetables, no smoking, a desirable body mass index, 
a physically active lifestyle) because this will lead not only to a reduction of coronary 
heart disease, but will also be accompanied by a more favorable risk profile with respect 
to other chronic diseases such as diabetes and cancer. 
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Samenvatting 
De sterfte aan coronaire hartziekte vormt in Nederland - mede door het vergrijzen van de 
bevolking - een belangrijk volksgezondheidsprobleem. In de afgelopen decennia is de voor 
leeftijd gestandaardiseerde sterfte aan coronaire hartziekte afgenomen. Of deze daling 
voornamelijk wordt veroorzaakt door een betere overleving na een hartinfarct, of dat 
primaire preventie aan deze daling heeft bijgedragen, is nog niet duidelijk. Het is van 
belang om over gegevens te beschikken over het cholesterolniveau in de algemene 
bevolking en veranderingen die daarin plaatsvinden. Ook kennis over factoren die het 
cholesterolgehalte beïnvloeden en informatie over de sterkte van de relatie tussen het 
cholesterolgehalte en de sterfte aan coronaire hartziekte is in dit kader van belang. 
Daarnaast is het noodzakelijk om te weten of het sterfte-risico voor met-cardiovasculaire 
ziekten mogelijk verhoogd is bij lage cholesterolniveaus. In dit proefschrift wordt op deze 
onderwerpen ingegaan. 
Veranderingen in het totaal cholesterolgehalte in de periode 1974-1986 zijn beschreven 
op basis van gegevens, verzameld in het kader van het Consultatiebureau Project Hart- en 
Vaatziekten (CB-Project, 1974-1980) en het Risicofactoren Onderzoek Hart-en Vaatziekten 
(RIFOH-Project, 1981-1986) (Hoofdstuk 2). Deze projecten werden uitgevoerd in vijf 
plaatsen in Nederland: Amsterdam, Doetinchem, Maastricht, Tilburg en Leiden. Tussen 
1974 en 1980 werden ruim 30.000 mannen en vrouwen in de leeftijd van 37-43 jaar 
onderzocht. In de periode 1981-1986 werden 80.000 mannen van 33-37 jaar onderzocht; 
in deze periode werden geen vrouwen onderzocht. Tussen 1974 en eind 1977 werd een 
daling in het totaal cholesterolgehalte geconstateerd, gevolgd door een stijging tot eind 
1980. De netto verandering over de periode 1974-1980 was een daling van 0,07 mmol/1 
bij mannen en een daling van 0,03 mmol/1 bij vrouwen. De prevalentie van 
hypercholesterolemie (totaal cholesterol > 6,5 mmol/1) daalde 3 procentpunten bij mannen 
en 2 procentpunten bij vrouwen. In de periode 1981-1986 nam het gemiddelde totaal 
cholesterolgehalte bij mannen van 33-37 jaar af met 0,20 mmol/1, waardoor de prevalentie 
van hypercholesterolemie met 4 procentpunten afnam. 
Het totaal- en HDL-cholesterolniveau en de veranderingen daarin gedurende de periode 
1987-1992 werden bestudeerd met gegevens van ruim 40.000 mannen en vrouwen van 20-
59 jaar die werden onderzocht in het kader van het Peilstationsproject Hart- en 
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Vaatziekten (Hoofdstuk 3). Het gemiddelde totaal cholesterolgehalte nam bij mannen toe 
met de leeftijd van 4,75 mmol/1 bij 20-29-jarigen tot 5,98 mmol/1 bij 50-59-jarigen, en bij 
vrouwen van 4,87 mmol/1 bij 20-29-jarigen tot 6,23 mmol/1 bij 50-59-jarigen. De 
prevalentie van hypercholesterolemie nam toe met de leeftijd van 5% tot 29% bij mannen 
en van 4% tot 38% bij vrouwen. Het gemiddelde HDL-cholesterolgehalte veranderde 
nauwelijks met de leeftijd, en was gemiddeld 1,15 mmol/1 bij mannen en 1,40 mmol/1 bij 
vrouwen. De prevalentie van een laag HDL-cholesterolgehalte (< 0,90 mmol/1) nam wel 
enigszins toe met de leeftijd, bij mannen van 15% tot 26% en bij vrouwen van 4% tot 7%. 
Het lipidenprofiel van de hoog opgeleiden was gunstiger dan dat van de laag opgeleiden. 
In de periode 1987-1992 nam bij mannen het totaal cholesterolgehalte af met 0,12 mmol/1, 
het HDL-cholesterolgehalte nam af met 0,07 mmol/1 en de non-HDL/HDL-cholesterol ratio 
nam toe met 0,22. Bij vrouwen werden geen statistisch significante veranderingen 
gedurende deze periode waargenomen. De verandering door de tijd verschilde niet naar 
leeftijd of opleiding. 
Bij vrouwen neemt de prevalentie van hypercholesterolemie sterk toe na ongeveer het 
veertigste levensjaar. De invloed van het optreden van de menopauze op deze stijging 
werd nagegaan door het vergelijken van ongeveer 2.600 premenopauzale vrouwen met 
1.700 postmenopauzale vrouwen in de leeftijdsgroep 45-54 jaar, de periode waarin bij de 
meeste vrouwen de menopauze optreedt (Hoofdstuk 4). Na correctie voor leeftijd en 
Quetelet index was het totaal cholesterolgehalte in niet-rokende postmenopauzale vrouwen 
0,45 mmol/1 hoger dan in niet-rokende premenopauzale vrouwen. Bij vrouwen die rookten 
was dit verschil 0,28 mmol/1. Na correctie voor leeftijd, sigaretten roken, Quetelet index, 
alcohol-consumptie en hchamelijke activiteit was het HDL cholesterolgehalte in 
postmenopauzale vrouwen 0,04 mmol/1 hoger dan in premenopauzale vrouwen. 
Geconcludeerd werd dat menopauze een belangrijke rol speelt bij de toename van het 
totaal cholesterolgehalte bij vrouwen rond de middelbare leeftijd. 
De invloed van leefstijlfactoren en biologische risicofactoren op verschillen tussen mannen 
en vrouwen in het totaal- en HDL-cholesterolgehalte werd onderzocht met gegevens van 
36.000 mannen en vrouwen van 20-59 jaar die deelnamen aan het Peilstationsproject Hart-
en Vaatziekten (Hoofdstuk 5). In de leeftijd van 30 tot 50 jaar, wanneer het totaal 
cholesterolgehalte hoger is bij mannen dan bij vrouwen, werd 19-38% van dit verschil 
verklaard door verschillen in Quetelet index en rookgewoonten tussen mannen en 
vrouwen. Na het vijftigste levensjaar was het totaal cholesterolgehalte hoger bij vrouwen 
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dan bij mannen en kon dit verschil niet meer verklaard worden uit verschillen in Quetelet 
index en rookgewoonten, maar voornamelijk door de toename van het cholesterolgehalte 
bij vrouwen door het optreden van de menopauze. Het verschil in HDL-cholesterol tussen 
mannen en vrouwen zou 0,02-0,04 mmol/l groter zijn wanneer er geen verschillen zouden 
zijn tussen mannen en vrouwen in Quetelet index (QI), rookgewoonten, alcohol-
consumptie en lichamelijke activiteit. Ook werd het effect op het cholesterolgehalte van 
een 'laag risico' leefstijl (QI=22,5 kg/m2, niet roken) versus een 'hoog risico' leefstijl 
(QI=30 kg/m2, wel roken) onderzocht. Het verschil in totaal cholesterol tussen de 'laag 
risico' en 'hoog risico' leefstijl was 0,58 mmol/l voor mannen en 0,40 mmol/l voor 
vrouwen. Het verschil in HDL-cholesterolgehalte tussen een 'laag risico' leefstijl (QI=22,5 
kg/m2, niet roken, 2 glazen alcohol per dag en lichamelijk actief) en een 'hoog risico' 
leefstijl (QI=30 kg/m2, wel roken, geen alcohol-gebruik en lichamelijk inactief) was 0,38 
mmol/l voor mannen en 0,45 mmol/l voor vrouwen. Tussen het twintigste en zestigste 
levensjaar neemt het totaal cholesterolgehalte toe met gemiddeld 1,7 mmol/l bij mannen 
en 1,6 mmol/l bij vrouwen. Geschat werd dat bij een 'laag risico' leefstijl deze toename 
0,3 mmol/l minder zou zijn bij mannen en 0,15 mmol/l minder bij vrouwen. 
De predictieve waarde van het totaal cholesterolgehalte voor sterfte aan coronaire 
hartziekte werd onderzocht in een cohort van 50.000 Nederlandse mannen en vrouwen die 
30-54 jaar waren bij aanvang van het onderzoek (CB-Project) (Hoofdstuk 6). Dit verband 
werd ook onderzocht in ruim 12.000 mannen uit zeven landen die 40-59 jaar oud waren 
bij aanvang van het onderzoek (Zeven Landen Studie) (Hoofdstuk 7). 
In het CB-Project waren na gemiddeld 12 jaar follow-up 818 mannen en 501 vrouwen 
overleden, waarvan 194 mannen en 38 vrouwen aan coronaire hartziekte (Hoofdstuk 6). 
Na correctie voor leeftijd, roken, bloeddruk en Quetelet index, was het relatieve risico 
voor sterfte aan coronaire hartziekte 3,0 (95%-betrouwbaarheidsinterval 1,8-5,1) voor 
mannen in het hoogste geslachts-specifieke cholesterol quintiel vergeleken met mannen 
in het laagste quintiel. Voor vrouwen bedroeg dit relatieve risico 3,8 (95%-
betrouwbaarheidsinterval 1,1-13,1). Alhoewel het relatieve risico voor sterfte aan coronaire 
hartziekte vergelijkbaar was voor mannen en vrouwen, was het absolute risico voor 
mannen vijf keer zo groot als voor vrouwen. De geschatte reductie in sterfte aan coronaire 
hartziekte ten gevolge van een cholesterolverlaging van 0,6 mmol/l in deze populatie was 
ongeveer 20% voor zowel mannen als vrouwen. 
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De relatie tussen het totaal cholesterolgehalte en sterfte aan coronaire hartziekte werd 
vergeleken in verschillende culturen. Hiervoor werd gebruik gemaakt van gegevens van 
de Zeven Landen Studie. Voor de statistische analyse werden de mannen in 6 cohorten 
gedeeld, gebaseerd op culturele overeenkomsten en overeenkomsten in cholesterolgehalte 
en veranderingen daarin tijdens de eerste 10 jaar follow-up (Hoofdstuk 7). De voor leeftijd 
gestandaardiseerde sterftecijfers varieerden tussen de 6 cohorten van 3% tot 20%. De 
relatieve risico's voor sterfte aan coronaire hartziekte voor het hoogste cholesterol quartiel 
ten opzichte van het laagste quartiel waren vergelijkbaar en varieerden van 1,5 tot 2,3, met 
uitzondering van Japan waar dit relatieve risico 1,1 was. Op grond van een lineaire 
schatting, nam het risico op coronaire hartziekte bij een toename in het totaal 
cholesterolgehalte van 0,5 mmol/1 toe met 12%. Wanneer werd gecorrigeerd voor 
'regression-dilution bias' bedroeg dit percentage 17. Hoewel de relatieve risico's 
vergelijkbaar waren in de verschillende cohorten, waren er grote verschillen in absolute 
risico's bij een gegeven cholesterolgehalte. Bij een cholesterolgehalte van 5,4 mmol/1 
hepen de sterftecijfers uiteen van 4% a 5% in de Japanse en de mediterrane Zuideuropese 
cohorten, tot ongeveer 15% in het Noordeuropese cohort. Wij concludeerden dat in 
verschillende culturen het risico op coronaire hartziekte continu toeneemt met het 
cholesterolgehalte en dat de grootte van deze toename vergelijkbaar is tussen culturen. Er 
zijn echter grote verschillen in absolute niveaus van stérfte aan coronaire hartziekte, 
waaruit blijkt dat andere factoren, zoals bijvoorbeeld het voedingspatroon, die kenmerkend 
zijn voor culturen met een lage sterfte aan coronaire hartziekte, van belang zijn voor 
primaire preventie van coronaire hartziekte. 
De associatie tussen een laag cholesterolgehalte en sterfte aan met-cardiovasculaire 
aandoeningen en totale sterfte werd onderzocht in het CB-Project en de Zeven Landen 
Studie. In het CB-Project (Hoofdstuk 6) werd geen verhoogde sterfte gevonden aan niet-
cardiovasculaire oorzaken (verdeeld in de subgroepen kanker en niet-cardiovasculaire/niet-
kanker oorzaken) bij lage totaal cholesterolniveaus. Er werd een positief verband gevonden 
tussen het totaal cholesterolgehalte en totale mortaliteit. De totale sterfte in het hoogste 
cholesterol quintiel ten opzichte van het laagste cholesterol quintiel was voor mannen en 
vrouwen verhoogd met respectievelijk 60% en 46%, na correctie voor leeftijd, roken, 
bloeddruk en Quetelet index. In de Zeven Landen Studie (Hoofdstuk 8) werd de associatie 
tussen een laag cholesterolgehalte en 25-jaars sterfte aan met-cardiovasculaire oorzaken 
onderzocht door het vergelijken van 4 cholesterol categorieën: < 4,15 mmol/1, 4,15-5,15 
mmol/1, 5,16-6,20 mmol/1 en > 6,20 mmol/1. Na correctie voor leeftijd, roken, bloeddruk 
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en cohort was alleen bij rokers het totaal cholesterolgehalte invers geassocieerd met sterfte 
aan kanker. Ook de niet-cardiovasculaire/niet-kanker sterfte was bij rokers invers 
geassocieerd met het totaal cholesterolgehalte. De sterfte aan deze groep oorzaken was bij 
niet-rokers in het laagste cholesterol quintiel (< 4,15 mol/1) verhoogd, maar nam niet 
verder af in de hogere cholesterol quintielen. Voor subgroepen van ziekten uit deze 
categorie (infecties en luchtwegaandoeningen) werden inverse associaties met het 
cholesterolgehalte gevonden voor zowel rokers als niet-rokers. Het verband tussen het 
totaal cholesterolgehalte en totale mortaliteit was bij niet-rokers J-vormig, (de laagste 
sterfte trad op in de cholesterol categorie 4,15-5,15 mmol/1), terwijl bij rokers geen 
verband werd gevonden tussen het totaal cholesterolgehalte en totale sterfte. De mogelijke 
rol van confounders in deze relaties werd nagegaan. Het uitsluiten van de eerste 10 jaar 
follow-up veranderde de resultaten niet. Een mogelijk verstorend effect van alcoholgebruik 
(dat niet was gemeten) werd onderzocht door te kijken naar de sterfte aan alcohol-
gerelateerde tumoren. In de laagste cholesterol categorie was het risico op sterfte aan deze 
groep kankers twee maal zo hoog als in de overige cholesterol categorieën. Deze 
resultaten suggereren dat de gevonden verbanden in ieder geval gedeeltelijk werden 
verklaard door verstorende factoren waarvoor niet gecorrigeerd kon worden. Voor niet-
rokers trad de laagste sterfte op bij cholesterolniveaus van 4,15-5,15 mmol/1. 
Geconcludeerd werd dat de totaal cholesterolniveaus in Nederland nog steeds relatief hoog 
zijn. Ondanks een lange traditie van gezondheidsvoorUchting is er nog geen substantiële 
verlaging van de cholesterolniveaus opgetreden, in tegenstelling tot bijvoorbeeld de 
Verenigde Staten. Ons onderzoek toonde aan dat het totaal cholesterolgehalte voor zowel 
mannen als vrouwen een belangrijke risicofactor is voor sterfte aan coronaire hartziekte. 
De sterkte van het verband tussen het totaal cholesterolgehalte en de sterfte aan coronaire 
hartziekte was vergelijkbaar in verschillende culturen. Het grote verschil in het absolute 
niveau van sterfte aan coronaire hartziekte bij een gegeven cholesterolgehalte tussen 
culturen, laat het belang zien van andere factoren, zoals voeding, voor deze relatie. Het 
feit dat in het CB-Project (mannen en vrouwen die relatief jong waren bij aanvang van het 
onderzoek) geen verhoging van de niet-cardiovasculaire sterfte werd gevonden bij een laag 
cholesterolgehalte, terwijl dit in de Zeven Landen Studie bij mannen van middelbare 
leeftijd wel het geval was, ondersteunt de hypothese dat dit verband afhankehjk is van de 
leeftijd van de onderzochte personen. Dit suggereert dat deze associatie in ieder geval 
gedeeltelijk verklaard wordt door de aanwezigheid van ongezonde personen in de lage 
cholesterol categorie. Omdat de prevalentie van lage cholesterolniveaus in Nederland niet 
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hoog is, de verhoogde sterfte bij lage cholesterolniveaus ten hoogste gedeeltelijk causaal 
is en de ziektelast ten gevolge van coronaire hartziekte hoog is, wordt geconcludeerd dat 
lage cholesterolniveaus in Nederland geen belangrijk volksgezondheidsprobleem vormen. 
Een cholesterolverlaging in de algemene bevolking blijft wenselijk om de ziektelast ten 
gevolge van coronaire hartziekte in de populatie te verminderen. Deze cholesterolverlaging 
moet bij voorkeur bereikt worden door veranderingen in leefstijl (een voeding met weinig 
verzadigd vet, veel groente en fruit, niet roken, geen overgewicht en regelmatige 
hchamelijk activiteit). Een dergelijke leefstijl leidt namelijk niet alleen tot een 
vermindering van het optreden van coronaire hartziekte maar ook tot een gunstiger 
risicoprofiel met betrekking tot andere chronische ziekten zoals diabetes en kanker. 
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Het is af! Het is een heerlijk gevoel om op de altijd goed bedoelde vraag "En ..? Is 
je proefschrift al af?" eindelijk te kunnen zeggen "Ja, het is af!". Maar natuurüjk zijn er 
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Allereerst Daan Kromhout, Beste Daan, alle data waarop de artikelen in dit 
proefschrift zijn gebaseerd zijn mede dankzij jou beschikbaar gekomen of verzameld. Je 
hebt een fijne neus om 'dode' data tot leven te brengen. Dit geldt niet alleen voor de 
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vruchten heeft afgeworpen. Ik heb veel van je geleerd. De wijze waarop je ook de -tigste 
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je aandacht ontsnapt), verbaast mij elke keer weer. 
Gatske Obermann-de Boer ben ik dank verschuldigd voor haar bijdrage aan het 
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worden gedaan om een project 'gewoon' te laten lopen. Een eervolle vermelding voor jou 
is daarom zeker op zijn plaats. 
Gegevens van ruim 40.000 Nederlanders komen er niet zomaar. De wil daarom graag 
de peilmedewerkers en locale projectleiders van de GGD-en in Amsterdam, Doetinchem 
en Maastricht bedanken, die deze gegevens verzameld hebben. En natuurlijk ben ik ook 
dank verschuldigd aan alle deelnemers die de moeite hebben genomen een lange 
vragenlijst in te vullen en een bezoek te brengen aan de GGD. 
Het werken met gegevens van de Zeven Landen Studie, die rond mijn geboorte gestart 
is, was fantastisch. Hiervoor ben ik alle medewerkers van het eerste uur (en de 
daaropvolgende 25 jaar) dankbaar. 
David Jacobs, it was a pleasure analyzing data and writing articles together with you. 
I learned a lot from your experience and I hope our cooperation will continu in the future. 
Ellen Röntgen-Pieper, het achterhalen van de vitale status van 50.000 deelnemers aan 
het CB-Project, bij honderden (vaak niet geautomatiseerde) gemeenten, leek onbegonnen 
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werk. Je hebt je echter ontpopt als een ware Sherlock Holmes. Dankzij jouw accuratesse 
en vomarding is bijna iedereen teruggevonden, waardoor er nu informatie is over 
risicofactoren bij een groot Nederlands cohort. 
Ik dank de Directie van het RIVM voor de gelegenheid die mij geboden is dit 
proefschrift af te ronden. Jantien Zoutman wil ik bedanken voor de secretariële 
ondersteuning en Jan Dorssers en Ruud Romme voor het soepel lopende computernetwerk. 
Alle niet met name genoemde collega's wil ik bedanken voor de prettige werksfeer op het 
CCM. 
Mijn paranimfen, Jet Smit en Annemarie Jansen, dank ik voor hun bijdrage aan het 
geheel. Jullie hebben mij niet alleen allerlei klusjes uit handen genomen die bij een 
promotie komen kijken, maar waren voor mij ook een onmisbaar klankbord. 
Ruth de Wijs wil ik bedanken voor de enthousiaste en snelle wijze waarop zij delen 
van de Engels tekst heeft gecorrigeerd. Mijn lieve zus Louki heeft de Nederlandse delen 
van de tekst vakkundig aangescherpt en daarnaast (minstens zo belangrijk) wist zij mij 
door haar komische kijk op dingen uit de onvermijdelijke 'dalletjes' te helpen. 
Miriam Slaats ben ik dankbaar voor het enthousiasme waarmee zij de - voor haar vast 
wat droge - materie heeft vertaald in een sprankelend schilderij, dat de omslag siert van 
dit proefschrift. 
En ten slotte is er natuurhjk Bennie, die voor elk probleem - van welke aard ook -
altijd tenminste twee oplossingen heeft. Bedankt voor het lay-outen van dit proefschrift, 
maar meer nog voor je 'onzichtbare' input (al meer dan 14 jaar). 
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